CA2411552A1 - Glucagon antagonists/inverse agonists - Google Patents

Glucagon antagonists/inverse agonists Download PDF

Info

Publication number
CA2411552A1
CA2411552A1 CA002411552A CA2411552A CA2411552A1 CA 2411552 A1 CA2411552 A1 CA 2411552A1 CA 002411552 A CA002411552 A CA 002411552A CA 2411552 A CA2411552 A CA 2411552A CA 2411552 A1 CA2411552 A1 CA 2411552A1
Authority
CA
Canada
Prior art keywords
alkyl
compound according
hydrogen
independently
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002411552A
Other languages
French (fr)
Inventor
Peter Madsen
Christian Sams
Carsten Behrens
Jesper Lau
Inge Thoger Christensen
Anker Steen Jorgensen
Janos Tibor Kodra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2411552A1 publication Critical patent/CA2411552A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/30—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • C07C275/34—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/38—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atom of at least one amino group being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfones
    • C07C317/42—Y being a hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/43—Y being a hetero atom
    • C07C323/44—X or Y being nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/08—1,3-Dioxanes; Hydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/36—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Abstract

A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any diseases and disorders, wherein a glucagon antagonistic action is beneficial, such as hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism and obesity.

Description

GLUCAGON ANTAGONISTS/INVERSE AGONISTS
FIELD OF THE INVENTION
The present invention relates to agents that act to antagonize the action of the glucagon pep tide hormone on the glucagon receptor. More particularly, it relates to glucagon antagonists or inverse agonists.
BACKGROUND OF THE INVENTION
Glucagon is a key hormonal agent that, in co-operation with insulin, mediates homeostatic regulation of the amount of glucose in the blood. Glucagon primarily acts by stimulating cer-tain cells (mostly liver cells) to release glucose when blood glucose levels fall. The action of glucagon is opposite to that of insulin, which stimulates cells to take up and store glucose whenever blood glucose levels rise. Both glucagon and insulin are peptide hormones.
Glucagon is produced in the alpha islet cells of the pancreas and insulin in the beta islet cells. Diabetes mellitus is a common disorder of glucose metabolism. The disease is charac-terized by hyperglycemia and may be classified as Type 1 diabetes, the insulin-dependent form, or Type 2 diabetes, which is non-insulin-dependent in character.
Subjects with Type 1 diabetes are hyperglycemic and hypoinsulinemic, and the conventional treatment for this form of the disease is to provide insulin. However, in some patients with Type 1 or Type 2 diabetes, absolute or relative elevated glucagon levels have been shown to contribute to the hyperglycemic state. Both in healthy control animals as well as in animal models of Type 1 and Type 2 diabetes, removal of circulating glucagon with selective and specific antibodies has resulted in reduction of the glycemic level (Brand et al., Diabetologia 37, 985 (1994);
Diabetes 43, [suppl 1], 172A (1994); Am. J. Physiol. 269, E469-E477 (1995);
Diabetes 44 [suppl 1], 134A (1995); Diabetes 45, 1076 (1996)). These studies suggest that glucagon suppression or an action that antagonizes glucagon could be a useful adjunct to conventional antihyperglycemia treatment of diabetes. The action of glucagon can be suppressed by pro-viding an antagonist or an inverse agonist, ie substances that inhibit or prevent glucagon-induced responses. The antagonist can be peptidic or non-peptidic in nature.
Native glucagon is a 29 amino acid peptide having the sequence:
His-Ser-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Arg-Arg-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr-NH2.

Glucagon exerts its action by binding to and activating its receptor, which is part of the Glu-cagon-Secretin branch of the 7-transmembrane G-protein coupled receptor family (Jelinek et al., Science 259, 1614, (1993)). The receptor functions by activating the adenylyl cyclase second messenger system and the result is an increase in cAMP levels.
Several publications disclose peptides that are stated to act as glucagon antagonists. Proba-bly, the most thoroughly characterized antagonist is DesHis'[Glu9]-glucagon amide (Unson et al., Peptides 10, 1171 (1989); Post et al., Proc. Natl. Acad. Sci. USA 90, 1662 (1993)). Other antagonists are DesHis',Phe6[Glu9]-glucagon amide (Azizh et al., Bioorganic &
Medicinal Chem. Lett. 16, 1849 (1995)) and NLeu9,Ala"''6-glucagon amide (Unson et al., J. Biol.
Chem. 269 (17), 12548 (1994)).
Peptide antagonists of peptide hormones are often quite potent. However, they are generally known not to be orally available because of degradation by physiological enzymes, and poor distribution in vivo. Therefore, orally available non-peptide antagonists of peptide hormones are generally preferred. Among the non-peptide glucagon antagonists, a quinoxaline deriva-tive, (2-styryl-3-[3-(dimethylamino)propylmethylamino]-6,7-dichloroquinoxaline was found to displace glucagon from the rat liver receptor (Collins, J.L. et al., Bioorganic and Medicinal Chemistry Letters 2(9):915-918 (1992)). WO 94/14426 discloses use of skyrin, a natural product comprising a pair of linked 9,10-anthracenedione groups, and its synthetic ana-logues, as glucagon antagonists. US patent No 4,359,474 discloses the glucagon antagonis-tic properties of 1-phenyl pyrazole derivatives. US patent No 4,374,130 discloses substituted disilacyclohexanes as glucagon antagonists. WO 98/04528 (Bayer Corporation) discloses substituted pyridines and biphenyls as glucagon antagonists. US patent No 5,776,954 (Merck & Co., Inc.) discloses substituted pyridyl pyrroles as glucagon antagonists and WO
98/21957, WO 98/22108, WO 98/22109 and US 5,880,139 (Merck & Co., Inc.) disclose 2,4-diaryl-5-pyridylimidazoles as glucagon antagonists. Furthermore, WO 97/16442 and US pat-ent No 5,837,719 (Merck & Co., Inc.) disclose 2,5-substituted aryl pyrroles as glucagon an-tagonists. WO 98/24780, WO 98/24782, WO 99/24404 and WO 99/32448 (Amgen Inc.) dis-close substituted pyrimidinone and pyridone compounds and substituted pyrimidine com-pounds, respectively, which are stated to possess glucagon antagonistic activity. Madsen et al. (J. Med. Chem. 1998 (41 ) 5151-7) discloses a series of 2-(benzimidazol-2-ylthio)-1-(3,4-dihydroxyphenyl)-1-ethanones as competitive human glucagon receptor antagonists.
WO 99/01423 and WO 00/39088 (Novo Nordisk A/S) disclose different series of alkylidene hydrazides as glucagon antagonists/inverse agonists.
These known glucagon antagonists differ structurally from the present compounds.
DEFINITIONS
The following is a detailed definition of the terms used to describe the compounds of the inven-tion:
"Halogen" designates an atom selected from the group consisting of F, CI, Br and I.
The term "C,_s-alkyl" as used herein represents a saturated, branched or straight hydrocarbon group having from 1 to 6 carbon atoms. Representative examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, butyl, isobutyl, sec-butyl, Pert butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, n-hexyl, isohexyl and the like.
The term "C~_s-alkenyl" as used herein represents a branched or straight hydrocarbon group having from 2 to 6 carbon atoms and at least one double bond. Examples of such groups in-clude, but are not limited to, vinyl, 1-propenyl, 2-propenyl, iso-propenyl, 1,3-butadienyl, 1-but-enyl, 2-butenyl, 3-butenyl, 2-methyl-1-propenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-penten-yl, 3-methyl-2-butenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 2,4-hexadienyl, 5-hexenyl and the like.
The term "C2~-alkynyl" as used herein represents a branched or straight hydrocarbon group having from 2 to 6 carbon atoms and at least one triple bond. Examples of such groups in-clude, but are not limited to, ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl, 2,4-hexadiynyl and the like.
3o The term "C~-s-alkoxy" as used herein refers to the radical -O-C~~-alkyl, wherein C~_s-alkyl is as defined above. Representative examples are methoxy, ethoxy, n-propoxy, isopropoxy, butoxy, sec-butoxy, tert-butoxy, pentoxy, isopentoxy, hexoxy, isohexoxy and the like.
The term "C,_s-alkanoyl" as used herein denotes a group -C(O)H or -C(O)-C~~-alkyl. Represen-tative examples are formyl, acetyl, propionyl, butyryl, valeryl, hexanoyl and the like.
The term "C3_a-cycloalkyl" as used herein represents a saturated, carbocyclic group having from 3 to 8 carbon atoms. Representative examples are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and the like.
The term "C4_8-cycloalkenyl" as used herein represents a non-aromatic, carbocyclic group hav-ing from 4 to 8 carbon atoms containing one or two double bonds.
Representative examples are 1-cyclopentenyl, 2-cyclopentenyl, 3-cyclopentenyl, 1-cyclohexenyl, 2-cyclohexenyl, 3-cyclohexenyl, 2-cycloheptenyl, 3-cycloheptenyl, 2-cyclooctenyl, 1,4-cyclooctadienyl and the like.
The term "heterocyclyl" as used herein represents a non-aromatic 3 to 10 membered ring con-taining one or more heteroatoms selected from nitrogen, oxygen and sulfur and optionally con-taining one or two double bonds. Representative examples are pyrrolidinyl, piperidyl, piperaz-inyl, morpholinyl, thiomorpholinyl, aziridinyl, tetrahydrofuranyl and the like.
The term "aryl" as used herein is intended to include carbocyclic aromatic ring systems such as phenyl, biphenylyl, naphthyl, anthracenyl, phenanthrenyl, fluorenyl, indenyl, pentalenyl, azulenyl and the like. Aryl is also intended to include the partially hydrogenated derivatives of the 2o carbocyclic systems enumerated above. Non-limiting examples of such partially hydro-genated derivatives are 1,2,3,4-tetrahydronaphthyl, 1,4-dihydronaphthyl and the like.
The term "arylene" as used herein is intended to include divalent carbocyclic aromatic ring systems such as phenylene, biphenylylene, naphthylene, anthracenylene, phenanthrenylene, fluorenylene, indenylene, pentalenylene, azulenylene and the like. Arylene is also intended to include the partially hydrogenated derivatives of the carbocyclic systems enumerated above.
Non-limiting examples of such partially hydrogenated derivatives are 1,2,3,4-tetrahydro-naphthylene, °1,4-dihydronaphthylene and the like.
3o The term "aryloxy" as used herein denotes a group -O-aryl, wherein aryl is as defined above.
The term "aroyl" as used herein denotes a group -C(O)-aryl, wherein aryl is as defined above.
The term "heteroaryl" as used herein is intended to include heterocyclic aromatic ring sys-terns containing one or more heteroatoms selected from nitrogen, oxygen and sulfur such as furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, isoxazolyl, isothiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, pyranyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5- triazinyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, tetrazolyl, thiadiazinyl, indo-5 1y1, isoindolyl, benzofuryl, benzothienyl, indazolyl, benzimidazolyl, benzthiazolyl, benzisothia-zolyl, benzoxazolyl, benzisoxazolyl, purinyl, quinazolinyl, quinolizinyl, quinolinyl, isoquinolinyl, quinoxalinyl, naphthyridinyl, pteridinyl, carbazolyl, azepinyl, diazepinyl, acridinyl and the like.
Heteroaryl is also intended to include the partially hydrogenated derivatives of the heterocyc-lic systems enumerated above. Non-limiting examples of such partially hydrogenated deriva-tives are 2,3-dihydrobenzofuranyl, pyrrolinyl, pyrazolinyl, indolinyl, oxazolidinyl, oxazolinyl, oxazepinyl and the like.
"Aryl-C~~-alkyl", "heteroaryl-C,~-alkyl", "aryl-C2_6-alkenyl" etc. mean C~_6-alkyl or C2~-alkenyl as defined above, substituted by an aryl or heteroaryl as defined above, for example:
S \ ~
~ ~ ~ ~ , ~ ~, / ~,, / ,, /
The term "optionally substituted" as used herein means that the groups in question are either unsubstituted or substituted with one or more of the substituents specified.
When the groups in question are substituted with more than one substituent the substituents may be the same or different.
Certain of the above defined terms may occur more than once in the structural formulae, and upon such occurrence each term shall be defined independently of the other.
Furthermore, when using the terms "independently are" and "independently selected from" it should be understood that the groups in question may be the same or different.
DESCRIPTION OF THE INVENTION
The present invention is based on the unexpected observation that the compounds of the gen-eral formula (I) disclosed below antagonize the action of glucagon.
The compounds are advantageous by being selective towards the glucagon receptor and show a higher binding affinity for the glucagon receptor compared to the binding affinity for the structurally relatedGIP (Gastric Inhibitory Peptide) receptor and GLP-1 receptor.
Accordingly, the present inventions relate to compounds of the general formula (I):

1 / \R/ \3 ~ ~ /Xw RO A N Z N D (I) wherein R', Rz, R3, R4 and R5 independently are hydrogen or C~_6-alkyl, A is -C(O)-, -CH(OR6)- or -CHF-, wherein R6 is hydrogen or C~_6-alkyl, Z is arylene or a divalent radical derived from a 5 or 6 membered heteroaromatic ring con-taining 1 or 2 heteroatoms selected from nitrogen, oxygen and sulfur, which may optionally be substituted with one or two groups R' and R8 selected from halogen, -CN, -CF3, -OCF3, -NO2, -OR9, -NR9R'° and C~_6-alkyl, wherein R9 and R'° independently are hydrogen or C~_6-alkyl, X is O
-(CH2)-(CR12R1s)( (CHZ)S , ~(CR12R1s)' (CHZ)S

~(CHa)q H=H-(CR12R1s)' (CH~)S , ~(CHa)q N11 (CR12R1s)f (CH2)S
R
O O
-~-(CH2)q N-(CR12R13)~ (CH2)S 0- , --lL-(CH~)q N1-I1-(CR1~R13)~ (CH2)S

-~I-(CH2)q NON-(CR'ZRIS)~ (CH2)S . -ll-(CH2)q N--LI-O-(CR12R1s)~ (CH2)S

-Nil--(CR12R1s)f (CH2)S Or -IJ--(CH2)q (CR12R13)f 0_(CH2)S

wherein ris0orl, q and s independently are 0, 1, 2 or 3, R11' R12~ R1s and R14 independently are hydrogen, C~_6-alkyl or C3_$-cycloalkyl, D is R15 R16 R17 R15 R16 p ~Rls ~ _~\_Rls ' ~ N_R1s R1' ' 15 / R ~f N R17 15 /
R R O
R15 , R15 R15 R15 / R ~Rls ' ~S~RIS ~Rls / N / s / f s R O
/~~Rls I R1s I ' /~~-R1s Or / , R15 N~R1s R1s O
R1 s Rzo R15 p 5 wherein R'S, R'6, R" and R'$ independently are ~ hydrogen, halogen, -CN, -CHFz, -CF3, -OCF3, -OCHFz, -OCHzCF3, -OCF2CHFz, 10 -S(O)zCF3, -SCF3, -NOz, -ORz~, -NRz~Rzz~ -SR21~ -NR21S(O)zRz2~
_S(O)zNRz~Raz~
-S(O)NRz~Rzz~ -S(O)Rz~~ _S(p)zRz~~ -C(O)NRz~Rzz -OC(O)NRz~Rzz~ -NRz~C(O)Rzz~
-CH2C(O)NRz'Rzz, -OCHzC(O)NRz'Rzz, -OC(O)Rz', -C(O)Rz' or-C(O)ORz', ~ C~_6-alkyl, Cz_6-alkenyl or Cz_6-alkynyl, which may optionally be substituted with one or more substituents selected from halogen, -CN, -CF3, -OCF3, -NOz, -ORz', -NRz'Rzz and C~_s-alkyl, ~ C3_8-cycloalkyl, C4_$-cycloalkenyl, heterocyclyl, C3_$-cycloalkyl-C~_6-alkyl, C~_$-cyclo-2o alkyl-C~_6-alkoxy, C3_8-cycloalkyloxy, C3_a-cycloalkyl-C~_6-alkylthio, C3_a-cycloalkylthio, C3_a-cycloalkyl-Cz_6-alkenyl, C3_a-cycloalkyl-Cz_6-alkynyl, C~_8-cycloalkenyl-C~_6-alkyl, C4_$-cycloalkenyl-C~_6-alkenyl, C4_$-cycloalkenyl-C2_6-alkynyl, heterocyclyl-C~_6-alkyl, heterocyclyl-C~_6-alkenyl, heterocyclyl-C2_6-alkynyl, aryl, aryloxy, aryloxycarbonyl, aroyl, aryl-C~_6-alkoxy, aryl-C~_6-alkyl, aryl-C2_6-alkenyl, aryl-Cz_6-alkynyl, heteroaryl, heteroaryl-C~_6-alkyl, heteroaryl-C~_6-aikenyl or heteroaryl-C~_6-alkynyl, of which the cyclic moieties optionally may be substituted with one or more sub-stituents selected from halogen, -C(O)OR2', -CN, -CF3, -OCF3, -N02, -OR2,, -NR2'R22 and C~_6-alkyl, wherein R2' and R22 independently are hydrogen, C~_6-alkyl, aryl-C~_s-alkyl or aryl, or R2' and R22 when attached to the same nitrogen atom together with the said nitrogen atom may form a 3 to 8 membered heterocyclic ring optionally containing one or two further heteroatoms selected from nitrogen, oxygen and sulfur, and optionally containing one or two double bonds, or two of the groups R'S to R'$ when placed in adjacent positions together may form a bridge -(CR~3R~4)a O_(CR25R26)~ O-, 2o wherein a is 0, 1 or 2, c is 1 or 2, Ras, R24, R2s and R26 independently are hydrogen, C~_6-alkyl or fluorine, R'9 and R2° independently are hydrogen, C~_6-alkyl, C3_$-cycloalkyl or C3_$-cyclo-alkyl-C~_6-alkyl, E is Rz8 Rao Rao Rao Rz~ ~ Rzs ~ Ray Rzs ~ Ray Rzs ~ as ' R
/ / /
Hz ( ~ Hz )z Rzs Ra° Rao Rao Rz~ ~ Rzs ~ Rai Rzs ~ Ray i W i W
Rza ' Rz~ ' CHz . ( i Hz )z ' Rze Rz7 H C CH H C CH C~_s alkyl~C~_s alkyl n a a a as or Rz~ Rza ' Rz~ Rzs i Hz /CHz wherein R2' and Rz$ independently are hydrogen, halogen, -CN, -CF3, -OR32, -NR3~R33, C~_6-alkyl, C3_a-cycloalkyl, C4_8-cycloalkenyl or aryl, wherein the aryl group optionally may be substituted with one or more substituents selected from halogen, -CN, -CF3, -N02, -OR32, -NR3~R33 and C,_6-alkyl, wherein R3z and R33 independently are hydrogen or C,_6-alkyl, or R3z and R33 when attached to the same nitrogen atom together with the said nitrogen atom may form a 3 to 8 membered heterocyclic ring optionally containing one or two further heteroatoms selected from nitrogen, oxygen and sulfur, and optionally containing one or two double bonds, R~9, R3° and R3' independently are ~ hydrogen, halogen, -CHF2, -CF3, -OCF3, -OCHF2, -OCHzCF3, -OCF~CHF~, -SCF3, -OR34' -NR34R35~ -SR34~ -S~O~R34~ -5~~~2R34~ -C,O'NR34R35' -OC~O)NR34R35~
-NR34C(O)R35, -OCH~C(O)NR34R35, -C(O)R34 or _C(O)OR34, ~ C,_s-alkyl, CZ_6-alkenyl or C2_6-alkynyl, which may optionally be substituted with one or more substituents selected from halogen, -CN, -CF3, -OCF3, -N02, -OR34, -NR34Ras and C~_6-alkyl, ~ C3_$-cycloalkyl, C4_$-cycloalkenyl, heterocyclyl, C3_$-cycloalkyl-C~_6-alkyl, C3_8-cyclo-alkyl-C~_6-alkenyl, C3_$-cycloalkyl-C2_6-alkynyl, C4_$-cycloalkenyl-C~_6-alkyl, C4_8-cyclo-alkenyl-C2_6-alkenyl, C4_$-cycloalkenyl-C~_6-alkynyl, heterocyclyl-C~_6-alkyl, heterocy-clyl-C2_6-alkenyl, heterocyclyl-C2_6-alkynyl, aryl, aryloxy, aroyl, aryl-C~_s-alkoxy, aryl-C~_6-alkyl, aryl-C~_6-alkenyl, aryl-C~_6-alkynyl, heteroaryl, heteroaryl-C~_6-alkyl, hetero-aryl-C2_6-alkenyl or heteroaryl-Cz_6-alkynyl, of which the cyclic moieties optionally may be substituted with one or more sub-stituents selected from halogen, -CN, -CF3, -OCF3, -N02, -OR34, -NR3~R35 and C~_6-alkyl, wherein R34 and R35 independently are hydrogen, C~_6-alkyl or aryl, or R34 and R35 when attached to the same nitrogen atom together with the said nitrogen atom may form a 3 to 8 membered heterocyclic ring optionally containing one or two further heteroatoms selected from nitrogen, oxygen and sulfur, and optionally containing one or two double bonds, 3o or two of the groups Rz9, R3° and R3' when attached to the same ring carbon atom or differ-ent ring carbon atoms together may form a radical -O-(CH2)t-CR36R3'-(CH2)~-O-, -(CH2)t-CR36Rs~-~CH2O or -S-(CHa)t-CR36Ra~-~CH2)nS-, wherein t and I independently are 0, 1, 2, 3, 4 or 5, R35 and R3' independently are hydrogen or C1_6-alkyl, as well as any optical or geometric isomer or tautomeric form thereof including mixtures of these or a pharmaceutically acceptable salt thereof.
In another aspect, the invention is concerned with compounds of the general formula (I') 1 /\R/\3/ \ ~ iXw RO A N Z N D (I) wherein R1, R~, R3, R4 and R5 independently are hydrogen or C1_6-alkyl, A is -C(O)-, -CH(OR6)- or -CHF-, 2o wherein R6 is hydrogen or C~_6-alkyl, Z is arylene or a divalent radical derived from a 5 or 6 membered heteroaromatic ring con-taining 1 or 2 heteroatoms selected from nitrogen, oxygen and sulfur, which may optionally be substituted with one or two groups R' and R$ selected from halogen, -CN, -CF3, -OCF3, -N02, -OR9, -NR9R1° and C1_6-alkyl, wherein R9 and R1° independently are hydrogen or C1_6-alkyl, X is O
(CH~)q (CR12R13)~ (CH~)S , -LL-(CR12R13)( (CH~)S
O O
-i~ (CH~)q H=H-(CR12R1a)~ (CH2)S , -)l--(CH2)q N1~ (CR12R13)~ (CH2)S
R
J.I-(CH2)q N-(CR12R13)~ (CH~)S O- , -11-(CHZ)q N-~l--(CR12R13)~ (CH~)S

-~l-(CHz)q N-ll-N-(CR12R1s)' (CHZ)S . -~(CH2)q N-~l-p-(CR1aR13)~ (CH2)S

O O

-N--~-(CR R )r (CH2)S or -~-(CH2)q (CR'2R13)r O-(CH2)s wherein ris0or1, q and s independently are 0, 1, 2 or 3, R11, R'~, R13 and R14 independently are hydrogen, C1_6-alkyl or C3_8-cycloalkyl, D is R~5 R1s R1~ R16 R1s O
~Rls ~ -~Rls ~ N~RIs J s / ~ . / s R'~ 16 R'8 N R'~ 15 R R O

/ R I / R1s ' ~S I / R1s r O ( / R1s 1s N
Ri6 R15 15 H R15 p S R
/~~Rls I R1s I ' /~~-R1s or ~ , R15 N~R1s R1s O
R1s Rzo R~5 O
wherein R'S, R'6, R" and R'$ independently are ~ hydrogen, halogen, -CN, -CHzCN, -CHFz, -CF3, -OCF3, -OCHFz, -OCH2CF3, -OCF2CHFz, -S(O)zCF3, -SCF3, -NOz, -ORz~, -NRz~R2z, -SRz', -NRz'S(O)zRz2 -S(O)2~1R2~Rz2 -S(O)NRz~R2a~ -S(O)Ra~ _S(O)zRz~ -C(O)NRz~R2z~ -OC(O)NRz'Rzz -NRz'C(O)Rzz, -CHzC(O)NRz'Rzz, -OCH2C(O)NRz'Rzz, -CHzORz~, -CHZNRz~Rzz, -OC(O)Rz', -C(O)Rz' or -C(O)ORz~, ~ C~_6-alkyl, Cz_s-alkenyl or Cz_6-alkynyl, which may optionally be substituted with one or more substituents selected from halogen, -CN, -CF3, -OCF3, -NOz, -ORz', -NRz'Rzz and C~_s-alkyl, ~ C3_$-cycloalkyl, Ca_a-cycloalkenyl, heterocyclyl, C3_$-cycloalkyl-C,_6-alkyl, C3_a-cyclo-alky4-C~_6-alkoxy, C3_$-cycloalkyloxy, C3_$-cycloalkyl-C~_6-alkylthio, C3_8-cycloalkylthio, C3_$-cycloalkyl-C2_s-alkenyl, C3_8-cycloalkyl-C2_6-alkynyl, C4_$-cycloalkenyl-C~_6-alkyl, C4_$-cycloalkenyl-Cz_6-alkenyl, C4_8-cycloalkenyl-C~_6-alkynyl, heterocyclyl-C~_6-alkyl, heterocyclyl-CZ_6-alkenyl, heterocyclyl-CZ_6-alkynyl, aryl, aryloxy, aryloxycarbonyl, aroyl, aryl-C~_6-alkoxy, aryl-C~_s-alkyl, aryl-C2_s-alkenyl, aryl-C2_6-alkynyl, heteroaryl, 5 heteroaryl-C~_6-alkyl, heteroaryl-C~_6-alkenyl or heteroaryl-C2~-alkynyl, of which the cyclic moieties optionally may be substituted with one or more sub-stituents selected from halogen, -C(O)OR2', -CN, -CF3, -OCF3, -N02, -OR2', -NR2'R22 and C~_6-alkyl, wherein Rz' and R~Z independently are hydrogen, C~_6-alkyl, aryl-C~_6-alkyl or aryl, or RZ' and R~2 when attached to the same nitrogen atom together with the said nitrogen atom may form a 3 to 8 membered heterocyclic ring optionally containing one or two further heteroatoms selected from nitrogen, oxygen and sulfur, and optionally containing one or two double bonds, or two of the groups R'5 to R'$ when placed in adjacent positions together may form a bridge -(CRz3R24)a-O-(CR25R26)C ~-' wherein a is 0, 1 or 2, c is 1 or 2, Rzs, Rza, R2s and R~6 independently are hydrogen, C~_6-alkyl or fluorine, R~9 and RZ° independently are hydrogen, C~_6-alkyl, C3_8-cycloalkyl or C3_$-cyclo-alkyl-C~_6-alkyl, E is Rza Rso R3o Rso Rv / Rzs ~ R31 Rzs ~ R3~ Rzs ~ Rat / , ~ /
Hz (CHz )z Rzs R3° R3° 30 Rz~ ~~ Rzs / Rat Rzs / R31 / ~ /
Rza , ' Rz~ ' ~ Hz ~ ( ~ Hz )z Rze Rz~ H C CH H C CH C~_s alkyl' 'Ci_s alkyl or Rz~ Rza ' Rz~ Rza ~Hz ,CHz wherein R~' and R28 independently are hydrogen, halogen, -CN, -CF3, -OR32, -NR32Rss, C~-6_alkyl, C3_$-cycloalkyl, C4_8-cycloalkenyl or aryl, wherein the aryl group optionally may be substituted with one or more substituents selected from halogen, -CN, -CF3, -NOZ, -OR32, -NR32Rss and C~_6-alkyl, wherein R3~ and R33 independently are hydrogen or C~_6-alkyl, or R32 and R33 when attached to the same nitrogen atom together with the said nitrogen atom may form a 3 to ~ membered heterocyclic ring optionally containing one or two further heteroatoms selected from nitrogen, oxygen and sulfur, and optionally containing one or two double bonds, R~9, R3° and R3' independently are ~ hydrogen, halogen, -CHF~, -CF3, -OCF3, -OCHF~, -OCH2CF3, -OCF~CHF2, -SCF3, -OR34~ -NR34R35~ -SR34' -S~O~R34~ -S~~~2R34~ -C/O'NR34R35' -OC~O~NR34R3s~
-NR34C(O)R35, -OCHzC(O)\NR134R35, -'C(O)R34 Or'-C(O)OR34, ~ C~_6-alkyl, C2_6-alkenyl or C2_6-alkynyl, which may optionally be substituted with one or more substituents selected from 1o halogen, -CN, -CF3, -OCF3, -NO2, -OR34, -NR34R3e and C~_6-alkyl, ~ C3_8-cycloalkyl, C4_8-cycloalkenyl, heterocyclyl, C3_8-cycloalkyl-C~_6-alkyl, C3_$-cyclo-alkyl-C2_6-alkenyl, C3_8-cycloalkyl-C~_6-alkynyl, C4_$-cycloalkenyl-C~_6-alkyl, C4_$-cyclo-alkenyl-C~_6-alkenyl, C4_$-cycloalkenyl-C2_6-alkynyl, heterocyclyl-C~_6-alkyl, heterocy-clyl-C~_6-alkenyl, heterocyclyl-C2_6-alkynyl, aryl, aryloxy, aroyl, aryl-C~_6-alkoxy, aryl-C~_6-alkyl, aryl-Cz_6-alkenyl, aryl-C~_6-alkynyl, heteroaryl, heteroaryl-C,_6-alkyl, hetero-aryl-C2_6-alkenyl or heteroaryl-C2_6-alkynyl, of which the cyclic moieties optionally may be substituted with one or more sub-2o stituents selected from halogen, -CN, -CF3, -OCF3, -N02, -OR34, -NR34R3s and C1_6-alkyl, wherein R34 and R35 independently are hydrogen, C~_6-alkyl or aryl, or R34 and R35 when attached to the same nitrogen atom together with the said nitrogen atom may form a 3 to 8 membered heterocyclic ring optionally containing one or two further heteroatoms selected from nitrogen, oxygen and sulfur, and optionally containing one or two double bonds, or two of the groups R29, R3° and R3' when attached to the same ring carbon atom or differ-ent ring carbon atoms together may form a radical -O-(CH2)t-CR36R3'-(CHI),-O-, -(CH2)rCR36R3~-~CL.IzO- or -S-(CH~)rCR36Rs'-(CH2)i-S-wherein t and I independently are 0, 1, 2, 3, 4 or 5, R36 and R3' independently are hydrogen or C~_6-alkyl, as well as any optical or geometric isomer ar tautomeric form thereof including mixtures of these or a pharmaceutically acceptable salt thereof.
In another aspect, the invention is concerned with compounds of the general formula (I"):

~ ~R~R3~
RO A N Z N D C ) wherein R', R2, R3, R4 and R5 independently are hydrogen or C~_6-alkyl, A is -C(O)-, -CH(OR6)- or -CHF-, wherein R6 is hydrogen, C,_6-alkyl or halogen, Z is arylene or a divalent radical derived from a 5 or 6 membered heteroaromatic ring con-taining 1 or 2 heteroatoms selected from nitrogen, oxygen and sulfur, which may optionally be substituted with one or two groups R' and Ra selected from halogen, -CN, -CF3, -OCF3, -NO~, -OR9, -NR9R'° and C~_6-alkyl, wherein R9 and R'° independently are hydrogen or C~_6-alkyl, X is O
-(CH2)q (CR12R~~)~ (CH2)S , ~L(CR~2R13)~ (CH2)S , O O
~(CH~)q H=H-(CRI~RIa)~ (CH2)S , --L~(CH2)q N11 (CR12R1s)~ (CHZ)S
R
-LI-(CHz)q IV-(CR12R1a)~ (CH2)S O- , --LI-(CH2)q N-~1-(CR12R1s)( (CH2)S

-1L-(CH2)q N-11-N-(CR12R1s)~ (CH2)S , -LI-(CHZ)q N-11-O-(CRI~RIS)( (CHZ)S

O O
-N--IL(CR'2Rls)~ (CHz)~ or -1l-(CHZ)q (CR1'R13)~ O_(CH2)S

wherein ris0or1, q and s independently are 0, 1, 2 or 3, R11, R1~, R13 and R14 independently are hydrogen or C1_6-alkyl, D is R15 R,s Rn R,5 R,s O
~R,s ~ -~\~R,s r ~ ~,R19 v\Ri~ ' ,5 / R' N R17 15 ~ 7 R R O
R15 R15 R,5 R,5 /R I/R,s ' ~NI/R,s ' O'/R,s R,s R,s ,5 H R,5 O
g R
/~~R,s I R,s I /S~R,s or Cue' , ~ , R, 5 ~Rj9 R1s O
R'9 Rzo 5 wherein R15, R's, R" and R~$ independently are ~ hydrogen, halogen, -CN, -CH2CN, -CHFz, -CF3, -OCF3, -OCHFz, -OCHzCF3, 10 -OCF2CHFz, -OS(O)zCF3, -SCF3, -NOz, -ORz', -NRz~R2z, -SRz', -NRz'S(O)zRzz, -S(O)zNRz~Rzz~ _S(O)NR21R22~ -S(O~Rz~ -S(O)zRz~' -OS(O)zRz~~ -C(O)NRz~Rzz -OC(O)NRz~Rzz, -NRz'C(O)Rzz, -CH2C(O)NRz'Rzz, -OCH2C(O)NRz'Rzz, -CH20Rz', -CH2NRz~(~zz, -OC(O)Rz~, -C(O)R2~ or-C(O)ORz', 15 ~ C~_s-alkyl, Cz_s-alkenyl or Cz_s-alkynyl, which may optionally be substituted with one or more substituents selected from halogen, -CN, -CF3, -OCF3, -NOz, -ORz', -NRz'Rzz and C~_s-alkyl, ~ C3_8-cycloalkyl, C4_$-cycloalkenyl, heterocyclyl, C3_$-cycloalkyl-C,_s-alkyl, C3_$-cyclo-alkyl-C~_s-alkoxy, C3_$-cycloalkyloxy, C3_8-cycloalkyl-C,_s-alkylthio, C3_$-cycloalkylthio, C3_a-cycloalkyl-C2_6-alkenyl, C3_a-cycloalkyl-CZ_6-alkynyl, C4_8-cycloalkenyl-C1_6-alkyl, C4_$-cycloalkenyl-CZ_6-alkenyl, C4_$-cycloalkenyl-CZ_6-alkynyl, heterocyclyl-C,_6-alkyl, heterocyclyl-C2_6-alkenyl, heterocyclyl-C2_6-alkynyl, aryl, aryloxy, aryloxycarbonyl, aroyl, aryl-C~_6-alkoxy, aryl-C~_6-alkyl, aryl-Cz_6-afkenyl, aryl-C~_6-alkynyl, heteroaryl, heteroaryl-C~_6-alkyl, heteroaryl-C~_6-alkenyl or heteroaryl-C2_6-alkynyl, of which the cyclic moieties optionally may be substituted with one or more sub stituents selected from halogen, -CN, -CF3, -OCF3, -NO2, -OR2', -NR~'R~2 and C~_6-alkyl, wherein R2' and R22 independently are hydrogen, C~_6-alkyl or aryl, or R2' and R~2 when attached to the same nitrogen atom together with the said nitrogen atom may form a 3 to 8 membered heterocyclic ring optionally containing one or two further heteroatoms selected from nitrogen, oxygen and sulfur, and optionally containing one or two double bonds, or two of the groups R'5 to R'8 when placed in adjacent positions together may form a bridge -(CR23R2a~a ~_~CR25R2s~~ 0-wherein a is 0, 1 or 2, c is 1 or 2, R23, R24, R25 and R26 independently are hydrogen, C~_6-alkyl or fluorine, R'9 and RZ° independently are hydrogen, C,_6-alkyl, C3_8-cycloalkyl or C3_$-cyclo-3o alkyl-C,_6-alkyl, E is Rze Rao R3o Rso Rz~ / Rzs ~ R3~ Rzs ~ R3~ Rzs ~ R31 H2 ~2 Rzs R3o Rao Rso Rz~ ~~ Rzs ~ Ray Rzs ~ Rs~
i ~ i Rzs ' Rz~ ' ~ Nz °r ~ i Hz ~z wherein R~' and R28 independently are hydrogen, halogen, -CN, -CF3, -OR32, -NR3~R33, C~_s-alkyl, C3_$-cycloalkyl, C~8-cycloalkenyl or aryl, wherein the aryl group optionally may be substituted with one or more substituents selected from halogen, -CN, -CF3, -NOa, -OR3~, -NR32Rsa and C~_6-alkyl, wherein R32 and R33 independently are hydrogen or C~_6-alkyl, or R32 and R33 when attached to the same nitrogen atom together with the said nitrogen atom may form a 3 to 8 membered heterocyclic ring optionally containing one or two further heteroatoms selected from nitrogen, oxygen and sulfur, and optionally containing one or two double bonds, R29, R3° and R3' independently are ~ hydrogen, -CHF2, -CF3, -OCF3, -OCHF2, -OCHZCF3, -OCF2CHF~, -SCF3, -OR34, -NR34R35 -SR34~ -S~~~R34~ -S~y2R34~ -C~O~NR34R35~ -OC~O~NR34Rss~ -NR34C~O~R35~
-OCH2C(O)NR34R35', -,C(O)R34 or -C(O)OR34, ~ C~_6-alkyl, C2_6-alkenyl or C~_6-alkynyl, which may optionally be substituted with one or more substituents selected from halogen, -CN, -CF3, -OCF3, -NO~, -OR34, -NR34Ras and C~_6-alkyl, ~ C3_8-cycloalkyl, C4_$-cycloalkenyl, heterocyclyl, C3_8-cycloalkyl-C~_6-alkyl, C3_$-cyclo-alkyl-CZ_6-alkenyl, C3_8-cycloalkyl-C2_6-alkynyl, C4_a-cycloalkenyl-C~_6-alkyl, C4_a-cyclo-alkenyl-CZ_6-alkenyl, C4_8-cycloalkenyl-C~_6-alkynyl, heterocyclyl-C~_6-alkyl, heterocy-clyl-C2_6-alkenyl, heterocyclyl-CZ_6-alkynyl, aryl, aryloxy, aroyl, aryl-C~_6-alkoxy, aryl-C~_ 6-alkyl, aryl-C2_6-alkenyl, aryl-C2_6-alkynyl, heteroaryl, heteroaryl-C,_6-alkyl, heteroaryl-C2_6-alkenyl or heteroaryl-C2_6-alkynyl, of which the cyclic moieties optionally may be substituted with one or more sub stituents selected from halogen, -CN, -CF3, -OCF3, -N02, -OR34, -NR34Rss and C~_6-alkyl, wherein R34 and R35 independently are hydrogen, C~_6-alkyl or aryl, or R34 and R35 when attached to the same nitrogen atom together with the said 2o nitrogen atom may form a 3 to 8 membered heterocyclic ring optionally containing one or two further heteroatoms selected from nitrogen, oxygen and sulfur, and optionally containing one or two double bonds, or two of the groups R29, R3° and R3' when attached to the same ring carbon atom or differ-ent ring carbon atoms together may form a radical -O-(CH~)t-CR36R3'-(CH2),-O-, -(CH~)t-CR36Rs~-~CH2)i- or -S-(CHa)rCR36Rs~-~CH2OS-wherein t and I independently are 0, 1, 2, 3, 4 or 5, R36 and R3' independently are hydrogen or C~_6-alkyl, as well as any optical or geometric isomer or tautomeric form thereof including mixtures of these or a pharmaceutically acceptable salt thereof.

In one embodiment, R', R2, R3, R4 and R5 are hydrogen.
In one embodiment, A is -CHF-In another embodiment, A is -CH(OR6)-, wherein R~ is as defined for formula (I), such as -CH(OH)-.
1o In one embodiment, Z is wherein R' and R$ are as defined for formula (I), such as In one embodiment, X is O O O
~(CH2)S , ~H=H- , ~(CH2)q H-(CH2)S
O O O
-~-(GH2)q H-ll-(CHZ)S ~ -~(CH2)q H-(CH2)S O- , O O O
-(CH2)S , -~-(GH2)q H-~l--O-(CH~)S , H-~(CH2)s O O
~(CR~~H)r O-(CH~)S , ~O-(CH2)S or O
~H-(CR~2R~3)~
5 wherein q is 0 or 1, r is 0 or 1, s is 0, 1 or 2, and R'2 and R'3 independently are hydrogen or C~_6-alkyl.
In another embodiment, X is -C(O)NH-, -C(O)NHCH2-, -C(O)NHCH(CH3)-, -C(O)NHC(CH3)~-, -C(O)NHCHzCH2-, -C(O)CH2-, -C(O)CH2CH~-, -C(O)CH=CH-, -(CH2)S , -C(O)-, -C(O)O-or 10 -NHC(O)-, wherein s is 0 or 1.
In yet another embodiment, X is -C(O)NH-, -C(O)NHCH2-, -C(O)NHCH(CH3)-, -C(O)NHCH2CH2-, -C(O)CHa-, -C(O)CH=CH-, -(CH2)S , -C(O)-, -C(O)O- or -NHC(O)-, wherein s is 0 or 1.
In still another embodiment, X is -C(O)NH-, -C(O)NHCH2-, -C(O)NHCH(CH3)-, -C(O)NHCH2CH~-, -C(O)CH2-, -CH2-, -C(O)- or -NHC(O)-.
In still a further embodiment, X is -C(O)NH-, -C(O)NHCH2-, -C(O)NHCH(CH3)-, -C(O)CH~- or -C(O)-, such as -C(O)NH-.

In one embodiment, D is R's R~s R~~ Ros R~6 O
Arts ~ S~R~s ' ~ N-R~s Ri~ ~ Rts / R's N / Rts ~ s O
O
R~s O R~5 Rts R~s S
/~~R~s ' /~~R~s or ~ Rzo Rss O
wherein R'S, R's, R", R'a, R'g and R2° are as defined for formula (I).
In another embodiment, D is Ris ~R~s ~''~~~~7Ri~' wherein R'S, R's and R" are as defined for formula (I).
In one embodiment, R'S, R's and R" are independently hydrogen, halogen, -CN, -NO2, -CF3, -OCF3, -SCF3, C~_s-alkyl, C~_s-alkoxy, -S-C,_s-alkyl, -C(O)ORS', -C(O)RZ', -CH20R2', -C(O)NR2'R2z, -S(O)RZ', -S(O)~R2', -S(O)2CF3, -S(O)~NR2'R2z, C3_$-cycloalkyl, C3_8-cycloalkyl-C~_s-alkoxy or C3_8-cycloalkyl-C~_s-thioalkyl, or aryl, heteroaryl or aryloxy, which may optionally be substituted with -CF3, -OCF3, C~_s-alkyl, halogen or -C(O)OR2', or two of the groups R'S, R's and R" when placed in adjacent positions together form a bridge -(CRz3R24)a-O-(CR2sR~s)~ O-wherein R2' and R22 independently are hydrogen or C~_s-alkyl, and a, c, Rz3, R2a, R2s and R2s are as defined for formula (I).

In another embodiment, R'S, R'6 and R" are independently hydrogen, halogen, -CN, -CF3, -OCF3 or C~_6-alkoxy or wherein R'5 and R'6 together form a bridge -CFZ-O-CF2-O- and R" is hydrogen.
In yet another embodiment, R'S, R'6 and R" independently are hydrogen, halogen, -CN, -CF3, -OCF3 or C~~-alkoxy.
In another embodiment, D is R1s O R1s 0 R1s ~ 1s or N-R
/ Rzo /

O
wherein R'S, R'6, R'9 and Ra° are as defined for formula (I).
In yet another embodiment, D is R's O
N-R1s R~Ss O
wherein R'S and R'6 are both hydrogen and R'9 is C~_6-alkyl, C3_8-cycloalkyl or C3_8-cycloalkyl-C~_6-alkyl.
In still another embodiment, D is R's O
R1 s / Rzo R~5 O
wherein R'5 and R'6 are both hydrogen and R'9 and R2° are both C,_6-alkyl.

In one embodiment, E is Rze Rao Rao Rao Rz~ / Rzs ~ Rai Rzs ~ Ray Rzs ~ Raa ~ ~ ~
IHz (IHz)z \ I w i i ~ i i Hz ~r (CHz )z , wherein RZ', RIB, R29, R3° and R3' are as defined for formula (I).
In another embodiment, E is Rze Rz~ i wherein R~' and R28 are as defined for formula (I).
In still another embodiment, E is Rz' Rze wherein R2' and Rz8 are as defined for formula (I).
In one embodiment, R2' and R2$ are independently hydrogen, C,_6-alkyl, C3_$-cycloalkyl, C4_$-cycloalkenyl or phenyl, wherein the phenyl group is optionally substituted as defined for formula (I).

In another embodiment, R2' and R28 are independently hydrogen, C~_6-alkyl, C3_8-cycloalkyl or C4_a-cycloalkenyl.
In still another embodiment, RZ' is hydrogen and R28 is C~_6-alkyl or C3_$-cycloalkyl, such as tent-butyl, cyclohexyl or cyclohexenyl.
In another embodiment, E is Rso Rzs ~ R31 /
wherein R29, R3° and R3' are as defined for formula (I).
In yet another embodiment, E is Rao Rzs ~ Ray wherein R~9, R3° and R3' are as defined for formula (I).
In one embodiment, R29, R3o and R3' are independently ~ hydrogen, -CHF~, -CF3, -OCF3, -OCHF2, -OCH2CF3, -OCF2CHFz, -SCF3, -OR34, -NR34R35' -SR34' -S(~)R34~ -S(~)2R34' -e(O)NR34R35' -~C(O)NR34R35' -NR34C(O)R35' -OCH2C(O)NR34R35, _C(O)R34 or -C(O)OR34, ~ C~_6-alkyl, C2_6-alkenyl or C2_6-alkynyl, which may optionally be substituted with one or more substituents selected from halogen, -CN, -CF3, -OCF3, -NO2, -OR34, -NR34R3s and C~_6-alkyl, ~ C3_$-cycloalkyl or C4_s-cycloalkenyl, which may optionally be substituted with one or more substituents selected from halogen, -CN, -CF3, -OCF3, -N02, -OR34, -NR34Rss and C~_6-alkyl, 5 wherein R3~ and R35 independently are hydrogen, C~_6-alkyl or aryl, or R34 and R35 when attached to the same nitrogen atom together with the said nitrogen atom may form a 3 to 8 membered heterocyclic ring optionally containing one or two further heteroatoms selected from nitrogen, oxygen and sulfur, and 10 optionally containing one or two double bonds.
In yet another embodiment, R29, R3° and R3' are independently hydrogen, C~_o-alkoxy, halogen, -CF3, -OCF3 or -NR34Rss, wherein R34 and R35 are as defined 15 for formula (I), or C~_6-alkyl, C3_$-cycloalkyl or C4_8-cycloalkenyl, which are optionally substituted as defined for formula (I).
20 In still another embodiment, R29, R3° and R3' are independently hydrogen or C~_6-alkyl, C3_$-cycloalkyl or C4_$-cycloalkenyl, which are optionally substituted as defined for 25 formula (1).
In yet another embodiment, R29, Rso and R3' are independently hydrogen or C~_6-alkyl, C3_$-cycloalkyl or C4_$-cycloalkenyl, ~ which may optionally be substituted with one or more substituents selected from halogen, -CN, -CF3, -OCF3, -NOZ, -OR34, -NR34Rss and C~_6-alkyl, ~ wherein R34 and R35 independently are hydrogen, C~_6-alkyl or aryl, ~ or R34 and R35 when attached to the same nitrogen atom together with the said nitro-gen atom may form a 3 to 8 membered heterocyclic ring optionally containing one or two further heteroatoms selected from nitrogen, oxygen and sulfur, and optionally containing one or two double bonds.
In another embodiment, R29 and R3' are both hydrogen, and R3° is different from hydrogen.
In still another embodiment, R29 and R3' are both hydrogen, and R3° is C3_$-cycloalkyl or 1 o C4_$-cycloalkenyl, ~ which may optionally be substituted with one or more substituents selected from halogen, -CN, -CF3, -OCF3, -NO2, -OR34, -NR34Rss and C~_6-alkyl, ~ wherein R~ and R35 independently are hydrogen, C~_6-alkyl or aryl, ~ or R34 and R35 when attached to the same nitrogen atom together with the said nitro-gen atom may form a 3 to 8 membered heterocyclic ring optionally containing one or two further heteroatoms selected from nitrogen, oxygen and sulfur, and optionally containing one or two double bonds.
In yet a further embodiment, Rz9 and R3' are both hydrogen, and R3° is C4_$-cycloalkenyl, ~ which may optionally be substituted with one or more substituents selected from halogen, -CN, -CF3, -OCF~, -NO2, -OR34, -NR34Ras and C~_6-alkyl, ~ wherein R34 and R35 independently are hydrogen, C~_6-alkyl or aryl, ~ or R34 and R35 when attached to the same nitrogen atom together with the said nitro-gen atom may form a 3 to 8 membered heterocyclic ring optionally containing one or two further heteroatoms selected from nitrogen, oxygen and sulfur, and optionally containing one or two double bonds.
In still a further embodiment R29 and R3' are both hydrogen, and R3° is cyclohexenyl, ~ which may optionally be substituted with one or more substituents selected from halogen, -CN, -CF3, -OCF3, -N02, -OR3~, -NR34Rss and C~_6-alkyl, ~ wherein R34 and R35 independently are hydrogen, C1_6-alkyl or aryl, ~ or R34 and R35 when attached to the same nitrogen atom together with the said nitro-gen atom may form a 3 to 8 membered heterocyclic ring optionally containing one or two further heteroatoms selected from nitrogen, oxygen and sulfur, and optionally containing one or two double bonds.
In another embodiment, R3° is substituted with one C1_6-alkyl substituent, such as tart-butyl or methyl.
In still another embodiment, Rz9, R3° and R31 are independently hydrogen, C1_6-alkyl, C3_$-cycloalkyl or C4_$-cycloalkenyl.
In yet another embodiment, Rz9 and R31 are both hydrogen and R3° is C1_6-alkyl, C3_$-cycloalkyl or C4_8-cycloalkenyl, such as tart-butyl, cyclohexyl or cyclohexenyl.
In one embodiment, the invention relates to a compound of the general formula (11):
O Rz Rs R10 ~ wN (11) wherein R1, Rz, R3, R4, R5, R6, R', Ra, X, D and E are as defined for formula (I) or in any one of the preceding embodiments.
In one embodiment, the invention relates to a compound of the general formula (1z):
O Rz Rs R O OR6 R N N ~Iz) ~D
O
wherein R1, R2, R3, R4, R5, R6, R', R8, D and E are as defined for formula (I) or in any one of the preceding embodiments.
In one embodiment, the invention relates to a compound of the general formula (13):
R29 Rso O RZ R3 O R~ ~ ~ ~ Rs1 R O 6 N4 ~ 7~ H R1s OR R / N N (Is) R' 5 I R16 R O
R1~
wherein R1, R2, R3, R4, R5, R6, R', R8, R15, Rls, R17, R2s, Rso~ and R31 are as defined for for-mula (I) or in any one of the preceding embodiments.
1o In one embodiment of the formulae (11), (I~) and (13), R1, R2, R3, R4, R5, R6, R' and R$ are hydrogen.
In one embodiment, the invention relates to a compound of the general formula (14):

F ~X~D
wherein R1, R2, R3, R4, R5, R', Rs, X, D and E are as defined for formula (I) or in any one of the preceding embodiments.

In one embodiment, the invention relates to a compound of the general formula (15):
O Rz Rs ~D
O
wherein R', R2, R3, R4, R5, R', R8, D and E are as defined for formula (I) or in any one of the preceding embodiments.
In one embodiment of the formulae (14) and (15), R', R2, R3, R4, R5, R' and R$
are hydrogen.
The compounds of the present invention may have one or more asymmetric centres and it is intended that any optical isomers, as separated, pure or partially purified optical isomers or racemic mixtures thereof are included within the scope of the invention.
Furthermore, when a double bond or a fully or partially saturated ring system is present in the molecule geometric isomers may be formed. It is intended that any geometric isomers, as separated, pure or partially purified geometric isomers or mixtures thereof are included within the scope of the invention. Likewise, molecules having a bond with restricted rotation may form geometric isomers. These are also intended to be included within the scope of the present invention.
~o Furthermore, some of the compounds of the present invention may exist in different tauto-meric forms and it is intended that any tautomeric forms that the compounds are able to form are included within the scope of the present invention.
The present invention also encompasses pharmaceutically acceptable salts of the present compounds. Such salts include pharmaceutically acceptable acid addition salts, pharma-ceutically acceptable metal salts, ammonium and alkylated ammonium salts. Acid addition salts include salts of inorganic acids as well as organic acids.
Representative examples of suitable inorganic acids include hydrochloric, hydrobromic, hydroiodic, phosphoric, sulfuric, nitric acids and the like. Representative examples of suitable organic acids include formic, acetic, trichloroacetic, trifluoroacetic, propionic, benzoic, cinnamic, citric, fumaric, glycolic, lactic, malefic, malic, malonic, mandelic, oxalic, picric, pyruvic, salicylic, succinic, methane-sulfonic, ethanesulfonic, tartaric, ascorbic, pamoic, bismethylene salicylic, ethanedisulfonic, gluconic, citraconic, aspartic, stearic, palmitic, EDTA, glycolic, p-aminobenzoic, glutamic, benzenesulfonic, p-toluenesulfonic acids and the like. Further examples of pharmaceutically acceptable inorganic or organic acid addition salts include the pharmaceutically acceptable 5 salts listed in J. Pharm. Sci. 1977, 66, 2, which is incorporated herein by reference.
Examples of metal salts include lithium, sodium, potassium, magnesium salts and the like.
Examples of ammonium and alkylated ammonium salts include ammonium, methyl-, dimethyl-, trimethyl-, ethyl-, hydroxyethyl-, diethyl-, n-butyl-, sec-butyl-, tert-butyl-, tetramethylammonium salts and the like.
Also intended as pharmaceutically acceptable acid addition salts are the hydrates, which the present compounds, are able to form.
Furthermore, the pharmaceutically acceptable salts comprise basic amino acid salts such as lysine, arginine and ornithine.
The acid addition salts may be obtained as the direct products of compound synthesis. In the alternative, the free base may be dissolved in a suitable solvent containing the appropriate acid, and the salt isolated by evaporating the solvent or otherwise separating the salt and solvent.
The compounds of the present invention may form solvates with standard low molecular weight solvents using methods well known to the person skilled in the art.
Such solvates are also contemplated as being within the scope of the present invention.
The invention also encompasses prodrugs of the present compounds, which on administra-tion undergo chemical conversion by metabolic processes before becoming pharmacologi-cally active substances. In general, such prodrugs will be functional derivatives of the com-pounds of the general formula (I), which are readily convertible in vivo into the required com-3o pound of the formula (I). Conventional procedures for the selection and preparation of suit-able prodrug derivatives are described, for example, in "Design of Prodrugs", ed. H. Bund-gaard, Elsevier, 1985.
The invention also encompasses active metabolites of the present compounds.

The compounds according to the present invention act to antagonize the action of glucagon and are accordingly useful for the treatment and/or prevention of disorders and diseases in which such an antagonism is beneficial.
Accordingly, the present compounds may be applicable for the treatment and/or prevention of hyperglycemia, IGT (impaired glucose tolerance), insulin resistance syndromes, syndrome X, Type 1 diabetes, Type 2 diabetes, hyperlipidemia, dyslipidemia, hypertriglyceridemia, hyperlipo-proteinemia, hypercholesterolemia, arteriosclerosis including atherosclerosis, glucagonomas, acute pancreatitis, cardiovascular diseases, hypertension, cardiac hypertrophy, gastrointestinal disorders, obesity, diabetes as a consequence of obesity, diabetic dyslipidemia, etc.
Furthermore, they may be applicable as diagnostic agents for identifying patients having a de-fect in the glucagon receptor, as a therapy to increase gastric acid secretions and to reverse intestinal hypomobility due to glucagon administration.
Accordingly, in a further aspect the invention relates to a compound according to the inven-tion for use as a medicament.
The invention also relates to pharmaceutical compositions comprising, as an active ingredi-2o ent, at least one compound according to the invention together with one or more pharmaceu-tically acceptable carriers or excipients.
The pharmaceutical composition is preferably in unit dosage form comprising from about 0.05 mg to about 1000 mg, preferably from about 0.1 mg to about 500 mg and especially preferred from about 0.5 mg to about 200 mg of the compound according to the invention.
Furthermore, the invention relates to the use of a compound according to the invention for the preparation of a pharmaceutical composition for the treatment and/or prevention of a disorder or disease, wherein a glucagon antagonistic action is beneficial.
The invention also relates to a method for the treatment and/or prevention of disorders or diseases, wherein a glucagon antagonistic action is beneficial the method comprising admin-istering to a subject in need thereof an effective amount of a compound according to the in-vention.

In a preferred embodiment of the invention the present compounds are used for the prepara-tion of a medicament for the treatment and/or prevention of any glucagon-mediated conditions and diseases.
In a preferred embodiment of the invention the present compounds are used for the prepara-tion of a medicament for the treatment and/or prevention of hyperglycemia.
In yet a preferred embodiment of the invention the present compounds are used for the preparation of a medicament for lowering blood glucose in a mammal.
In another preferred embodiment of the invention the present compounds are used for the preparation of a pharmaceutical composition for the treatment and/or prevention of IGT.
In still another preferred embodiment of the invention the present compounds are used for the preparation of a pharmaceutical composition for the treatment and/or prevention of Type 2 diabetes.
In yet another preferred embodiment of the invention the present compounds are used for the preparation of a pharmaceutical composition for the delaying or prevention of the pro-gression from IGT to Type 2 diabetes.
In yet another preferred embodiment of the invention the present compounds are used for the preparation of a pharmaceutical composition for the delaying or prevention of the pro-gression from non-insulin requiring Type 2 diabetes to insulin requiring Type 2 diabetes.
In a further preferred embodiment of the invention the present compounds are used for the preparation of a pharmaceutical composition for the treatment and/or prevention of Type 1 diabetes. Such treatment and/or prevention is normally accompanied by insulin therapy.
In a further preferred embodiment of the invention the present compounds are used for the preparation of a pharmaceutical composition for the treatment and/or prevention of obesity.
In yet a further preferred embodiment of the invention the present compounds are used for the preparation of a pharmaceutical composition for the treatment andlor prevention of disor ders of the lipid metabolism, such as dyslipidemia.

In still a further embodiment of the invention the present compounds are used for the prepa-ration of a pharmaceutical composition for the treatment and/or prevention of an appetite regulation or energy expenditure disorder.
In a further aspect of the invention the present compounds are combined with diet and/or ex-ercise.
In yet a further aspect of the invention the present compounds are administered in combina-tion with one or more further active substances in any suitable ratios. Such further active agents may be selected from antidiabetic agents, antihyperlipidemic agents, antiobesity agents, antihypertensive agents and agents for the treatment of complications resulting from or associated with diabetes.
Suitable antidiabetic agents comprise insulin, insulin analogues and derivatives such as those disclosed in EP 792 290 (Novo Nordisk A/S), eg NEB29-tetradecanoyl des (B30) human insulin, EP 214 826 and EP 705 275 (Novo Nordisk A/S), eg AspBZ$ human insulin, US
5,504,188 (Eli Lilly), eg LysB28 ProB~9 human insulin, EP 368 187 (Aventis), eg Lantus, which are all incorporated herein by reference, GLP-1 derivatives such as those disclosed in WO
98/08871 (Novo Nordisk A/S), which is incorporated herein by reference, as well as orally active hypoglycaemic agents.
The orally active hypoglycaemic agents preferably comprise imidazolines, sulphonylureas, biguanides, meglitinides, oxadiazolidinediones, thiazolidinediones, glucosidase inhibitors, glucagon antagonists, GLP-1 agonists, agents acting an the ATP-dependent potassium channel of the a-cells eg potassium channel openers such as those disclosed in WO
97/26265, WO 99/03861 and WO 00/37474 (Novo Nordisk A/S) which are incorporated herein by reference, or nateglinide or potassium channel blockers such as BTS-67582, insulin sensitizers, DPP-IV (dipeptidyl peptidase-IV) inhibitors, PTPase inhibitors, inhibitors of hepatic enzymes involved in stimulation of gluconeogenesis and/or glycogenolysis, glucose uptake modulators, GSK-3 (glycogen synthase kinase-3) inhibitors, compounds modifying the lipid metabolism such as antihyperlipidemic agents and antilipidemic agents, compounds lowering food intake, PPAR (peroxisome proliferator-activated receptor) and RXR (retinoid X
receptor) agonists such as ALRT-268, LG-1268 or LG-1069.

In one embodiment of the invention the present compounds are administered in combination with insulin or an insulin analogue or derivative, such as NEB29-tetradecanoyl des (B30) human insulin, AspB2$ human insulin, Lyss2$ Proe29 human insulin, Lantus, or a mix-preparation comprising one or more of these.
In a further embodiment of the invention the present compounds are administered in com-bination with a sulphonylurea eg tolbutamide, chlorpropamide, tolazamide, glibenclamide, glyburide, glipizide or glicazide.
1o In another embodiment of the invention the present compounds are administered in com-bination with a biguanide eg metformin.
In yet another embodiment of the invention the present compounds are administered in combination with a meglitinide eg repaglinide or nateglinide.
In still another embodiment of the invention the present compounds are administered in combination with a thiazolidinedione insulin sensitizer eg troglitazone, ciglitazone, pioglita-zone, rosiglitazone, isaglitazone, darglitazone, englitazone, CS-011/CI-1037 or T174 or the compounds disclosed in WO 97/41097, WO 97/41119, WO 97/41120, WO 00/41121 and WO 98/45292 (Dr. Reddy's Research Foundation).
In still another embodiment of the invention the present compounds may be administered in combination with an insulin sensitizer such as GI 262570, YM-440, MCC-555, JTT-501, AR-H039242, KRP-297, GW-409544, CRE-16336, AR-H049020, LY510929, MBX-102, CLX-0940, GW-501516 or the compounds disclosed in WO 99/19313, WO 00/50414, WO 00/63191, WO 00/63192, WO 00/63193 (Dr. Reddy's Research Foundation) and W O 00/23425, W O 00/23415, W O 00/23451, W O 00/23445, W O 00/23417, W O
00/23416, WO 00/63153, WO 00/63196, WO 00/63209, WO 00/63190 and WO 00/63189 (Novo Nord-isk A/S).
In a further embodiment of the invention the present compounds are administered in combi-nation with an a-glucosidase inhibitor eg voglibose, emiglitate, miglitol or acarbose.
In another embodiment of the invention the present compounds are administered in combination with an agent acting on the ATP-dependent potassium channel of the (3-cells eg tolbutamide, chlorpropamide, tolazamide, glibenclamide, glyburide, glipizide, glicazide, BTS-67582, repaglinide or nateglinide.
In still another embodiment of the invention the present compounds are administered in 5 combination with an antihyperlipidemic agent or antilipidemic agent eg cholestyramine, colestipol, clofibrate, gemfibrozil, lovastatin, pravastatin, simvastatin, probucol or dextrothy-roxine.
In another aspect of the invention, the present compounds are administered in combination 10 with more than one of the above-mentioned compounds eg in combination with metformin and a sulphonylurea such as glibenclamide or glyburide; a sulphonylurea and acarbose; met-formin and a meglitinide such as repaglinide; acarbose and metformin; a sulfonylurea, met-formin and troglitazone; a sulfonylurea, metformin and pioglitazone; a sulfonylurea, met-formin and an insulin sensitizer such as disclosed in WO 00/63189 or WO
97141097; a me-15 glitinide such as repaglinide, metformin and troglitazone; a meglitinide such as repaglinide, metformin and pioglitazone; a meglitinide such as repaglinide, metformin and an insulin sen-sitizer such as disclosed in WO 00/63189 or WO 97/41097; insulin and a sulfonylurea; insulin and a meglitinide such as repaglinide; insulin and metformin; insulin, metformin and a meglit-inide such as repaglinide; insulin, metformin and a sulfonylurea; insulin and troglitazone; in-2o sulin and pioglitazone; insulin and an insulin sensitizer such as such as disclosed in WO 00/63189 or WO 97/41097; insulin and lovastatin; an insulin analogue or derivative, met-formin and a meglitinide such as repaglinide; an insulin analogue or derivative, metformin and a sulfonylurea; an insulin analogue or derivative and troglitazone; an insulin analogue or derivative and pioglitazone; an insulin analogue or derivative and an insulin sensitizer such 25 as disclosed in WO 00/63189 or WO 97/41097; an insulin analogue or derivative and lovas-tatin; etc.
Furthermore, the compounds according to the invention may be administered in combination with one or more antiobesity agents or appetite regulating agents.
Such agents may be selected from the group consisting of CART (cocaine amphetamine regulated transcript) agonists, NPY (neuropeptide Y) antagonists, MC4 (melanocortin 4) agonists, orexin antagonists, TNF (tumor necrosis factor) modulators, CRF
(corticotropin re-leasing factor) agonists, CRF BP (corticotropin releasing factor binding protein) antagonists, urocortin agonists, (33 adrenergic agonists such as CL-316243, AJ-9677, GW-0604, LY362884, LY377267 or AZ-40140, MSH (melanocyte-stimulating hormone) agonists, MCH
(melanocyte-concentrating hormone) antagonists, CCK (cholecystokinin) agonists, serotonin re-uptake inhibitors such as filuoxetine, seroxat or citalopram, serotonin and noradrenaline re-uptake inhibitors, 5HT (serotonin) agonists, bombesin agonists, galanin antagonists, growth hormone, growth hormone releasing compounds, TRH (thyreotropin releasing hormone) agonists, UCP 2 or 3 (uncoupling protein 2 or 3) modulators, leptin agonists, DA (dopamine) agonists (bromocriptin, doprexin), lipase/amylase inhibitors, PPAR modulators, RXR modula-tors or TR (3 agonists.
1o In one embodiment of the invention the antiobesity agent is leptin.
In another embodiment of the invention the antiobesity agent is dexamphetamine or amphetamine.
In another embodiment of the invention the antiobesity agent is fenfluramine or dexfienfiluramine.
In still another embodiment of the invention the antiobesity agent is sibutramine.
In a further embodiment of the invention the antiobesity agent is orlistat.
In another embodiment of the invention the antiobesity agent is mazindol or phentermine.
Furthermore, the present compounds may be administered in combination with one or more antihypertensive agents. Examples of antihypertensive agents are (3-blockers such as alprenolol, atenolol, timolol, pindolol, propranolol and metoprolol, ACE
(angiotensin converting enzyme) inhibitors such as benazepril, captopril, enalapril, fosinopril, lisinopril, quinapril and ramipril, calcium channel blockers such as nifedipine, felodipine, nicardipine, isradipine, nimodipine, diltiazem and verapamil, and a-blockers such as doxazosin, urapidil, prazosin and terazosin. Further reference can be made to Remington: The Science and 3o Practice of Pharmacy, 19th Edition, Gennaro, Ed., Mack Publishing Co., Easton, PA, 1995.
It should be understood that any suitable combination of the compounds according to the in-vention with diet andlor exercise, one or more of the above-mentioned compounds and op-tionally one or more other active substances are considered to be within the scope of the present invention.

PHARMACEUTICAL COMPOSITIONS
The compounds of the invention may be administered alone or in combination with pharma-ceutically acceptable carriers or excipients, in either single or multiple doses. The pharmaceu-tical compositions according to the invention may be formulated with pharmaceutically ac-ceptable carriers or diluents as well as any other known adjuvants and excipients in accor-dance with conventional techniques such as those disclosed in Remington: The Science and Practice of Pharmacy, 19'" Edition, Gennaro, Ed., Mack Publishing Co., Easton, PA, 1995.
The pharmaceutical compositions may be specifically formulated for administration by any suitable route such as the oral, rectal, nasal, pulmonary, topical (including buccal and sublin-gual), transdermal, intracisternal, intraperitoneal, vaginal and parenteral (including subcuta-neous, intramuscular, intrathecal, intravenous and intradermal) route, the oral route being preferred: It will be appreciated that the preferred route will depend on the general condition and age of the subject to be treated, the nature of the condition to be treated and the active ingredient chosen.
Pharmaceutical compositions for oral administration include solid dosage forms such as cap-sules, tablets, dragees, pills, lozenges, powders and granules. Where appropriate, they can 2o be prepared with coatings such as enteric coatings or they can be formulated so as to pro-vide controlled release of the active ingredient such as sustained or prolonged release according to methods well known in the art.
Liquid dosage forms for oral administration include solutions, emulsions, suspensions, syr-ups and elixirs.
Pharmaceutical compositions for parenteral administration include sterile aqueous and non-aqueous injectable solutions, dispersions, suspensions or emulsions as well as sterile pow-ders to be reconstituted in sterile injectable solutions or dispersions prior to use. Depot in-3o jectable formulations are also contemplated as being within the scope of the present inven-tion.
Other suitable administration forms include suppositories, sprays, ointments, cremes, gels, inhalants, dermal patches, implants etc.

~.3 A typical oral dosage is in the range of from about 0.001 to about 100 mg/kg body weight per day, preferably from about 0.01 to about 50 mg/kg body weight per day, and more preferred from about 0.05 to about 10 mg/kg body weight per day administered in one or more dos-ages such as 1 to 3 dosages. The exact dosage will depend upon the frequency and mode of administration, the sex, age, weight and general condition of the subject treated, the nature and severity of the condition treated and any concomitant diseases to be treated and other factors evident to those skilled in the art.
The formulations may conveniently be presented in unit dosage form by methods known to those skilled in the art. A typical unit dosage form for oral administration one or more times per day such as 1 to 3 times per day may contain from 0.05 to about 1000 mg, preferably from about 0.1 to about 500 mg, and more preferred from about 0.5 mg to about 200 mg.
For parenteral routes such as intravenous, intrathecal, intramuscular and similar administration, typically doses are in the order of about half the dose employed for oral administration.
The compounds of this invention are generally utilized as the free substance or as a pharma-ceutically acceptable salt thereof. One example is a base addition salt of a compound having the utility of a free acid. When a compound of the formula (I) contains a free acid such salts are 2o prepared in a conventional manner by treating a solution or suspension of a free acid of the formula (I) with a chemical equivalent of a pharmaceutically acceptable base.
Representative examples are mentioned above.
For parenteral administration, solutions of the novel compounds of the formula (I) in sterile aqueous solution, aqueous propylene glycol, aqueous vitamin E or sesame or peanut oil may be employed. Such aqueous solutions should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. The aqueous solutions are par-ticularly suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administra-tion. The sterile aqueous media employed are all readily available by standard techniques known to those skilled in the art.
Suitable pharmaceutical carriers include inert solid diluents or fillers, sterile aqueous solution and various organic solvents. Examples of solid carriers are lactose, terra albs, sucrose, cycfodextrin, talc, gelatine, agar, pectin, acacia, magnesium stearate, stearic acid and Power alkyl ethers of cellulose. Examples of liquid carriers are syrup, peanut oil, olive oil, phospho-lipids, fatty acids, fatty acid amines, polyoxyethylene and water. Similarly, the carrier or dilu-ent may include any sustained release material known in the art, such as glyceryl mono-stearate or glyceryl distearate, alone or mixed with a wax. The pharmaceutical compositions formed by combining the novel compounds of the formula (I) and the pharmaceutically accept-s able carriers are then readily administered in a variety of dosage forms suitable for the disclosed routes of administration. The formulations may conveniently be presented in unit dosage form by methods known in the art of pharmacy.
Formulations of the present invention suitable for oral administration may be presented as dis-Crete units such as capsules or tablets, each containing a predetermined.
amount of the active ingredient, and which may include a suitable excipient. Furthermore, the orally available formu-lations may be in the form of a powder or granules, a solution or suspension in an aqueous or non-aqueous liquid, or an oil-in-water or water-in-oil liquid emulsion.
If a solid carrier is used for oral administration, the preparation may be tabletted, placed in a hard gelatine capsule in powder or pellet form or it can be in the form of a troche or lozenge.
The amount of solid carrier will vary widely but will usually be from about 25 mg to about 1 g.
If a liquid carrier is used, the preparation may be in the form of a syrup, emulsion, soft gela-tine capsule or sterile injectable liquid such as an aqueous or non-aqueous liquid suspension or solution.
A typical tablet that may be prepared by conventional tabletting techniques may contain:
Core:
Active compound (as free compound or salt thereof) 5.0 mg Lactosum Ph. Eur. 67.8 mg Cellulose, microcryst. (Avicel)31.4 mg Amberlite~ IRP88* 1.0 mg Magnesii stearas Ph. Eur. q.s.

Coating:

Hydroxypropyl methylcelluloseapprox. 9 mg Mywacett 9-40 T** . approx. 0.9 mg * Polacrillin potassium NF, tablet disintegrant, Rohm and Haas.

** Acylated monoglyceride used as plasticizes for film coating.
If desired, the pharmaceutical composition of the invention may comprise the compound of the formula (I) in combination with further pharmacologically active substances such as those 5 described in the foregoing.
EXAMPLES
The following examples and general procedures refer to intermediate compounds and final products identified in the specification and in the synthesis schemes. The preparation of the 1o compounds of the present invention is described in detail using the following examples, but the chemical reactions described are disclosed in terms of their general applicability to the preparation of the glucagon antagonists of the invention. Occasionally, the reaction may not be applicable as described to each compound included within the disclosed scope of the in-vention. The compounds for which this occurs will be readily recognised by those skilled in 15 the art. In these cases the reactions can be successfully performed by conventional modifica-tions known to those skilled in the art, that is, by appropriate protection of interfering groups, by changing to other conventional reagents, or by routine modification of reaction conditions.
Alternatively, other reactions disclosed herein or otherwise conventional will be applicable to the preparation of the corresponding compounds of the invention. In all preparative methods, 2o all starting materials are known or may easily be prepared from known starting materials. All temperatures are set forth in degrees Celsius and unless otherwise indicated, all parts and percentages are by weight when referring to yields and all parts are by volume when refer-ring to solvents and eluents.
25 Some of the NMR data shown in the following examples are only selected data.
In the examples and pharmacological methods the following terms are intended to have the following meanings:
DCM: dichloromethane DMF: N,N-dimethylformamide DMSO: dimethyl sulphoxide M.p.: melting point TFA: trifluoroacetic acid THF: tetrahydrofuran EDAC: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride HOBt: 1-hydroxybenzotriazole HOAt: 3-hydroxy-3H-[1,2,3]triazolo[4,5-b]pyridine, also denoted 1-hydroxy-7-azabenzotriazole EGTA: ethylene glycol bis([i-aminoethyl ether) N,N,N;N'-tetracetic acid BSA: N,O-bis(trimethylsilyl)acetimidate IBMX: isobutylmethylxanthine HPLC-MS (Method A) The following instrumentation was used:
~ Sciex API 100 Single quadropole mass spectrometer ~ Perkin Elmer Series 200 Quard pump ~ Perkin Elmer Series 200 autosampler ~ Applied Biosystems 785A UV detector ~ Sedex 55 evaporative light scattering detector ~ A Valco column switch with a Valco actuator controlled by timed events from the pump.
The Sciex Sample control software running on a Macintosh PowerPC 7200 computer was used for the instrument control and data acquisition.
The HPLC pump was connected to four eluent reservoirs containing:
A: acetonitrile B: water C: 0.5% TFA in water D: 0.02 M ammonium acetate The requirements for samples are that they contain approximately 500 p,g/mL of the com-pound to be analysed in an acceptable solvent such as methanol, ethanol, acetonitrile, THF, water and mixtures thereof. (High concentrations of strongly eluting solvents will interfere with the chromatography at low acetonitrile concentrations.) The analysis was performed at room temperature by injecting 20 p,L of the sample solution on the column, which was eluted with a gradient of acetonitrile in either 0.05% TFA or 0.002 M ammonium acetate. Depending on the analysis method varying elution conditions were used.
The eluate from the column was passed through a flow splitting T-connector, which passed approximately 20 ~.L/min through approx. 1 m. 75 p fused silica capillary to the API interface of API 100 spectrometer.
The remaining 1.48 mL/min was passed through the UV detector and to the ELS
detector.
During the LC-analysis the detection data were acquired concurrently from the mass spec-trometer, the UV detector and the ELS detector.
The LC conditions, detector settings and mass spectrometer settings used for the different methods are given in the following table.
Column YMC ODS-A 120A s - 5p 3 mm x 50 mm id Gradient5% - 90% acetonitrile in 0.05% TFA linearly during 7.5 min at 1.5 mL/min DetectionUV: 214 nm ELS: 40 C

MS Experiment: Start: 100 amu Stop: 800 amu Step: 0.2 amu Dwell: 0.571 msec Method: Scan 284 times =
9.5 min HPLC-MS (Method B) The following instrumentation was used:
~ Hewlett Packard series 1100 G1312A Bin Pump ~ Hewlett Packard series 1100 Column compartment ~ Hewlett Packard series 1100 G13 15A DAD diode array detector ~ Hewlett Packard series 1100 MSD
The instrument was controlled by HP Chemstation software.
The HPLC pump was connected to two eluent reservoirs containing:
A: 0.01 % TFA in water B: 0.01 % TFA in acetonitrile The analysis was performed at 40 °C by injecting an appropriate volume of the sample (pref-erably 1 p,L) onto the column, which was eluted with a gradient of acetonitrile.
The HPLC conditions, detector settings and mass spectrometer settings used are given in the following table.
Column Waters Xterra MS C-18 X 3 mm id Gradient 10% - 100% acetonitrile lineary during 7.5 min at 1.0 mLlmin DetectionUV: 210 nm (analog output from DAD) MS Ionisation mode: API-ES

Scan 100-1000 amu step 0.1 amu HPLC-MS (Method C) The following instrumentation was used:
~ Hewlett Packard series 1100 G1312A Bin Pump ~ Hewlett Packard series 1100 G13 15A DAD diode array detector ~ Sciex 300 triplequadropole mass spectrometer ~ Gilson 215 micro injector ~ Sedex 55 evaporative light scattering detector Pumps and detectors were controlled by MassChrom 1.1.1 software running on a Macintosh G3 computer. Gilson Unipoint Version 1.90 controls the auto-injector.
The HPLC pump was connected to two eluent reservoirs containing:
A: 0.01 % TFA in water B: 0.01 % TFA in acetonitrile The analysis was performed at room temperature by injecting an appropriate volume of the sample (preferably 1 ~,L) onto the column that was eluted with a gradient of acetonitrile.

The HPLC conditions, detector settings and mass spectrometer settings are given in the fol-lowing table.
Column YMC ODS-A 120 s 5g 3 mm X 50 mm id Gradient 5% - 90% acetonitrile linearly during 7.5 min at 1.5 mL/min Detection210 nm (analog output from DAD) MS Ionisation mode: API-ES

Scan 100-1000 amu step 0.1 amu Preparation of building blocks used in the following examples Buildings block 1: (RS)-Isoserine ethyl ester hydrochloride Dry ethanol (40 mL) was cooled on an ice bath and thionyl chloride (4 mL) was added drop-wise maintaining the temperature below 5 °C. To this cold solution was added (RS)-isoserine (2.5 g, 23.79 mmol) and stirring was continued until a homogeneous solution was obtained.
The ice bath was removed and stirring was continued for 17 hours at room temperature. The solution was concentrated in vacuo to afford 4.0 g (100%) of (RS)-isoserine ethyl ester hy-drochloride as an oil.
'H-NMR (DMSO-ds): ~ 1.22 (t, 3H), 3.00 (dm, 2H), 4.15 (q, 2H), 4.40 (dd, 1 H), 6.30 (br s, 1 H), 8.32 (br s, 2H).'3C-NMR (DMSO-ds): b' 14.7 (q), 42.4 (t), 61.7 (t), 67.7 (d), 171 (s).
Building block 2: (R)-Isoserine ethyl ester hydrochloride Step A: (R)-(2,2-Dimethyl-5-oxo-'~~dioxolan-4-yl)acetic acid 2o To a suspension of D-(+)-malic acid (15.0 g, 0.1119 mol) in dry toluene (150 mL) was added 2,2-dimethoxypropane (50 mL, 0.392 mmol). The mixture was refluxed at 100 °C for 2 hours and evaporated in vacuo. The residue was dissolved in diethyl ether (150 mL) and subjected to flash column chromatography using diethyl ether as eluent (200 mL). The pure fractions were pooled and evaporated in vacuo and the residue was stirred in n-hexane.
The precipi-tate was collected, washed with n-hexane and dried to afford 15.7 g (81 %) of (R)-(2,2-di-methyl-5-oxo-[1,3]dioxolan-4-yi)acetic acid as a solid.
H-NMR (Acetone-ds): 8 1.57 (ds, 6H), 2.85 (m, 2H), 4.80 (dd, 1 H), 11.0 (br s, 1 H). '3C-NMR
(Acetone-d6): s 25.9 (q), 26.8 (q), 36.2 (t), 71.5 (d), 111.2 (s), 170.7 (s), 172.7 (s).

Microanalysis: Calculated for C~H~o05:
C, 48.28%; H, 5.79%. Found:
C, 48.31 %; H, 6.09%.

Step B' (R)-(2 2-Dimethyl-5-oxo-f1 3ldioxolan-4-ylmethyl)carbamic acid benzyl ester A mixture of (R)-(2,2-dimethyl-5-oxo-[1,3]dioxolan-4-yl)acetic acid (10.0 g, 57.41 mmol), triethylamine (10 mL, 68.89 mmol) and diphenylphosphoryl azide (14 mL, 63.15 mmol) in dry toluene (100 mL) was heated and stirred at 85 °C. When the gas evolution had ceased stir-1o ring was continued for an additional hour. Dry benzyl alcohol (6.3 mL, 63.15 mmol) was added and heating was continued for 17 hours. After evaporation in vacuo, the residue was partitioned between dichloromethane, water and brine. The aqueous phase was further ex-tracted twice with dichloromethane. The combined organic phases were washed twice with saturated sodium hydrogen carbonate. After drying (magnesium sulphate), filtration, and 15 concentration in vacuo of the organic phase, the residue was subjected to flash column chromatography with dichloromethane as eluent. This afforded 6.4 g (40%) of (R)-(2,2-di-methyl-5-oxo-[1,3]dioxolan-4-ylmethyl)carbamic acid benzyl ester as an oil.
'H-NMR (Acetone-ds): ~ 1.56 (s, 6H), 3.61 (m, 2H), 4.64 (dd, 1 H), 5.08 (dd, 2H), 6.51 (br s, 20 1 H), 7.29-7.38 (m, 5H).
Step C: (R)-3-Benzyloxycarbonylamino-2-hydroxypropionic acid To a solution of (R)-(2,2-dimethyl-5-oxo-[1,3]dioxolan-4-ylmethyl)carbamic acid benzyl ester (6.0 g, 25.08 mmol) in acetonitrife (100 mL) was added hydrochloric acid, (1 N, 100 mL). The 25 mixture was stirred for 3 hours at 40 °C and concentrated in vacuo to half the original vol-ume. The solid was collected by filtration and washed with water. The crude product was stirred for 5 min in acetone (100 mL) and filtered. Toluene was added to the clear and color-less filtrate and the whole was concentrated in vacuo until a precipitate was obtained. The precipitate was collected by filtration and dried to afford 4.45 g (87%) of (R)-3-benzyloxy-30 carbonylamino-2-hydroxypropionic acid.
H-NMR(Acetone-ds): ~ 3.45 (ddd, 1 H), 3.58 (ddd, 1 H), 4.29 (dd, 1 H), 5.08 (s, 2H), 6.41 (br s, 1H), 7.29-7.38 (m, 5H).'3C-NMR (Acetone-ds): 845.1 (t), 66.4 (t), 70.4 (d), 128.3 (d), 128.9 (d), 138.0 (d), 157.2 (s), 173.8 (s); HPLC-MS (Method C): m/z = 262 (M+Na+);
Rt = 2.20 min.
35 M.p.' 131-132 °C.

5~
Microanalysis: Calculated for C~~H~gNOS:
C, 55.23%; H, 5.48%; N, 5.85%. Found:
C, 55.35%; H, 5.72%; N, 5.82%.
Step D:(R)-Isoserine (R)-3-Benzyloxycarbonylamino-2-hydroxypropionic acid (4.4 g, 18.39 mmol) was dissolved in absolute ethanol (150 mL). Under a nitrogen atmosphere palladium on activated carbon (10 °l°, 0.5 g) was added, and the mixture was hydrogenated at 1 atmosphere for 17 hours. The , 1 o catalyst was filtered off and washed with water. The combined filtrate and washings were concentrated to about 20 mL by evaporation in vacuo. A precipitate was obtained by drop-wise addition of methanol (100 mL). The precipitate was filtered off, washed with methanol and dried to afford 1.78 g (92%) of (R)-isoserine as a solid.
~ 5 'H-NMR (D20): ~ 3.07 (dd, 1 H), 3.30 (dd, 1 H), 4.19 (dd, 1 H). '3C-NMR
(D20): 8 43.0 (t), 68.9 (d), 177.5 (s). M.p. 200-201 °C.
Step E: (R)-Isoserine ethyl ester hydrochloride The compound was prepared in analogy with the method outlined above for (RS)-isoserine 20 ethyl ester hydrochloride.
'H-NMR (DMSO-ds): 81.22 (t, 3H), 2.88 (dd, 1 H), 3.10 (dd, 1 H), 4.14 (q, 2H), 4.40 (m, 1 H), 6.32 (d, 1 H), 8.28 (br s, 2H). '~C-NMR (DMSO-ds): 813.9 (q), 41.4 (t), 60.7 (t), 66.9 (d), 25 170.9 (s).
Buildin~c block 3: (S)-2,2-Dimethyl-5-oxo-f1,31dioxolan-4-ylmethylammonium trifluoroacetate Step A_(S)-(2,2-Dimethyl-5-oxo-f 1,3ldioxolan-4- rLl)acetic acid 30 To a suspension of L-malic acid (3 g, 22.4 mmol) in toluene (25 mL) was added 2,2-dimeth-oxypropane (8.5 g, 81 mmol). The suspension was heated to reflux for 20 min.
The solvent was removed by evaporation in vacuo to afford (S)-(2,2-dimethyl-5-oxo [1,3]-4-yl)-acetic acid.
'H-NMR (DMSO-ds): 8 1.52 (6H, d), 2.75 (2H, t), 4.78 (1 H, t), 12.52 (1 H, br s).

Step B: (S)-(2 2-Dimethyl-5-oxo-f 1,3ldioxolan-4-ylmeth rLl)carbamic acid benzyl ester To (S)-(2,2-dimethyl-5-oxo-[1,3]dioxolan-4-yl)acetic acid (1 g, 5.7 mmol) and triethylamine (0.66 g, 6.5 mmol) in toluene (20 mL) was added phosphorazidic acid diphenyl ester (1.7 g, 6.2 mmol). The solution was heated to reflux for 1 hour. Benzyl alcohol (0.54 g, 5 mmol) was added and reflux was maintained for additional 6 hours. After cooling, the solution was parti-tinned between ethyl acetate (2 x 50 mL) and aqueous sodium hydrogen carbonate (10%, 2 x 50 mL). The organic layers were collected, dried (sodium sulphate) and the solvent re-moved by evaporation in vacuo to afford 976 mg of crude (S)-(2,2-dimethyl-5-oxo-[1,3]dioxo-Ian-4-ylmethyl)carbamic acid benzyl ester as an oil.
'H-NMR (DMSO-ds): 81.53 (6H, d), 3.34 (1 H, m), 3.50 (1 H, m), 4.50 (1 H, d), 4.64 (1 H, t), 5.03 (2H, d), 7.32 (5H, m) Stea C: (S)-2,2-Dimethyl-5-oxo-f1,31dioxolan-4-ylmethylammonium trifluoroacetate The crude (S)-(2,2-dimethyl-5-oxo-[1,3]dioxolan-4-ylmethyl)carbamic acid benzyl ester (976 mg, 3.5 mmol) was dissolved in ethanol (14 mL), and palladium (10% on activated charcoal, 300 mg) and 1,3-cyclohexadiene (2.8 g, 35 mmol) were added and the reaction was stirred for 1 hour at room temperature, and heated to 40 °C for 10 min. After filtration, TFA (0.4 g, 3.5 mmol) was added and the solvent was removed by evaporation to afford crude (S)-2,2-di-methyl-5-oxo-[1,3]dioxolan-4-ylmethylammonium trifluoroacetate as an oil.
~H-NMR (CDCI3): 81.46 (6H, d), 3.40-3.70 (2H, m), 4.38 (1 H, m), 7.25 (>4H, br s); HPLC-MS
(Method B): m/z = 146 (M~); Rt = 0.38 min.
Buildings block 4: 3-Amino-2-fluoropropionic acid methyl ester Dry methanol (5.3 mL) was cooled to -15 °C on an ice bath and thionyl chloride (2.5 mL) was added dropwise maintain-ing the temperature below 5 °C. To this cold solution was added (RS)-3-amino-2-fluoropropionic acid (0.27 g, 2.52 mmol) and stirring was continued until a homogeneous so-lution was obtained. The ice bath was removed and stirring was continued for 17 hours at 3o room temperature. The solution was concentrated in vacuo and further co-evaporated three times with dry methanol. The residue was filtered off, washed with DCM and dried to afford 0.13 g (33 %) of 3-amino-2-fluoropropionic acid methyl ester hydrochloride as a solid.
'H-NMR (DMSO-ds): 83.36 (m, 2H), 3.76 (s, 3H), 5.51 (d, 2H), 8.59 (br s, 3H).

Building block 5: 3-Amino-2(R)-methoxypropionic acid methyl ester hydrochloride Step (A): (R)-2-Hydroxysuccinic acid dimethyl ester To an ice cooled solution of methanol (250 mL) was added acetyl chloride (12.5 mL), and the solution was stirred for 1 hour at 0 °C. (R)-Malic acid (20.0 g) was added, and the solution was stirred for 16 hours at room temperature. Solvent was removed by evaporation in vacuo leaving a quantitative yield of (R)-2-hydroxysuccinic acid dimethyl ester as an oil.
'H-NMR (CDCI3): 84.52 (dd, 1 H), 3.80 (s, 3H), 3.71 (s, 3H), 3.55 (bs, 1 H), 2.88 (dd, 1 H), 2.80 (dd, 1 H).
Step (B): (R)-2-Methoxysuccinic acid dimeth~ ester The above (R)-2-hydroxysuccinic acid dimethyl ester was re-dissolved in methyl iodide (100 mL), freshly prepared silver oxide (30.2 g) was added and the mixture was stirred for 24 hours at room temperature. The reaction mixture was diluted with acetonitrile (200 mL), and filtered through celite to remove silver salts and excess silver hydroxide.
The filtrate was taken to dryness to leave (R)-2-methoxysuccinic acid dimethyl ester as an oil (23.2 g, 88 %).
'H-NMR (CDCI3): 84.20 (dd, 1H), 3.78 (s, 3H), 3.71 (s, 3H), 3.48 (s, 3H), 2.80 (dd, 2H).
Step (C): (R)-2-Methoxysuccinic acid 1-methyl ester The above (R)-2-methoxysuccinic acid dimethyl ester was suspended in 2 N
aqueous hydro-chloric acid, and heated to reflux for 30 min to give a clear solution. Upon evaporation of sol-vent in vacuo a quantitative yield of 2(R)-methoxysuccinic acid was obtained as an oil. The oil was redissolved in acetic anhydride (120 mL) and heated to 110 °C
for 2 hours. Solvent was removed by rotary evaporation to leave an oil. Ice cooled methanol (150 mL) was added, and the mixture was stirred for 3 hours at 0 °C followed by 16 hours at room tempera-ture. The solvent was removed to leave (R)-2-methoxysuccinic acid 1-methyl ester.
'H-NMR (CDCI3): 810.30' (bs, 1 H), 4.19 (dd, 1 H), 3.80 (s, 3H), 3.50 (s, 3H), 2.86 (dd, 1 H), 2.78 (dd, 1 H).
Step (D): 3-tent-Butoxycarbonylamino-2(R)-methoxypropionic acid methyl ester Without further purification, the above (R)-2-methoxysuccinic acid 1-methyl ester (5.0 g, 30.8 mmol) was dissolved in thionyl chloride (16 mL), and heated to reflux for 2 hours Thionyl chloride and traces thereof was removed by rotary evaporation followed by co-evaporation with acetonitrile.
' H-NMR (CDCI3): 8 3.27 (dd, 1 H), 3.48 (dd, 1 H), 3.51 (s, 3H), 3.80 (s, 3H), 4.22 (dd, 1 H).
The neat acid chloride was dissolved in toluene (50 mL). Trimethylsilylazide (5.0 mL, 38.2 mmol) was added and the mixture was heated to 100 °C overnight. Then tent-butanol (30 mL) was added, and heating was continued for an additional 16 hours. The reaction mixture was cooled and insoluble material was removed by filtration. The organic phase was washed with 1o water (100 mL), saturated sodium hydrogen carbonate solution (100 mL), 10%
citric acid so-lution (100 mL), water (100 mL) and saturated sodium chloride solution (100 mL), then dried over anhydrous sodium sulphate. Solvent was removed by rotary evaporation. The residual oil was further purified by column chromatography using 20 % ethyl acetate/heptane as elu-ent. Pure fractions (TLC plates were stained with ammonium molybdate/cerium sul-phatelsulphuric acid) were pooled and taken to dryness. The final yield of 3-tert butoxy-carbonylamino-2(R)-methoxypropionic acid methyl ester was 600 mg (9 %).
' H-NMR (CDCI3): 86.93 (t, 1 H), 3.83 (t, 1 H), 3.64 (s, 3H), 3.25 (s, 3H), 3.18 {dd, 2H), 1.36 (s, 9H).
Step (E): 3-Amino-2(R)-methoxypropionic acid methyl ester hydrochloride 3-tert-Butoxycarbonylamino-2-methoxypropionic acid methyl ester (500 mg, 2 mmol) was dissolved in 10 % TFA in DCM (20 mL), and the reaction mixture was stirred at 30 min at ambient temperature. Solvent was removed and the residue co-evaporated twice from 30 mL
of 1 N hydrochloric acid in ether. Yield: 320 mg (88 %).
H-NMR (CDCI3): ~ 8.25 ( s, 3H), 4.21 (dd, 1 H), 3.71 (s, 3H), 3.40 (s, 3H), 3.15 (m, 1 H), 2.98 (m, 1 H).
Building block 6: (R)-3-(9H-Fluoren-9-ylmethoxycarbonylamino)-2-hydroxypropionic acid ((R)-Fmoc-isoserine To (R)-(2,2-dimethyl-5-oxo[1,3]dioxolan-4-yl)acetic acid (5.88 g, 33.8 mmol) was added tolu-ene (100 mL), triethylamine (4.7 mL, 33.8 mmol) and diphenoxyphosphoryl azide (8.0 mL, 37.2 mmol). The reaction mixture was heated to a 100 °C and stirred under nitrogen at this temperature for 1.5 hour. 9-Fluorenemethanol (5.1 g, 26 mmol) was added and the reaction mixture was refluxed for 6 hours. After cooling to room temperature the mixture was trans-ferred to a separatory funnel and washed with water (2 x 50 mL). The solvent was removed in vacuo and co-evaporated with acetonitrile (100 mL). The remaining light brown oil was dissolved in DCM (20 mL) and purified on silica gel column with DCM as eluent.
The DCM
5 was removed by evaporation to yield a light yellow oil, which was redissolved in acetonitrile (150 mL) and aqueous hydrochloric acid was added (1 N, 75 mL). The yellow reaction mix-ture was stirred for 3 hours at room temperature. The solvent was removed in vacuo, toluene (100 mL) was added and the suspension was heated to reflux and allowed to cool to room temperature. (R)-Fmoc-isoserine (3.1 g, 28 %) was isolated as a powder by filtration. Mp:
10 165-166 °C.
H-NMR (DMSO-d6): ~ 12.5 (br s, 1 H), 7.90 (m, 2H), 7.70 (m, 2 H), 7.50-7.30 (m, 4 H), 5.45 (br s, 1 H), 4.23 (m, 3 H), 4.05 (m, 1 H), 3.17 (m, 1 H); HPLC-MS (Method B):
m/z = 350 (M+Na); Rt = 3.20 min.
Buildinc~block 7: 3-(tent Butyldimethylsilanyloxymethyll-4-trifluoromethoxyphenyl amine Step A: 5-Nitro-2-trifluoromethoxybenzoic acid methyl ester In a three-necked round bottom flask, equipped with a thermometer and a separatory funnel, 2o HN03 (5 mL fuming, 100%) was cooled in an ice bath. Methyl 2-(trifluoromethoxy)benzoate (5 g, 22.7 mmol) was slowly added to the cooled HN03within 0.5 hour while keeping the tem-perature below 15 °C. The reaction was then stirred at 60 °C for 1 hour and 2 hours at room temperature. The mixture was added to ice water and an oil separated. The oily residue was added water (50 mL), neutralised with an aqueous solution of sodium hydrogen carbonate and then extracted with ethyl acetate (25 mL). The aqueous phase was extracted with ethyl acetate (15 mL) once more. The combined organic phases were washed with saturated sodium chloride (2 x 15 mL), dried (magnesium sulphate), and concentrated in vacuo to give 5.69 g of 5-nitro-2-trifluoromethoxybenzoic acid methyl ester.
'H-NMR (DMSO-d6): 83.93 (3H, s), 7.82 (1H, d), 8.58 (1H, d), 8.67 (1H, s).
Step B: 5-Amino-2-trifluoromethoxybenzoic acid methyl ester 5-Nitro-2-trifluoromethoxybenzoic acid methyl ester (5.69 g, 21.5 mmol) was dissolved in ethanol 99.9% (80 mL) and added stannous(II)chloride dihydrate (24.2 g, 107 mmol). The suspension was stirred at 75 °C for 2 hours and then concentrated in vacuo. The residue was added ethyl acetate (100 mL) and water (50 mL) and pH was adjusted to pH 8 with 4 N
sodium hydroxide (50 mL). The liquid was decanted from the fine precipitation, which oc-curred, and the precipitate was washed with ethyl acetate and decanted twice.
The combinde organic phases were washed with water:saturated sodium chloride (1:1 ) solution (2 x 100 mL), dried (magnesium sulphate) and concentrated in vacuo. The residue was purified by column chromatography (120 g silica) using ethyl acetate:heptane (1:1 ) as eluent to give 3.8 g of 5-amino-2-trifluoromethoxybenzoic acid methyl ester.
'H-NMR (DMSO-d6): 83.82 (3H,s), 5.63 (2H, s), 6.79 (1 H, d), 7.07 (1 H, s), 7.11 (1 H, d).
Step C: (5-Amino-2-trifluoromethoxyphenyl)methanol 5-Amino-2-trifluoromethoxybenzoic acid methyl ester (3.0 g, 12.8 mmol) was dissolved under nitrogen in THF (20 mL) in a three-necked flask equipped with a thermometer and a separa-tory funnel. With stirring and ice-cooling lithium aluminium hydride (1 M in THF, 15 mL) was added dropwise over 10 min. Stirring was continued at room temperature for 1 hour, and the reaction mixture was concentrated in vacuo. The residue was suspended in DCM
(150 mL) and water (50 mL), and filtered through celite. The filtrate was partitioned between DCM and water. The combined organic phases were washed with water (2 x 20 mL), dried (magne-sium sulphate) and concentrated in vacuo to give 2.47 g of (5-amino-2-trifluoromethoxy-phenyl)methanol 'H-NMR (DMSO-d6): 83.92 (2H, d), 5.18 (1 H, t), 5.28 (2H, s), 6.45 (1 H, d), 6.91 (1 H, d).
Step (D): 3-(fert Butyldimethylsilanyloxymethyl)-4-trifluoromethox~henylaniline (5-Amino-2-trifluoromethoxyphenyl)methanol (1.2 g, 5.8 mmol) was dissolved in DMF (5 mL) and imidazole (0.48 g, 7.1 mmol) and tert butyldimethylsilylchforide (0.99 g, 6.6 mmol) were added and the mixture was stirred for 16 hours. The reaction mixture was extracted with ethyl acetate (50 mL) and water (20 mL). The aqueous phase was extracted once more with ethyl acetate (20 mL). The combined organic phases were washed with water (10 mL), aque-ous citric acid (10 mL, 10%) and water (2 x 10 mL), dried (magnesium sulphate) and concen-trated in vacuo. The residue was purified by column chromatography (110 g, silica gel) using ethyl acetate and heptane (1:3) as eluent to give 1.2 g of 3-(tert butyldimethylsilanyloxy-methyl)-4-trifluoromethoxyphenylaniline.

'H-NMR (DMSO-d~): X0.82 (9H, s), 3.25 (6H, s), 4.52 (2H,s), 5.23 (2H, s), 6.41 (1 H, d), 6.61 (1 H, s), 6.86 (1 H,d).
Building block 8: 4-CVclohex-1-enylaniline This compound was prepared similarly as described in J. v. Braun et al., J.
Liebigs Ann.
Chem., 472 (1929), 1-89, from refluxing aniline (2 equivalents), cyclohexanone (1 equivalent) in ethanol and 37% hydrochloric acid for 4-5 days, followed by addition of ethyl acetate, wa-ter, and sodium hydroxide, neutralisation with 85% phosphoric acid, phase separation, and distillation of the organic phase. The residue was added a catalytic amount of sulfuric acid and distilled (180°C, 5-7 mbar). The distillate was redistilled (120°C, 3 mbar) to afford (in the residue) the desired 4-cyclohex-1-enylaniline.
'H NMR (DMSO-d6): 61.50-1.60 (m, 2H), 1.60-1.70 (m, 2H), 2.10-2.15 (m, 2H), 2.20-2.30 (brd s, 2H), 5.00 (s, 2H), 5.90 (t, 1 H), 6.50 (d, 2H), 7.10 (d, 2H).
Building block 9: 4-Cyclohexylaniline This compound is commercially available (e.g. from Lancaster or Avocado).
Building block 10: 4-Cyclohexylcyclohexylamine The preparation of this compound is described in the literature, see H. Booth et al., J. Chem.
Soc. (8), 1971, 1047-1050.
Building block 11: 4-(2-MethLrlcyclohex-1-enyl)aniline and (R,S)-4-(6-methylcyclohex-1-enyl)aniline NHz NHZ
A mixture of 2-methyl-cyclohexanone (112 g, 1,0 mol), aniline (186 g, 2 mol) and ethanol (26 mL) was stirred at room temperature and 12 M hydrochloric acid (167 mL) was added during min. The dark yellow solution was refluxed at 85°C for seven days. The solution was 3o cooled and diluted with ethyl acetate. The mixture was stirred in an ice bath and made alkaline (pH=9) with a 27% sodium hydroxide solution, keeping the temperature below 30°C.

The organic layer was separated and washed with brine (3 x), dried over magnesium sulphate, and concentrated to give a brown oil (131 g). Excess of aniline was removed under reduced pressure. A catalytic amount of 12 M hydrochloric acid (1 mL) was added, and the residue was fractionated under high vacuum. The fraction distilling at 145-175°C (0,2 mmHg) was collected and subjected to column chromatography (silica gel) and eluated with 30°l°
ethyl acetate/toluene to afford a 9:1 mixture (8.7 g) of 4-(2-methylcyclohex-1-enyl)aniline and (R,S)-4-(6-methylcyclohex-1-enyl)aniline, respectively.
4-(2-Methylcyclohex-1-enyl)aniline:
'H NMR (DMSO-d6): 81,53 (s,3H), 1,61 (m,4H), 2,00 (bs,2H), 2,13 (bs,2H), 4,92 (s,2H), 6,50 (d,2H), 6,79 (d,2H); HPLC-MS (Method B): m/z = 188 (M~); Rt = 2,96 min.
(R,S)-4-(6-Methylcyclohex-1-enyl)aniline:
'H NMR (DMSO-d6): 80,88 (d,3H), 1,61 (m,4H), 2,00 (bs,2H), 2,13 (bs,2H), 2,74 (m,1H), 4,92 (s,2H), 5,68 (t,1H), 6,50 (d,2H), 6,79 (d,2H).
Building block 12: 4-(4-tent Butylcyclohex-1-enyl)aniline NHz 4-(4-tert Butylcyclohex-1-enyl)aniline was prepared in analogy to procedure for preparation of building block 11 using 4-tent-butylcyclohexanone (0.59 mol) and aniline.
~H NMR (DMSO-d6): d'0,88 (s,9H), 1,21 (m,2H), 1,90 (m,2H), 2,10-2,50 (m,3H), 4,97 (s,2H), 5,90 (m,1 H), 6,50 (d,2H), 7,06 (d,2H); HPLC-MS (Method B): m/z = 230 (M+); Rt = 4,07 min.

Buildinc~block 13: (R S)-4-~-Methylcyclohex-1-enyl)aniline and (R.S)-4-(3-methylcyclohex-1-enyl)aniline (R,S) ~

A mixture of (R,S)-3-methylcyclohexanone (123 mL, 1.0 mol), aniline (182 mL, 2.0 mol), 12 M hydrochloric acid (167 mL, 2.0 mol), and ethanol (26 mL) was refluxed at 90 °C for ten days. The solution was cooled.and diluted with ethyl acetate. The aqueous layer was made alkaline (pH=10) with a 6 M sodium hydroxide solution. The organic layer was separated and washed with brine (3 x), dried over magnesium sulphate, and concentrated to give a brown oil. Excess of aniline was removed under reduced pressure. A catalytic amount of 12 M
hydrochloric acid (1 mL) was added, and the residue was fractionated under high vacuum.
The fraction distilling at 123-128 °C (0.15-0.20 mmHg) was collected to afford 21.0 g of an oil.'H-NMR showed presence of a 3:2 mixture of (R,S)-4-(5-methylcyclohex-1-enyl)aniline and (R,S)-4-(3-methylcyclohex-1-enyl)aniline, respectively.
(R,S)-4-(5-Methylcyclohex-1-enyl)aniline:
'H NMR (DMSO-d6): s 1.00 (d, 3H), 1.45-1.95 (m, 3H), 2.10-2.45 (m, 3H), 5.04 (s, 2H), 5.86 (t, 1 H), 6.48 (d, 2H), 7.06 (d, 2H).
(R,S)-4-(3-Methylcyclohex-1-enyl)aniline:
~H NMR (DMSO-ds): ~ 1.00 (d, 3H), 1.45-1.95 (m, 3H), 2.10-2.45 (m, 3H), 5.04 (s, 2H), 5.75 (d, 1 H), 6.48 (d, 2H), 7.06 (d, 2H).

General procedure (A) for solution phase synthesis of compounds of the general for-mulae (la) and (1b):
0 ~ E-NHS
R NaCNBH3 0 ~ R
C~.e alkyl.0 D-N=C=O Ci_e alkyl I ~ C~_e alkyl.0 E ~--~ O I E H
I ' Step 2 / N~N.D
RB CHO Step 1 / NH Re O
Re Step 2a aq. NaOH
0 ~ E-NHz NaCNBH3 O ~ D-N=C=O 0 R' H
HO I / Step 1 HO I NH St~ HO I i N N.
Re CHO
R Re ~ D
O
EDAC
HOBt or HOAt Step 3 O RZ R3 C1,8 alkyI~O~A~CNH2 R~R 0 R~ aq. NaOH O Rz Rs O
HO A N~E H .E C~_e alkyI~O~A~N E H
H R I i N~N.D Step 4 H 8I ~ N N-D
a IOI R O
(1b) (la) wherein RZ, R3, R', R8, A, E and D are as defined for formula (I).

Compounds made according to this general procedure (A) can either be prepared via the es-ter route or the carboxylic acid route. The only difference between these two routes is the protection of the benzoic acid as an ester. The deprotection of the ester (step 2a) provides intermediates identical with those of the carboxylic acid route.
This procedure according to the ester route is illustrated in examples 1 and 2 and according to the carboxylic acid route in example 3.

Example 1 (General procedure (A)) (R)-3-~4-f1-l4-Cvclohexvlahenvl)-3-l3-methoxv-5-trifluoromethvlahenvl)ureidomethvllbenzo amino}-2-hydroxypropionic acid HON
OH H I / N N 0.

(Ft) O
FFF
Step 1: 4-(C4-Cyclohexylphenylamino)methyl)benzoic acid methyl ester 4-Formylbenzoic acid methyl ester (6.65 g, 40.5 mmol) was dissolved in hot methanol (175 mL). To this mixture, 4-cyclohexylaniline (7.1 g, 40.5 mmol) was added. To the resulting sus-pension, more methanol (75 mL) was added and the mixture was heated at reflux for 1 hour.
After cooling to 0 °C, the mixture was filtered and the solid was washed with ice-cold metha-nol and dried in vacuo at 40 °C for 16 hours to afford 10.95 g of 4-[(4-cyclohexylphenylimino)-methyl]benzoic acid methyl ester. This compound (10.93 g, 34 mmol) was suspended in methanol (200 mL) and glacial acetic acid (27 mL) was added followed by sodium cyano borohydride (1.9 g, 30 mmol) in small portions. The mixture was stirred at room temperature for 1 hour and concentrated in vacuo. The residue was dissolved in DCM (200 mL) and washed with 5°l° aqueous sodium carbonate (5 x 80 mL), dried (magnesium sulphate) and concentrated in vacuo. The residue was added ethyl acetate (100 mL) and n-heptane (200 mL) and concentrated in vacuo to half the original volume. The solid was filtered, washed with n-heptane and dried in vacuo at 40 °C for 16 hours to afford 9.52 g (87%) of 4-((4-cyclo-2o hexylphenylamino)methyl)benzoic acid methyl ester.
'H-NMR (DMSO-ds): 81.2-1.4 (5H, m), 1.65 (5H, m), 2.30 (1H, t), 3.84 (3H, s), 4.30 (2H, d), 6.18 (1 H, t), 6.50 (2H, d), 6.87 (2H, d), 7.49 (2H, d), 7.92 (2H, d); HPLC-MS
(Method B): m/z = 324 (M+1 ); Rt = 7.18 min.
Step 2: 4-f1-(Cyclohexylphenyl)-3-(3-methoxy-5-trifluoromethylphenyl)ureidomethyllbenzoic acid methyl ester 5-Methoxy-3-(trifluoromethyl)aniline (2.0 g, 10.5 mmol) was dissolved in ethyl acetate (10 mL), and dry HCI in ethyl acetate (15 mL) was added and the solvent was removed in vacuo.

The solid was co-evaporated with toluene (3 x 15 mL). Toluene (75 mL) and diphosgene (13 mL) were added and the reaction mixture was refluxed under a nitrogen atmosphere for 2.5 hours. Excess diphosgene was removed in vacuo and the clear oil was co-evaporated with toluene. The obtained isocyanate was used without further purification.
The above isocyanate was dissolved in DCM (75 mL) and 4-((4-cyclohexylphenylamino)-methyl)benzoic acid methyl ester (2.3 g, 7.1 mmol) was added. The reaction mixture was stirred overnight at room temperature, the solvent was removed in vacuo and the residual oil was purified by column chromatography on silica gel, eluting with a mixture of heptane and ethyl acetate (7:3). This afforded 3 g of 4-[1-(cyclohexylphenyl)-3-(3-methoxy-5-trifluoro-methylphenyl)ureidomethyl]benzoic acid methyl ester as an oil.
H-NMR (DMSO-d6): ~ 1.22 (broad, 1 H), 1.37 (broad, 4H), 1.7 (broad, 1 H), 1.79 (broad, 4H), 3.77 (s, 3H), 3.83 (s, 3H), 4.98 (s, 2H), 6.81 (s, 1 H), 7.18 (d, 2H), 7.23 (d, 2H), 7.42 (m, 3H), 7.51 (s, 1 H), 7.90 (d, 2H), 8.53 (s, 1 H), 10.01 (s, 1 H); HPLC-MS (Method A): m/z = 541 (M+1 ); Rt = 8.98 min.
Step 2a: 4-f1-(Cyclohexylphenyl)-3-(3-methoxy-5-trifluoromethylphenyl)ureidomethyllbenzoic acid 4-[1-(Cyclohexylphenyl)-3-(3-methoxy-5-trifluoromethylphenyl)ureidomethyl]benzoic acid methyl ester (3.0 g ) was dissolved in absolute ethanol (50 mL), sodium hydroxide (4 N, 15 mL) was added and the reaction mixture was stirred at room temperature for 16 hours. The organic solvent was removed in vacuo, and additional water (50 mL) was added, pH was ad-justed with hydrochloric acid (4 N) to acidic reaction and then ethyl acetate (200 mL) was added. The organic phase was washed with water (5 x 50 mL), dried (magnesium sulphate), filtered and evaporated in vacuo. The residue was recrystallised from acetonitrile (25 mL) to afford 4-[1-(cyclohexylphenyl)-3-(3-methoxy-5-trifluoromethylphenyl)ureidomethyl]benzoic acid (1.83 g) as crystals.
' H-NMR (DMSO-d6): 81.22 (m, 1 H), 1.37 (m, 4H), 1.70 (m, 1 H), 1.79 (m, 4H), 3.77 (s, 3H), 4.95 (s, 2H), 6.81 (s, 1 H), 7.18 (d, 2H), 7.23 (d, 2H), 7.40 (d, 2H), 7.42 (s, 1 H), 7.51 (s, 1 H), 7.89 (d, 2H), 8.55 (s, 1 H), 12.90 (s, 1 H); HPLC-MS (Method A): m/z = 527 (M+1 ); Rt = 8.23 min; M.p. 148-150 °C.

Microanalysis: Calculated for C~9HZ9N2F304:
C, 66.15%; H 5.55%; N 5.32%. Found:
C, 66.65%; H 5.70%; N 5.33%.
Step 3: !R)-3-f4-f1-(4-Cyclohexylphenyll-3-(3-methoxy-5-trifluoromethylphenyl)ureidomethyll-benzoylamino~-2-hydroxypropionic acid eth I~ster 4-[1-(Cyclohexylphenyl)-3-(3-methoxy-5-trifluoromethylphenyl)ureidomethyl]benzoic acid (420 mg, 0.8 mmol) was dissolved in DMF (10 mL), and then HOBt (160 mg, 1.2 mmol) and EDAC (230 mg, 1.2 mmol) were added. The reaction mixture was allowed to stand for 30 1o min, then (R)-isoserine ethyl ester (260 mg, 1.2 mmol) and diisopropylethylamine (210 mL, 1.2 mmol) dissolved in DMF (5 mL) were added and the reaction mixture was stirred at room temperature for 16 hours. Water (50 mL) and ethyl acetate (100 mL) were added and the or-ganic phase was washed with water (5 x 50 mL), dried (magnesium sulphate), filtered and evaporated in vacuo. The residue was purified by column chromatography on silica gel, eluting with a mixture of heptane and ethyl acetate (1:3) to afford 510 mg of (R)-3-{4-[1-(4-cyclohexylphenyl)-3-(3-methoxy-5-trifluoromethylphenyl)ureidomethyl]benzoylamino}-2-hydroxypropionic acid ethyl ester as an amorphous solid.
H-NMR (DMSO-d6): 81.12 (t, 3H), 1.22 (m, 1 H), 1.37 (m, 4H), 1.70 (m, 1 H), 1.79 (broad, 4H), 3.41 (m, 1 H), 3.52 (m, 1 H), 3.77 (s, 3H), 4.06 (q, 2H), 4.21 (q, 1 H), 4.95 (s, 2H), 5.68 (d, 1 H), 6.81 (s, 1 H), 7.18 (d, 2H), 7.23 (d, 2H), 7.33 (d, 2H), 7.42 (s, 1 H), 7.51 (s, 1 H), 7.77 (d, 2H), 8.47 (t, 1 H), 8.53 (s, 1 H); HPLC-MS (Method A): m/z = 658 (M+1 ); Rt =
8.17 min.
Step 4:
(R)-3-{4-[1-(4-Cyclohexylphenyl)-3-(3-methoxy-5-trifluoromethylphenyl)ureidomethyl]benzoyl-amino)-2-hydroxypropionic acid ethyl ester was dissolved in ethanol (15 mL) and sodium hy-droxide (2 N, 2 mL) was added. The reaction mixture was stirred at room temperature for 60 min. Then ethanol was removed in vacuo, water (50 mL) was added and pH was adjusted with 4 N hydrochloric acid to acidic reaction. Filtration and washing with water (5 x 5 mL) and drying in vacuo afforded 460 mg of the title compound as a crystalline solid.
'H-NMR (DMSO-d6): ~ 1.22 (m, 1 H), 1.37 (m, 4H), 1.70 (m, 1 H), 1.79 (broad, 4H), 3.37 (m, 1 H), 3.51 (m, 1 H), 3.77 (s, 3H), 4.09 (t, 1 H), 4.95 (s, 2H), 6.80 (s, 1 H), 7.18 (d, 2H), 7.23 (d, 2H), 7.33 (d, 2H), 7.42 (s, 1 H), 7.51 (s, 1 H), 7.77 (d, 2H), 8.47 (t, 1 H), 8.53 (s, 1 H); HPLC-MS
(Method A): m/z = 614 (M+1 ); R, = 7.67 min.

Microanalysis: Calculated for C3~H34N3F3O6 (+ 1.25 Hz0):
C, 60.42%; H, 5.78%; N, 6.61 %. Found:
C, 60.25%; H, 5.55%; N, 6.50%.
Example 2 (General procedure (A)) (R)-3-~4-f3-(3,5-Bis(trifluorometh I)y phenyl)-1-(4-cyclohexylphenyl)ureidomethyllbenzoyl-amino~-2-hydroxypropionic acid HON ~ ~ H F
OH H I ~ N N
~R) O I / F F
F
F F
Step 2: 4-f3-(3,5-Bis(trifluoromethyl)phenyl)-1-(4-cyclohexylphenyl)ureidomethyllbenzoic acid methyl ester 4-((4-Cyclohexylphenylamino)methyl)benzoic acid methyl ester (2.38 g, 7.36 mmol) was dis-solved in DCM (150 mL) and 3,5-bis(trifluoromethyl)phenyl isocyanate (1.36 mL, 8.10 mmol) was added and the mixture was stirred at room temperature for 16 hours. The reaction mix-ture was washed with water (3 x 15 mL), dried (magnesium sulphate) and concentrated in vacuo to afford 4.3 g of 4-[3-(3,5-bis(trifluoromethyl)phenyl)-1-(4-cyclohexylphenyl)ureido-methyl]benzoic acid methyl ester.
'H-NMR (DMSO-d6): b'1.17-1.44 (m, 5H), 1.66-1.82 (m, 5H), 3.83 (s, 3H), 4.98 (s, 2H, 7.20-7.28 (m, 4H), 7.44 (d, 2H), 7.62 (s, 1 H), 7.93 (d, 2H), 8.24 (s, 2H), 8.94 (s, 1 H); HPLC-MS
(Method A): m/z = 579 (M+1 ); Rt = 9.50 min.
Step 2a: 4-.f3-(3.5-Bis(trifluorometh~~henyl)-1-(4-cyclohexylphenyl)ureidomethyllbenzoic acid 4-[3-(3,5-Bis(trifluoromethyl)phenyl)-1-(4-cyclohexylphenyl)ureidomethyl]benzoic acid methyl ester (4.2 g, 7.36 mmol) was suspended in ethanol (80 mL) and added sodium hydroxide (4 N, 11 mL) and stirred at room temperature for 16 hours. The reaction mixture was concen-trated to dryness in vacuo, and the residue was added water (50 mL) and acidified with hy-drochloric acid (4 N, 12 mL). The aqueous phase was extracted twice with ethyl acetate (75 mL and 25 mL) and the combined organic phases were washed with water (3 x 15 mL), dried (magnesium sulphate) and concentrated in vacuo to afford 4-[3-(3,5-bis(trifluoromethyl)-phenyl)-1-(4-cyclohexylphenyl)ureidomethyl]benzoic acid.

'H-NMR (DMSO-d6): 81.32-1.43 (m, 5H), 1.7 (m, 1H), 1.75-1.85 (5H), 4.98 (s, 2H), 7.20-7.28 (m, 4H), 7.4 (d, 2H), 7.61 (d, 1 H), 7.88 (d, 2H), 8.25 (s, 2H), 8.93 (s, 1 H), 12.90 (s, 1 H);
HPLC-MS (Method B): m /z = 565 (M+1 ); Rt = 8.65 min; M.p. 148.5-149.5 °C.
10 Microanalysis: Calculated for CZ9H26F6N~03:
C, 61.70%; H, 4.64%; N, 4.96%. Found:
C, 61.54%; H, 4.71 %; N, 4.92%.
Step 3: (R)-3-~4-f3-(3,5-Bis(trifluoromethyl)phenyl)-1-(4-cyclohexylphenyl)ureidometh rLl]'-15 benzoylamino~-2-hydroxypropionic acid ethyl ester 4-[3-(3,5-Bis(trifluoromethyl)phenyl)-1-(4-cyclohexylphenyl)ureidomethyl]benzoic acid (0.22 g, 0.39 mmol) was dissolved in DMF (3 mL) and 1-hydroxy-7-azabenzotriazole (0.06 g, 0.47 mmol) and EDAC (0.09 g, 1.2 mmol) were added. The mixture was stirred for 1.5 hour, and (R)-isoserine ethyl ester (0.10 g, 0.59 mmol) and diisopropylethylamine (0.10 mL, 0.59 mmol) 20 in DMF (2 mL) were added. The mixture was stirred at room temperature for 16 hours. The reaction mixture was diluted with water (10 mL) and extracted with ethyl acetate (25 mL).
The aqueous phase was extracted with ethyl acetate (10 mL). The combined organic phases were washed with hydrochloric acid (0.2 N, 3 x 10 mL) and wateraaturated sodium chloride (1:1 ), dried (magnesium sulphate) and concentrated in vacuo. The residue was purified by 25 column chromatography (35 g silica gel) using ethyl acetate and n-heptane (6:4) as eluent to afford 0.27 g of (R)-3-{4-[3-(3,5-bis(trifluoromethyl)phenyl)-1-(4-cyclohexylphenyl)ureido-methyl]benzoylamino}-2-hydroxypropionic acid ethyl ester.
'H-NMR (DMSO-d6): s 1.14 (t, 3H), 1.19-1.42 (m, 5H), 1.67-1.85 (m, 5H), 3.38-3.48 (m, 1 H), 30 3.49-3.57 (m, 1 H), 4.08 (q, 2H), 4.20 (m, 1 H), 4.97 (s, 2H), 5.67 (d, 1 H), 7.20-7.27 (m, 4H), 7.36 (d, 2H), 7.62 (s, 1 H), 7.75 (d, 2H), 8.24 (s, 2H), 8.48 (t, 1 H), 8.90 (s, 1 H); HPLC-MS
(Method A): m/z = 680 (M+1 ); R~ = 8.42 min.

Stets 4:
(R)-3-{4-[3-(3,5-Bis(trifluoromethyl)phenyl)-1-(4-cyclohexylphenyl)ureidomethylJbenzoyl-amino}-2-hydroxypropionic acid ethyl ester (0.26 g, 0.38 mmol) was dissolved in ethanol (96%, 15 mL) and added sodium hydroxide (4 N, 0.57 mL, 2.3 mmol). After stirring at 25 °C
for 1 hour the mixture was evaporated in vacuo, and the residue was added water (30 mL) and acidified with hydrochloric acid (4 N, 0.62 mL). The aqueous phase was extracted twice with ethyl acetate (25 mL and 10 mL) and the combined organic phases were washed with saturated sodium chloride:water (1:1 ), dried (magnesium sulphate) and concentrated in vacuo to afford 0.21 g of the title compound.
'H-NMR (DMSO-d6): 81.21-1.45 (m, 5H), 1.66-1.86 (m, 5H), 3.37-3.44 (m, 1H), 3.53-3.60 (m, 1 H), 4.18 (t, 1 H), 4.95 (s, 2H), 7.18-7.27 (m, 4H), 7.45 (d, 2H), 7.60 (s, 1 H), 7.78 (d, 2H), 8.24 (s, 2H), 8.44 (t, 1 H), 8.90 (s, 1 H); HPLC-MS (Method B): m/z = 652 (M+1 ); Rt = 7.93 min.
Example 3 (General procedure (A)) (R)- 3-f4-f3-(3-Bromoahenvl)-1-(4-cvclohexvlphenvl)ureidomethvllbenzoylamino~-2-~rdrox~~
pro~ionic acid HON ~ ~
OH H I / N~N ~ Br (R) IOI ~ i Step 1: 4-f(4-Cyclohexylphenylaminolmethyllbenzoic acid 4-Cyclohexylaniline (8.0 g, 53 mmol) was dissolved in methanol (200 mL) and a suspension of 4-formylbenzoic acid (9.4 g, 53 mmol) in glacial acetic acid (12 mL) was added in portions and the resulting mixture was heated at reflux temperature for 1.5 hour. After cooling to room temperature a mixture of sodium cyano borohydride (5.0 g, 80 mmol) in methanol (100 mL) was added in portions, and the resulting mixture was stirred at room temperature for 16 hours. The mixture was filtered and washed thoroughly with water and dried in vacuo at 50 °C for 3 days to afford 12.8 g (78%) of 4-[(4-cyclohexylphenylamino)methylJbenzoic acid.

'H-NMR (DMSO-ds): s1.1-1.35 (5H, m), 1.65-1.75 (5H, m), 2.29 (1H, m), 4.31 (2H, s), 6.15 (1 H, bs), 6.45 (2H, d), 6.89 (2H, d), 7.46 (2H, d), 7.88 (2H, d).
Stea 2: 4-f3-(3-Bromoahenyl)-1-(4-cyclohexyahenyl)ureidomethyllbenzoic acid 3-Bromoaniline (1.4 g, 8.1 mmol) was dissolved in diethyl ether (50 mL) and 3.5 M dry HCI in ethyl acetate (2.3 mL) was added. The mixture was concentrated in vacuo. The residue was added toluene (100 mL) and concentrated in vacuo. The residue was added toluene (100 mL) and diphosgene (8.1 g, 41 mmol) and the resulting mixture was refluxed for 1.5 hour.
After cooling, the mixture was concentrated in vacuo. The residue was dissolved in toluene (100 mL) and concentrated in vacuo. The residue was dissolved in DMF (30 mL) and 4-[(4-cyclohexylphenylamino)methyl]benzoic acid (1.3 g, 4.1 mmol) was added. The mixture was stirred at room temperature for 16 hours. The mixture was added ethyl acetate (150 mL) and washed with water:brine (1:1) (2 x 100 mL). The organic phase was dried with sodium sul-phate and concentrated in vacuo. The residue was purified by column chromatography on silica gel eluting first with a mixture of ethyl acetate:n-heptaneariethylamine (7:2:1 ), then with ethyl acetate and finally with methanol to afford 1.95 g (94%) of 4-[3-(3-bromophenyl)-1-(4-cyclohexylphenyl)ureidomethyl]benzoic acid.
'H-NMR (CDCl3): 81.2-1.4 (5H, m), 1.7-1.8 (5H, m), 4.94 (2H, s), 7.1-7.25 (6H, m), 7.30 (2H, d), 7.44 (1 H, d), 7.78 (1 H, t), 7.83 (2H, d), 8.38 (1 H, s); HPLC-MS (Method B): m/z = 507 (M+1 ); Rt = 5.52 min.
Stea 3: (R)-3-f4~3-(3-Bromoahenyl)-1-(4-cycfohexylahenyl)ureidomethyllbenzoylamino)-2-hydroxyaropionic acid ethyl ester 4-[3-(3-Bromophenyl)-1-(4-cyclohexylphenyl)ureidomethyl]benzoic acid (0.20 g, 0.39 mmol) was dissolved in DMF (2.5 mL) and EDAC (0.12 g, 0.6 mmol) and HOBt (0.089 mg, 0.6 mmol) were added and the mixture was stirred at room temperature for 10 min.
(R)-Isoserine ethyl ester hydrochloride (0.10 g, 0.6 mmol) and N,N-diisopropylethylamine (130 wL) dis-solved in DMF (2.5 mL) were added and the resulting mixture was stirred at room tempera-ture for 16 hours. The mixture was added ethyl acetate (70 mL) and washed with water (2 x 100 mL), the organic phase was dried with sodium sulphate and concentrated in vacuo. The residue was purified by column chromatography on silica gel eluting with a mixture of ethyl acetate:n-heptane (1:2) containing 10% acetic acid. This afforded 100 mg of (R)-3-{4-[3-(3-bromophenyl)-1-(4-cyclohexylphenyl)ureidomethyl]benzoyfamino~-2-hydroxypropionic acid ethyl ester.

HPLC-MS (Method B): m/z = 624 (M+1 ); Rt = 5.33 min.
Step 4: R)-3-f4-f3~3-Bromophenyl)-1-(4-cyclohexylphenyl)ureidomethyllbenzoylamino)-2-hydroxypropionic acid (R)-3-{4-[3-(3-Bromophenyl)-1-(4-cyclohexylphenyl)ureidomethyl]benzoylamino}-2-hydroxy-propionic acid ethyl ester (100 mg) was dissolved in ethanol (10 mL), 1 N
sodium hydroxide (480 p.L) was added and the resulting mixture was stirred at room temperature for 1 hour. 1 N
Hydrochloric acid (480 wL) was added and the mixture was concentrated in vacuo. The resi-due was suspended in water (50 mL) and filtered to afford 38 mg of the title compound.
' H-NMR (CDCI3): 81.2-1.4 (5H, m), 1.7-1.85 (5H, m). 2.45 (1 H, s), 3.7 (2H, m), 4.30 (1 H, m), 4.78 (2H, s), 6.23 (1 H, s), 6.95-7.3 (8H, m), 7.42 (1 H, s), 7.60 (2H, d);
HPLC-MS (Method A):
m/z = 595 (M+1 ); Rt = 7.48 min.
Example 4 (General procedure (A)) (R)-3-(4-f 1-(4-CyclohexylphenVl)-3-(4-trifluoromethoxy,_phenyl)ureidomethyllbenzoylamino~-2-hydroxypropionic acid H
F
p~F
F
'H-NMR (DMSO-d6): 81.2-1.4 (5H, m), 1.7-1.8 (5H, m), 3.40 (1 H, m), 3.56 (1 H, dt), 4.18 (1 H, t), 4.97 (2H, s), 5.5 (1 H, brd) 7.14-7.25, (6H, m), 7.34 (2H, d), 7.55 (2H, d), 7.79 (2H, d), 8.38 (1 H, s), 8.44 (1 H, t); HPLC-MS (Method A): m/z = 600 (M+1 ); Rt = 7.38 min.

Example 5 (General procedure (A)) (R)-3-f4-f1-(4-Cyclohex IYphenyl)-3-(3-trifluoromethylphenyl)ureidomethyllbenzoylamino?-2-hydroxypro~ionic acid o ° ~I
HO N
~H ~ i N N F F
OH ~ w F
(R) O ~ i 'H-NMR (400 MHz, DMSO-d6): ~' 1.15-1-45 (m, 5H), 1.60-1.90 (m, 5H), 4.95 (s, 2H), 7.12 (d, 2H), 7.19 (d, 2H), 7.24 (d, 1 H), 7.45 (t, 1 H), 7.72 (d, 2H), 7.75 (s br, 1 H), 7.90 (s, 1 H), 8.55 (s, 1 H), 8.58 (s br, 1 H); HPLC-MS (Method B): mlz = 584 (M+1 ); Rt = 4.99 min.
Example 6 (General procedure (A)) (R)-3-~4-f 1-(4-Cyclohexylphenyl)-3~3-fluoro-5-trifluoromethy~~he ~1)ureidomethyllbenzoyl-amino~-2-hydroxypropionic acid FF
~F
(R) O ~ i F
'H-NMR (200 MHz, DMSO-d6): X1.15-1-45 (m, 5H), 1.60-1.85 (m, 5H), 3.25-3.65 (m, 3H), 4.13 (t, 1 H), 4.95 (s, 2H), 7.10-7.22 (m, 5H), 7.30 (d, 2H), 7.75 (m, 3H), 8.45 (t, 1 H), 8.78 (s, 1 H); HPLC-MS (Method A): m/z = 602 (M+1 ); Rt = 7.83 min.

Example 7 (General procedure (A)) (R)-3-f4-f3-(3-Cyano-5-trifluoromethylphenyl)-1-(4-cyclohex-1-enylphenyl)ureidomethylL
benzoylamino)-2-hydroxypropionic acid HON
OH H I / NuN ~ F F
IOI
(R) I I
N

'H-NMR (200 MHz, DMSO-d6): 81.15-1.70 (m, 4H), 2.12 (s, 2H), 2.35 (s, 2H), 5.00 (s, 2H), 6.15 (s, 1 H), 7.10-7.40 (m, 6H), 7.78 (m, 3H), 8.20 (d, 2H), 8.90 (s, 1 H);
HPLC-MS (Method A): m/z = 607 (M+1 ); Rt = 7.42 min.
10 Example 8 (General procedure (A)) (R)-3-~4-f3-(3-Cyano-5-trifluoromethylphenyl)-1-(4-cyclohexylphenyl)ureidomethyllbenzoyl-amino-2-hydroxy~ropionic acid HON
OH H I i NuN ~ F F
(R) IOI ~ i II
N
15 'H-NMR (400 MHz, DMSO-ds): X1.15-1.45 (m, 5H), 1.60-1.85 (m, 5), 3.45-3.60 (m, 3H), 4.15 (t, 1 H) 4.95 (s, 2H), 7.20 (dd, 4H), 7.35 (d, 2H), 7.76 (d, 2H), 7.88 (s, 1 H), 8.18 (s, 1 H), 8.21 (s, 1 H), 8.45 (t, 1 H), 8.95 (s, 1 H); HPLC-MS (Method A): m/z = 609 (M+1 );
Rt = 7.58 min.

Example 9 (General procedure (A)) lR)-3-f4-f3-l3-Bromo-5-trifluoromethvlphenvl )-1-(4-cvclohex-1-envlphenvl)ureidometh benzoylamino~-2-hydroxypropionic acid HON
OH H I / N N ~ F F
(R) O ~ i Br 'H-NMR (DMSO-ds): 81.50-1.76 (m, 4H), 2.15 (m, 2H), 2.33 (m, 2H), 3.37 (m, 2H), 3.54 (m, 1 H), 4.14 (dd, 1 H), 4.95 (s, 2H), 6.17 (t, 1 H), 7.17 (d, 2H), 7.33 (d, 2H), 7.40 (d, 2H), 7.46 (s, 1 H), 7.75 (d, 2H), 7.91 (s, 1 H), 8.07 (s, 1 H), 8.44 (t, 1 H), 8.66 (s, 1 H).
Example 10 (General procedure (A)) (R)-3-f4-f1-(4-Cyclohex-1-enylphenyl)-3-(3-methoxy-5-trifluorometh I~nyl)ureidomethyll-benzoylamino~-2-hydroxypropionic acid HON ~ ~ H F F
OH H I / N~N I ~ F
(R) IO1 /
H3C.0 'H-NMR (DMSO-d6): 81.51-1.76 (m, 4H), 2.15 (m, 2H), 2.34 (m, 2H), 3.37 (m, 2H), 3.54 (m, 1 H), 3.75 (s, 3H), 4.14 (dd, 1 H), 4.95 (s, 2H), 6.16 (t, 3H), 6.78 (s, 1 H), 7.16 (d, 2H), 7.32 (d, 2H), 7.38 (d, 2H), 7.43 (s, 1 H), 7.76 (d, 2H), 8.44 (t, 1 H), 8.51 (s, 1 H).

Bxample 11 (General procedure (A)) ( ~-3-f4-f3-(3-BromophenLrl -1-(4-cyclohex-1-enylphenyl)ureidomethyllbenzoylamino}-2-hydroxypropionic acid i HON
OH H I i N.~N ~ Br (R) COI ~ i The title compound was prepared according to general procedure (A) modifying step 2 as follows:
Step 2: 4-f3-(3-Bromophenyl)-1-(4-cyclohex-1-enylphenyl)ureidomethyllbenzoic acid methyl ester To 3-bromobenzoic acid (1.2 g, 5.7 mmol) in toluene (20 mL) was added triethylamine (0.91 mL, 6.5 mmol) and diphenoxyphosphoryl azide (1.3 mL, 6.2 mmol) and the mixture was heated to 100 °C while stirring. After 1 hour 4-[(4-cyclohex-1-enylphenylamino)methyl]-benzoic acid methyl ester (prepared similarly as described in example 1, step 1) (1.6 g, 5 mmol) was added and heating was continued for additional 1.5 hour. After cooling to room temperature the mixture was transferred with ethyl acetate (50 mL) to a separatory funnel.
The organic mixture was washed with saturated aqueous sodium hydrogen carbonate (2 x 50 mL), backwash with ethyl acetate (50 mL). The organic phases were collected, dried (so-dium sulphate) and the solvent removed in vacuo to yield a brown oil that was purified on sil-ica column eluted with DCM to afford 700 mg of 4-[3-(3-bromophenyl)-1-(4-cyclohex-1-enylphenyl)ureidomethyl]benzoic acid methyl ester.
HPLC-MS (Method B): m/z = 521 (M+1 ); Rt = 6.1 min.
Data for the title compound:
'H-NMR (CDCI3): 81.54 (s, 2H), 1.65 (s, 2H); 2.15 (s, 2H), 2.36 (s, 2H), 3.56 (br s, 2H), 4.19 (br s, 1 H), 4.71 (s, 2H), 6.09 (s, 1 H), 6.42 (s, 1 H), 6.90-7.18 (m, 6H), 7.30.7.70 (m, 6H);
HPLC-MS (Method B): m/z = 592.5 (M+1 ); Rt = 4.73 min.

Example 12 (General procedure (A)) (R)-3-f4-f3-(3-Bromo-5-trifluoromethvlahenvl)-1-(4-cvclohexvlphenVl)ureidomethyllbenzovl-amino)-2-hydroxypro~ionic acid HON
OH H ~ i N~N ~ F F
(R) IOI
Br 'H-NMR (DMSO-d6): ~ 1.14-1.43 (m, 5H), 1.64-1.83 (m, 5H), 3.40-3.45 (m, 1 H), 3.45-3.53 (m, 1 H), 4.00 (t, 1 H), 4.95 (s, 2H), 7.13-7.27 (m, 4H), 7.33 (d, 2H), 7.48 (s, 1 H), 7.77 (d, 2H), 7.92 (s, 1 H), 8.07 (s, 1 H), 8.43 (t, 1 H), 8.71 (s, 1 H); HPLC-MS (Method A): m/z = 662 (M+1 );
Rt = 8.17 min.
Example 13 (General procedure (A)) (S)-Trans-3-f4-f3-(3 5-Bis(trifluoromethyl)phenyl)-1-(4-tent butylcyclohexyl)ureidomethyll-benzoylamino~-2-hydroxypropionic acid O O Trans HON ~ F
OH H ~ / NuN \ F
II F
(S) O ~ i F F
F

Stet' 1: trans-4-f(4-tart butylcyclohexylamino)meth~l]benzoic acid methyl ester MeOOC ~ /C'H3 w + HzN~CHs cis/frans (17:83) Me00C pure frans 78% yield i N ~~ CHs H~CH3 MeOH 3.54 ppm (CDCl3) 3.17 ppm (CDCI3) Me00C H CH3 '' \~CH3 ~ i N CHs 22 °!° cis with traces of the traps isomer 4-Formylbenzoic acid methyl ester (10.6 g, 64.4 mmol) was dissolved in methanol (200 mL).
A 17:83 cisltrans mixture of 4-tent butylcyclohexylamine (10.0 g, 64.4 mmol, Aldrich) was ad-ded, leading to immediate precipitation of white crystals. The mixture was heated to reflux for 30 min to complete imine formation, then cooled to 0 °C on an ice bath.
The crystalline pure traps-4-[(4-tart butylcyclohexylimino)methyl]benzoic acid methyl ester was then collected by 1o filtration, and dried overnight in vacuo. Yield: 15.3 g (78%).
'H NMR (CDCI3), 300 MHz: 88.37 (s, 1 H); 8.06 (d, 2H); 7.77 (d, 2H); 3.92 (s, 3H); 3.17 (m, 1 H); 1.83 (m, 4H); 1.60 (m, 2H), 1.09 (m, 3H); 0.87 (s, 9H).
Microanalysis: Calculated for C~9H2~NOz C, 75.71 %; H, 9.03%; N, 4.65%. Found:
C, 75.60%; H, 9.37%; N, 4.68%.
The mother liquid was taken to dryness to leave 4.2 g (22%) white solid, which according to NMR consisted mainly of the imino cis isomer.
'H NMR (CDCl3), 300 MHz: 88.36 (s, 1H); 8.07 (d, 2H); 7.81 (d, 2H); 3.92 (s, 3H); 3.54 (m, 1 H); 1.55 - 1.92 (m, 8H); 1.14 (m, 1 H); 0.90 (s, 9H).

Me00C Me00C
CH3 NaBH3CN
NCH '~ W I NCH
CH3 3 f-IOAc/MeOH CH3 s traps-4-[(4-tert-Butylcyclohexylimino)methyl]benzoic acid methyl ester (21.0 g, 69.2 mmol) was suspended in methanol (300 mL), and acetic acid (50 mL) was added. To the resulting 5 clear solution was added sodium cyanoborohydride (3.5 g, 55.5 mmol), and the mixture was stirred at ambient temperature for 30 min. The reaction volume was then reduced to one third by rotary evaporation, and ethyl acetate (500 mL) was added. The organic phase was washed with sodium carbonate solution (5%, 500 mL), and dried with sodium sulphate. The solvent was removed by rotary evaporation to leave the title material as a white crystalline 10 solid sufficiently pure for further reactions. Yield: 21.1 g (100%).
'H NMR (CDCI3), 300 MHz: c~7.98 (d, 2H); 7.38 (d, 2H); 3.90 (s, 3H); 3.86 (s, 2H); 2.39 (m, 1 H); 2.01 (m, 2H); 1.77 (m, 2H);1.51 (bs, 1 H); 0.93-1.18 (m, 5H); 0.82 (s, 9H); HPLC-MS
(Method B: Rt = 4.87 m/z = 304 (M + 1 ).
Step 2: Traps-4-j1-(3,5-bis(trifluoromethyl)phenyl)-3-(4-tent-butylcyclohexyl)ureidomethyll-benzoic acid methyl ester Traps-4-((4-tert-butylcyclohexylamino)methyl]benzoic acid methyl ester (1.0 g, 3.3 mmol) was dissolved in acetonitrile (40 mL), 3,5-bis(trifluoromethyl)phenylisocyanate (0.9 g, 3.6 mmol) was added and the reaction mixture was stirred at room temperature overnight.
The solvent was concentrated in vacuo to 5 - 10 mL and the crystals were isolated by filtration to afford 1.45 g (81 %) of traps-4-[1-(3,5-bis(trifluoromethyl)phenyl)-3-(4-tert-butylcyclohexyl)ureido-methyl]benzoic acid methyl ester:
'H-NMR (DMSO-ds): ~ 9.08 (s, 1 H); 8.25 (s, 2H); 7.91 (d, 2H); 7.60 (s, 1 H);
7.40 (d, 2H);
4.65 (s, 2H); 4.07 (broad, 1 H); 3.83 (s, 3H); 1.71 (broad, 4H); 1.42 (broad, 2H); 1.11 (broad, 2H); 0.93 (broad, 1 H); HPLC-MS (Method B): m/z = 559 (M+1 ); Rt = 9.40 min;
M.p. 188-190 °C (CH3CN).
Microanalysis: Calculated for C~gHg~N~FgO3:
C, 60.21 %; H, 5.77%; N, 5.02%. Found:
C, 60.46%; H, 5.94%; N, 5.00%.

Step 2a' Trans-4-f1-(3 5-bis(trifluoromethyl)phenyl)-3-(4-tert butylcyclohexyl)ureidomethyll-benzoic acid Trans-4-[1-(3,5-bis(trifluoromethyl)phenyl)-3-(4-tert-butylcyclohexyl)ureidomethyl]benzoic acid methyl ester (1.4g) was suspended in absolute ethanol (20 mL), sodium hydroxide (2N, 11 mL) was added and the reaction mixture was gently refluxed for 2 hours. The ethanol was removed in vacuo, additional water (40 mL) was added, pH was adjusted with hydrochloride (4 N) to acidic reaction and then ethyl acetate (200 mL) was added. The organic phase was isolated, washed with water (4 x 50 mL), dried with magnesium sulphate, filtered and evapo-rated in vacuo, affording 1.1 g (85%) traps-4-[1-(3,5-bis(trifluoromethyl)phenyl)-3-(4-tert-butylcyclohexyl)ureidomethyl]benzoic acid as a solid.
' H-NMR (DMSO-d6): S 12.85 (s, 1 H); 9.08 (s, 1 H); 8.25 (s, 2H); 7.89 (d, 2H); 7.61 (s, 1 H);
7.38 (d, 2H); 4.65 (s, 2H); 4.07 (m, 1 H); 1.73 (m, 4H); 1.43 (m, 2H); 1.11 (m, 2H); 0.93 (m, 1 H); 0.82 (s, 9H); M.p. 239-241 °C (MeCN).
Microanalysis: Calculated for C2~H3oN2F603:
C, 59.55%; H, 5.55%; N, 5.14%. Found:
C, 59.58%; H, 5.65%; N, 5.11 %.
Following steps 3 and 4 afforded the title compound.
'H-NMR (DMSO-ds): 80.83 (s, 9H), 0.90-0.99 (m, 1H), 1.06-1.15 (m, 2H), 1.37-1.50 (m, 2H), 1.64-1.80 (m, 4H), 3.35-3.43 (m, 1 H), 3.52-3.61 (m, 1 H), 4.01-4.11 (m, 1 H), 4.18 (t, 1 H), 4.63 (s, 2H), 7.35 (d, 2H), 7.61 (s, 1 H), 7.81 (d, 2H), 8.27 (s, 2H), 8.43 (t, 1 H), 9.07 (s, 1 H), 12.46 (broad, 1 H); HPLC-MS (Method A): m/z = 632 (M+1 ); Rt = 8.00 min; M.p. 185-187 °C.
Microanalysis: Calculated for C3oH35FsN3O5~
C, 57.05%; H, 5.59%; N, 6.65%. Found:
C, 57.32%; H, 5.70%; N, 6.27%.

Example 14 (General procedure (A)) lRl-Trans-3-f4-f3-(3.5-bis(trifluoromethvl)phenyl)-1-(4-terl-butvlcyclohexvl)ureidometh benzoylamino)-2-h rLdroxypropionic acid Trans O O
HON
OH H I / N N ~ .F F
(R) 0 F F F
'H-NMR (DMSO-d6): 80.82 (s, 9H), 0.93 (m, 1H), 1.11 (m, 2H), 1.43 (m, 2H), 1.71 (m, 4H), 3.38 (m, 1 H), 3.56 (m, 1 H), 4.05 (m, 1 H), 4.16 (t, 1 H), 4.63 (s, 2H), 7.33 (d, 2H), 7.61 (s, 1 H), 7.80 (d, 2H), 8.26 (s, 2H), 8.43 (t, 1 H); HPLC-MS (Method A): mlz = 632 (M+1 ); Rt = 8.17 min; M.p. 184 -187 °C.
Microanalysis: Calculated for C3oH3sNsFsOs (+ 0.5 ethyl acetate):
C, 56.88%; H, 5.82%; N, 6.22%. Found:
C, 56.63%; H, 5.66%; N, 6.47%.
Example 15 (General procedure (A)) Trans~R)-3-~4-f3-(3-methyl-5-trifluoromethylphenyl)-1-(4-Pert butylcyclohexyl)ureidomethyll-benzoylamino)-2-hydroxypropionic acid Trans O O
HON ~ H F
OH H I / N~N I ~ F
(R) IOI /

'H-NMR (DMSO-ds): 80.82 (s, 9H), 0.93 (m, 1H), 1.11 (m, 2H), 1.43 (m, 2H), 1.71 (m, 4H), 2.33 (s, 3H), 3.38 (m, 1 H), 3.56 (m, 1 H), 4.05 (m, 1 H), 4.16 (t, 1 H), 4.63 (s, 2H), 7.10 (s, 1 H), 7.33 (d, 2H), 7.73 (s, 1 H), 7.80 (d, 2H), 8.43 (t, 1 H), 8.62 (s, 1 H); HPLC-MS (Method A): m/z = 578 (M+1 ); Rt = 7.45 min.

Example 16 (General procedure (A)) (RS)-3-f4-f1-(4-tert Butylphenyl)-3-(4-trifluoromethoxyphenyl)ureidomethyllbenzoylamino}-2-hydroxypropionic acid HON
OH H I / NuN
FI' (R5) O I ~ O~F
Step 1: 4-f 1-(4-tent-But r~l ~henyl)-3-(4-trifluoromethoxyphenyl)ureidomethyllbenzoic acid 4-Formylbenzoic acid methyl ester (10.6 g, 64 mmol) was dissolved in methanol (200 mL).
4-tent-Butylaniline (9.61 g, 64 mmol) was added and the resulting suspension was refluxed for 15 min. After cooling to room temperature, TFA (5.18 mL, 68 mmol) was added followed by portion wise addition of sodium cyanoborohydride (3.26 g, 52 mmol). The resulting mix-ture was stirred at room temperature for 2 hours and concentrated in vacuo.
The residue was partitioned between ethyl acetate (200 mL) and 1 N aqueous sodium hydroxide (150 and 100 mL). The organic phase was dried (magnesium sulphate) and evaporated in vacuo to afford 19.0 g (99%) of 4-[(4-tert-butylphenylamino)methyl]benzoic acid methyl ester as a solid.
'H-NMR (CDC13): X1.28 (9H, s), 3.92 (3H, s), 4.39 (2H, s), 6.57 (2H, d), 7.20 (2H, d), 7.44 (2H, d), 8.00 (2H, d).
Step 2:
The above benzoic acid methyl ester (0.73 g, 2.44 mmol) was dissolved in acetonitrile (7 mL) and 4-trifluoromethoxyphenylisocyanate (405 ~.L, 2.68 mmol) was added. The resulting mix-ture was stirred at room temperature for 3 hours and then refluxed for 1.5 hour. After cooling and concentration in vacuo, the residue was purified by column chromatography on silica gel, eluting first with a mixture of ethyl acetate and heptane (1:6), then with a mixture of ethyl ace-tate and heptane (1:3) to afford 1.14 g (94%) of 4-[1-(4-tert butylphenyl)-3-(4-trifluoro-methoxyphenyl)ureidomethyl]benzoic acid methyl ester as an oil.
'H-NMR (CDCI3): 8 1.35 (9H, s), 3.91 (3H, s), 4.97 (2H, s), 6.30 (1H, s), 7.1 (4H, m), 7.32 7.43 (6H, m), 7.96 (2H, d). TLC: Rf = 0.11 (Si02; ethyl acetate/heptane (1:6)); HPLC-MS
(Method B): m/z = 501 (M+1 ); Rt = 9.05 min.

Step 2a:
The above ureidomethylbenzoic acid methyl ester (1.14 g, 2.28 mmol) was dissolved in 1,4-dioxane (25 mL) and added 1 N aqueous sodium hydroxide (5 mL). The resulting mixture was stirred at room temperature for 1 hour. Ethanol (15 mL) and 1 N aqueous sodium hy-droxide (5 mL) were added and the resulting mixture was stirred at room temperature for 16 hours. The mixture was concentrated in vacuo and partitioned between 1 N
hydrochloric acid (100 mL) and ethyl acetate (2 x 50 mL). The combined organic phases were dried (magne sium sulphate) and concentrated in vacuo to afford 847 mg (76%) of 4-[1-(4-tart-butylphenyl) 3-(4-trifluoromethoxyphenyl)ureidomethyl]benzoic acid as a solid.
'H-NMR {CDC13): 8 1.33 (9H, s), 3.91 (3H, s), 4.97 (2H, s), 6.30 (1 H, s), 7.1 (4H, m), 7.33 (2H, d), 7.43 (4H, m), 8.03 (2H, d).
Step 3: (RS)-3-f4-f1-(4-tart ButLrlphenyl)-3-(4-trifluoromethoxyphenyl)ureidomethyllbenzoyl-amino}-2-hydroxypropionic acid ethyl ester To a solution of [1-(4-tart butylphenyl)-3-(4-trifluoromethoxyphenyl)ureidomethyl]benzoic acid (1.0 g, 2.06 mmol) in DMF (1 mL) and DCM (10 mL) was added 1-hydroxy-7-azabenzo-triazole (0.33 g, 2.47 mmol). After stirring for 1 hour at room temperature, EDAC (0.47 g, 2.47 mmol), (RS)-isoserine ethyl ester hydrochloride (0.52 g, 3.09 mmol) and diisopro-pylethylamine (1.1 mL, 6.18 mmol) were added, successively. After stirring for 17 hours at ambient temperature the reaction mixture was partitioned between water, brine and ethyl acetate. The aqueous phase was further extracted with ethyl acetate. The combined organic phases were washed with water and brine. After drying (magnesium sulphate) and filtration, the organic phase was evaporated in vacuo. The residue was purified by column chromatog-raphy on silica gel eluting with a mixture of toluene and ethyl acetate (6:4).
This afforded 1.2 g (97%) of (RS)-3-~4-[1-(4-tart butylphenyl)-3-(4-trifluoromethoxyphenyl)ureidomethyl]
benzoylamino}-2-hydroxypropionic acid ethyl ester as an oil.
'H-NMR (DMSO-ds): 81.12 (t, 3H), 1.27 (s, 9H), 3.45 (m, 2H), 4.05 (q, 2H), 4.21 (dd, 1 H), 4.98 (s, 2H), 5.67 (d, 1 H), 7.20 (dd, 4H), 7.35 (dd, 4H), 7.55 (d, 2H), 5.77 (d, 2H), 8.42 (s, 1 H), 8.48 (t, 1 H); HPLC-MS (Method B): m/z = 602 (M+1 ); Rt = 3.38 min.
St_ ep 4:
A solution of 3-(4-[1-(4-tart-butylphenyl)-3-(4-trifluoromethoxyphenyl)ureidomethyl]benzoyl-amino}-2-hydroxypropionic acid ethyl ester was stirred in absolute ethanol (20 mL) and 1 M

sodium hydroxide (6 mL) was added. Stirring was continued for 17 hours and the solution was acidified with aqueous hydrochloric acid. The solvent was decanted and the remaining oil was dissolved in acetonitrile (20 mL) by heating. Water (20 mL) was added dropwise un-der vigorous stirring and the mixture was allowed to cool to room temperature.
The precipi-5 tate was filtered off, washed with water and dried to afford 0.51 g (43%) of the title compound as a solid.
' H-NMR (DMSO-ds): s 1.25 (s, 9H), 3.50 (ddd, 2H), 4.18 (dd, 1 H), 4.95 (s, 2H), 7.20 (dd, 4H), 7.39 (dd, 4H), 7.52 (d, 2H), 7.78 (d, 2H), 8.32 (s, 1 H), 8.46 (t, 1 H); HPLC-MS (Method B):
10 m/z = 574 (M+1 ); Rt = 3.07 min.
Microanalysis: Calculated for C29H3oF3N3Os~
C, 60.73%; H, 5.27%; N, 7.33%. Found:
C, 60.77%; H, 5.37; N%, 7.26%.
Example 17 (General procedure (A) (RSl-3-f4-f 1-(4-Cvclohex-1-envlahenvl)-3-(3.5-d ich loroahenvl)ureidomethvllbenzovlaminol-2-hydroxypropionic acid HON
OH H I / N~N ~ CI
(RS) O I i CI
Step 3: (RSl-3-f4-f1-~4-Cyclohex-1-enylphenyl)-3-(3,5-dichlorophenyl)ureidomethyllbenzoyl-aminol-2-hydro~pro~ionic acid ethyl ester Yield: 0.33 g (89%).
'H-NMR (CDCI3): 81.30 (t, 3H), 1.68 (m, 2H), 1.79 (m, 2H), 2.23 (m, 2H), 2.38 (m, 2H), 3.41 {d, 1 H), 3.83 {m, 2H), 4.27 (q, 2H), 4.37 (dd, 1 H), 4.92 (s, 2H), 6.20 (m, 1 H), 6.27 (s, 1 H), 6.51 (t, 1 H), 6.98 (s, 1 H), 7.04 (d, 2H), 7.18 (d, 2H), 7.33 (d, 2H), 7.42 (d, 2H), 7.68 (d, 2H).

Step 4: (RS)-3-f4-f1-(4-Cyclohex-1-enylphenyl)-3~3,5-dichlorophenLrl)ureidomethyllbenzoyl-amino-2-hvdroxypro~ionic acid A solution of (RS)-3-f4-[1-(4-cyclohex-1-enylphenyl)-3-(3,5-dichlorophenyl)ureidomethyl]-benzoylamino}-2-hydroxypropionic acid ethyl ester (0.99 g, 1.61 mmol) in ethanol (15 mL) and THF (15 mL) was stirred and 1 M sodium hydroxide (6 mL) was added. The mixture was stirred at 40 °C for 4 hours and acidified with 1 N hydrochloric acid.
After evaporation in vacuo the residue was purified on semipreperative HPLC (Gilson system). The pure fractions were combined and evaporated in vacuo to afford 0.74 g (79%) of the title compound as a solid.
'H-NMR (DMSO-ds): b'1.56 (m, 2H), 1.70 (m, 2H), 2.17 (s, 2H), 2.33 (s, 2H), 3.35 (m, 2H), 3.55 (m, 2H), 4.15 (dd, 1 H), 4.95 (s, 2H), 6.20 (s. 1 H), 7.12 (s, 1 H), 7.18 (d, 2H), 7.33 (d, 2H), 7.40 (d, 2H), 7.62 (s, 2H), 7.76 (d, 2H), 8.43 (t, 1 H), 8.55 (s, 1 H);
HPLC-MS (Method B):
m/z = 582 (M+1 ); Rt = 5.13 min.
Microanalysis: Calculated for C29H3oCIzN3O5:
C, 61.86%; H, 5.02%; N, 7.21 %. Found:
C, 61.10%; H, 5.05%; N, 7.03%.
Example 18 (S)-3-f4-f1-(4-Cyclohex-1-enylphenyl)-3-(3.5-dichlorophenyl)ureidomethyllbenzoylamino~-2-hydroxypropionic acid /

HON
OH H I / N~N ~ CI
LS) IOI I
CI
4-[1-(4-Cyclohex-1-enylphenyl)-3-(3,5-dichlorophenyl)ureidomethyl]benzoic acid (130 mg, 0.26 mmol) was dissolved in DMF (2 mL), then EDAC (50 mg, 0.26 mmol) and HOBt (43 mg, 0.32 mmol) were added and the reaction mixture was stirred at room temperature for 1 hour.
The above crude (S)-2,2-dimethyl-5-oxo-[1,3]dioxolan-4-ylmethylammonium trifluoroacetate was dissolved in DMF (1 mL) and added to the reaction mixture together with diisopropyl-ethylamine (450 mg, 3.5 mmol). The mixture was stirred at room temperature for 16 hours.

The reaction mixture was transferred to a silica gel column and eluted with DCM to afford crude (S)-4-[1-(4-cyclohex-1-enylphenyl)-3-(3,5-dichlorophenyl)ureidomethyl]-N-(2,2-di-methyl-5-oxo-[1,3]dioxolan-4-ylmethyl)benzamide as an oil after evaporation.
The oil was re-dissolved in acetonitrile (5 mL), hydrochloric acid (1 N, 5 mL) was added and the mixture was stirred at room temperature for 1.5 hour. The solvent was removed by evaporation and the crude product was purified on semipreperative HPLC (acetonitrileiwater gradient) to afford the title compound.
HPLC-MS (Method B): m/z = 582 (M+1 ); R~ = 5.10 min.
Example 19 (General procedure (A)) lR)-3-f4-f1-l4-Cvclohex-1-envlahenvl)-3-(3.5-dichloroahenvl)ureidomethvllbenzovlamino)-2-h~/droxypropionic acid HON
OH H I / N N ~ CI
(R) O
CI
Step 3: (R)-3-f4-f1-(4-C~iclohex-1-enylphenyl~3-~,5-dichlorophenyl)ureidomethyllbenzoyl-amino~-2-hydroxypropionic acid ethyl ester 'H-NMR (Acetone-ds): X1.20 (t, 3H), 1.70 (dm, 4H), 2.31 (dm, 4H), 3.70 (m, 2H), 4.15 (q, 2H), 4.35 (dd, 1 H), 5.02 (s, 2H), 6.22 (m, 1 H), 7.00 (s, 1 H), 7.20 (d, 2H), 7.40 (dd, 4H), 7.61 (ds, 2H), 7.80 (d, 3H), 7.89 (s, 1 H).
St_ ep 4:
A solution of (R)-3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(3,5-dichlorophenyl)ureidomethyl]-benzoylamino}-2-hydroxypropionic acid ethyl ester (0.60 g, 0.98 mmol) in ethanol (5 mL) and THF (5 mL) was stirred and 4 N sodium hydroxide (0.76 mL, 2.94 mmol) was added. The so-lution was stirred for 3 hours at room temperature and then acidified with 1 N
hydrochloric acid. Evaporation in vacuo afforded an oil, which was partitioned between ethyl acetate, wa-ter and brine. The aqueous phase was extracted twice with ethyl acetate and the combined organic phases were washed with water and brine. Drying (magnesium sulphate), filtration, and evaporation in vacuo afforded 0.43 g (73%) of the title compound as a solid.
'H-NMR (DMSO-ds): 81.50-1.80 (4H, m), 2.08-2.38 (4H, m), 3.36-3.65 (2H, m), 4.14-4.24 (1 H, m), 4.96 (2H, m), 6.17 (1 H, t), 7.14 (1 H, t), 7.18 (2H, d), 7.35 (2H, d), 7.42 (2H, d), 7.63 (2H, d), 7.78 (2H, d), 8.48 (1 H, t), 8.55 (1 H, s); HPLC-MS (Method B): m/z =
582 (M+1 ); Rt =
5.11 min.
Example 20 (General procedure (A)) (R)-3-f4-I'3-(3-Chlorophenyl)-1-(4-cyclohex-1-en Iphen~i~ureidomethyllbenzoylamino~-2-hydroxypropionic acid HON
OH H I i N N CI
(R) 0 'H-NMR (DMSO-d6): 81.56-1.71 (m, 4H), 2.15-2.33 (m, 4H), 3.37-3.51 (m, 2H), 4.14-4.17 (m, 1 H), 4.96 (s, 1 H), 6.17 (t, 1 H), 7.12 (dd, 1 H), 7.27-7.41 (m, 8H), 7.62 (t, 1 H), 7.87 (d, 2H), 8.38-8.43 (m, 3H); HPLC-MS (Method B): m/z = 548 (M+1 ); Rt = 4.69 min.
Example 21 (General procedure (A)) (R)-3-f4-f1-(4-Cyclohex-1-enylphenyl)-3-phenylureidomethyllbenzoylamino)-2-hydroxy-propionic acid HO~N~ ~
OH H I / N N
(R) O ~ i 'H-NMR (DMSO-d6): 81.56-1.71 (m, 4H), 2.15-2.40 (m, 4H), 3.30-3.51 (m, 2H), 4.14-4.19 (m, 1 H), 4.97 (s, 1 H), 6.16 (t, 1 H), 6.98 (t, 1 H), 7.12-7.48 (m, 1 OH), 7.79 (d, 2H), 8.15 (s, 1 H), 8.43 (t, 1 H).
Example 22 (General procedure (A)) (R)-3-f4-f3-Benzyl-1-(4-cyclohex-1-enylphenyl)ureidomethyllbenzoylamino)-2-hydroxy-pro~ionic acid HON ~ ~ H
OH H I i N N
(R) O
'H-NMR (DMSO-ds): 81.50-1.75 (m, 4H), 1.86 (s, 2H), 2.08 (s, 2H), 3.30-3.60 (m, 2H), 4.13-4.20 (m, 1 H), 4.25 (d, 2H)~ 4.87 (s, 2H), 6.18 (t, 1 H), 6.55 (t, 1 H), 7.08-7.42 (m, 11 H), 7.77 (d, 2H), 8.48 (t, 1 H).
Example 23 (General procedure (A)) (RS)-3-f4-(1-(4-Cyclohex-1-enylphenyl )3-(3,5-dichlorophenyl)ureidomethyllbenzoylamino~-2-fluoropropionic acid HON
F H I / N~N ~ CI
IOI
CI
Steps 1 and 2: 4-f1-(4-Cyclohex-1-enylphenyl)-3-(3 5-dichlorophenyl)ureidomethyllbenzoic 2o acid 'H-NMR (DMSO-ds): 81.52-1.77 (m, 4H), 2.10-2.23 (m, 2H), 2.26-2.38 (m, 2H), 4.95 (s, 2H), 6.18 (t, 1 H), 7.14 (t, 1 H), 7.17 (d, 2H), 7.34 (d, 2H), 7.40 (d, 2H), 7.64 (dd, 2H), 7.85 (d, 2H), 8.55 (s, 1 H).

Microanalysis: Calculated for CZ~H~4N203Ch:
C, 65.46%; H, 4.88%; N, 5.65%. Found:
C, 65.43%; H, 5.10%; N, 5.66%.
5 Step 3: (RS)-3-f4-f1-(4-Cyclohex-1-enylphenyl)-3-(3,5-dichlorophenyl)ureidomethyllbenzo r~l-amino)-2-fluoropropionic acid methyl ester 'H-NMR (DMSO-d6): 81.52-1.75 (m, 4H), 2.10-2.40 (m, 4H), 3.60-3.81 (m, 5H), 4.95 (s, 2H), 5.04-5.35 (m, 1 H), 6.18 (m, 1 H), 7.10-7.80 (m, 11 H), 8.55 (s, 1 H), 8.75 (t, 1 H), 13.45 (br s, 1 H).
Step 4:
Hydrolysis of (RS)-3-~4-[1-(4-cyclohex-1-enylphenyl)-3-(3,5-dichlorophenyl)ureidomethyl]-benzoylamino}-2-fluoropropionic acid methyl ester in a mixture of THF and methanol afforded the title compound.
'H-NMR (DMSO-d6): 81.59-1.72 (m, 4H), 2.15-2.33 (m, 4H), 3.58-3.81 (m, 2H), 4.96 (s, 2H), 5.17-5.23 (m, 1 H), 6.18 (m, 1 H), 7.13-7.80 (m, 11 H), 8.54 (s, 1 H), 8.73 (t, 1 H), 13.45 (br s, 1 H).
2o Example 24 (General procedure (A)) ~R)-3-f4-f 1-(4-Cyclohexylphenyl)-3-(4-trifluoromethylsulfanylphenyl)ureidomethyllbenzoyl-amino)-2-hydroxypropionic acid HO~N~ ~
OH H I / N N
~R) O I i ~G F
S F
Step 2: 4-f1-(4-Cyclohexylphenyl)-3-(4-trifluoromethylsulfanylphenyl)ureidomethyllbenzoic acid methyl ester 4-((4-Cyclohexylphenylamino)methyl)benzoic acid methyl ester (0.32 g, 1 mmol) was sus-pended in acetonitrile (5 mL) and 4-(trifluoromethylthio)phenyl isocyanate (0.24 g, 1.1 mmol) was added. Additional amounts (0.05 g) of the isocyanate was added after the first day and again after the second day (0.05 g). The reaction was stopped on the'third day and concen-trated in vacuo. The residue was purified by column chromatography on silica gel (30 g) us-ing ethyl acetate: n-heptane (400 mL 1:4 and 100 mL 1:1) as eluent to afford 0.53 g of 4-[1-(4-cyclohexylphenyl)-3-(4-trifluoromethylsulfanylphenyl)ureidomethyl]benzoic acid methyl es-ter.
'H-NMR (DMSO-d6): X1.16-1.43 (m, 5H), 1.65-1.82 (m, 5H), 3.84 (s, 3H), 4.99 (s, 2H), 8.62 (s, 1 H); HPLC-MS (Method B): m/z = 543 (M+1 ); Rt = 9,35 min.
Step 2a: 4-f1-(4-CVclohexylphenyl)-3-(4-trifluoromethylsulfanylphenyl)ureidomethyllbenzoic acid 4-[1-(4-Cyclohexylphenyl)-3-(4-trifluoromethylsulfanylphenyl)ureidomethyl]benzoic acid methyl ester (0.53 g, 0.98 mmol) was dissolved in ethanol (96%, 11 mL) and sodium hydrox-ide (4 N, 1.47 mL) was added. The mixture was stirred overnight. The reaction was concen-trated to dryness and added water (15 mL) and acidified with hydrochloric acid (4 N, 1.6 mL) to pH 2-3 and extracted with ethyl acetate (25 mL). The aqueous phase was extracted once more with ethyl acetate (15 mL) and the combined organic phases were washed 3 times with water (10 mL), dried over magnesium sulphate, filtered and concentrated in vacuo. Crystalli sation from ethyl acetate:n-heptane gave 0.34 g of 4-[1-(4-cyclohexylphenyl)-3-(4-trifluoro methylsulfanylphenyl)ureidomethyl]benzoic acid.
'H-NMR (DMSO-ds): s 1.5-1.42 (m, 5H), 1.67-1.83 (m, 5H), 2.45 (m, 1 H), 5.00 (s, 2H), 7.15-7.25 (dd, 4H), 7.40 (d, 2H), 7.54-7.63 (dd, 4H), 7.88 (d, 2H), 7.62 (s, 1 H), 12.90 (broad, 1 H), HPLC-MS (Method B): m/z = 529 (M+1 ); Rt = 8.55 min; M.p. 162.0-164.0 °C.
Microanalysis: Calculated for CpgH27F3NzO3S:
C, 63.62°!°; H, 5.15°!°; N, 5.30%. Found:
C, 63.97%; H, 5.28%; N, 5.26%.
Step 3: (R)-3-f4-f1-(4-Cyclohexylphenyl)-3-(4-trifluorometh~ilsulfanylphenyl)ureidomethyll-benzoylamino~-2-hydroxypropionic acid methyl ester 4-[1-(4-Cyclohexylphenyl)-3-(4-trifluoromethylsulfanylphenyl)ureidomethyl]benzoic acid (0.32 g, 0.606 mmol) was dissolved in DMF (7 mL) and HOAt (0.10 g, 0.727 mmol) and EDAC
(0.14 g, 0.727 mmol) were added. The mixture was stirred for 30 min. Then (R)-3-amino-2-hydroxypropionic acid methyl ester hydrochloride (0.14 g) and diisopropylethylamine (0.16 mL, 0.909 mmol) were added. The reaction was stirred overnight. The reaction mixture was transferred to a separatory funnel with ethyl acetate (30 mL) and water (15 mL) and ex-tracted. The aqueous phase was extracted once more with ethyl acetate (15 mL) and the combined organic phases were washed with hydrochloric acid (0.2 N, 3 x 10 mL) and an aqueous solution of saturated sodium chloride (3 x 10 mL), dried over magnesium sulphate, filtered and concentrated in vacuo. The residue was purified on a column (silica gel, 30 g) using a mixture of ethyl acetate and n-heptane (200 mL, 40:60 and 450 mL 1:1 ) as eluent to afford 0.33 g of (R)-3-{4-[1-(4-cyclohexylphenyl)-3-(4-trifluoromethylsulfanylphenyl)-ureidomethyl]benzoylamino}-2-hydroxypropionic acid methyl ester.
'H-NMR (DMSO-ds) s 1.16-1.43 (m, 5H), 1.66-1.81 (m, 5H), 2.47 (m, 1 H), 3.4 (m, 1 H), 3.51 (m, 1 H), 3.63 (s, 3H), 4.22 (q, 1 H), 4.97 (s, 2H), 5.73 (d, 1 H), 7.2 (dd, (4H), 7.35 (d, 2H), 7.60 (dd, 4H), 7.76 (d, 2H), 8.50 (t, 1 H), 8.60 (s, 1 H), HPLC-MS (Method B): m/z = 630 (M+1 ); Rt = 8.07 min.
Step 4:
(R)-3-{4-[1-(4-Cyclohexylphenyl)-3-(4-trifluoromethylsulfanylphenyl)ureidomethyl]benzoyl amino}-2-hydroxypropionic acid methyl ester (0.32 g, 0.508 mmol) was dissolved in ethanol (15 mL) and sodium hydroxide (4 N, 0.76 mL, 3.05 mmol) was added. The reaction mixture was stirred for 1.5 hour. The reaction was evaporated and added water (15 mL) and acidified with hydrochloric acid (4 N, 0.8 mL). The mixture was extracted with ethyl acetate (20 mL).
The aqueous phase was extracted once more with ethyl acetate (15 mL) and the combined organic phases were washed with water (3 x 10 mL), dried over magnesium sulphate, filtered and concentrated to give the title compound (0.3 g).
'H-NMR (DMSO-ds): ~ 1.12-1.42 (m, 5H), 1.66-1.82 (m, 5H), 2.45 (m, 1 H), 3.38 (m, 1 H), 3.54 (m, 1 H), 4.17 (q, 1 H), 4.96 (s, 2H), 5.45 (broad, 1 H), 7.20 (dd, 4H), 7.34 (d, 2H), 7.60 (dd, 4H), 7.78 (d, 2H), 8.45 (t, 1 H), 8.60 (s, 1 H), 12.53 (broad, 1 H), HPLC-MS
(Method B): mlz =
616 (M+1 ); Rt = 7.68 min.
3o Microanalysis: Calculated for C3~H3zF3N3O5S~
C, 60.48%; H, 5.24%; N, 6.83%. Found:
C, 60.25%; H, 5.52%; N, 6.53%.

Example 25 (General procedure (A)) (R)-3-(4J~1-(4-Cyclohexen-1-ylphenyl)-3-(3-methanesulfo~l-4-trifluoromethoxyphenyl)ureido-methyllbenzoylamino)-2-hydroxypropionic acid HON
O O
OH H I ~ N~N ~ ~S' H
s O
F-~--F
F
Preparation of 3-methylsulfonyl-4-trifluoromethoxyphenyl isocyanate, intermediate D-N=C=O
used in step 2:
To a solution of methyl iodide (59.0 g, 0.41 mol) in DMF (150 mL) was added potassium car-bonate (23.0 g, 0.16 mol). 2-(Triffuoromethoxy)thiophenol (16.0 g, 0.08 mol) was added in portions during 30 min. The reaction mixture was then stirred vigorously overnight. Water (250 mL) was added. The reaction mixture was extracted with ethyl acetate (2 x 150 mL).
The combined organic phases were washed with a 50% saturated aqueous solution of so-dium chloride (4 x 100 mL), dried (magnesium sulphate), and concentrated in vacuo to give 15.0 g of 1-methylsulfanyl-2-trifluoromethoxybenzene.
1-Methylsulfanyl-2-trifluoromethoxybenzene (15.0 g, 72 mmol) was dissolved in DCM (200 mL) and m-chloroperoxybenzoic acid (39.0 g, 216 mmol) was added in small portions during 30 min. The reaction mixture was then allowed to stand overnight. DCM (200 mL) was added 2o followed by slow addition of sodium hydroxide (2 N, 200 mL). The organic phase was sepa-rated and washed with sodium hydroxide (2 N, 3 x 150 mL), dried (magnesium sulphate) and concentrated in vacuo to give 15.8 g of 1-methylsulfonyl-2-trifluoromethoxybenzene 'H-NMR (400 MHz, CDCI3): 88.11 (d, 1 H), 7.71 (t, 1 H), 7.48 (m, 2H) 3.23(s 1 H);
M.p. 44-46 °C.
Microanalysis: Calculated for C$H,F303S:
C, 40.00%; H, 2.94°t°. Found:
C, 40.22%; H, 2.92%.

1-Methylsulfonyl-2-trifluoromethoxybenzene (15.7 g, 65 mmol) was dissolved in concentrated sulfuric acid (27 mL) and the solution was heated to 40 °C. Nitric acid (100%, 27 mL) was added dropwise over 45 min. The reaction mixture was allowed to stand overnight at 60 °C, cooled, and then poured on crushed ice (300 mL). The precipitated product was isolated by filtration, washed with water (10 x 50 mL) and dried (magnesium sulphate), affording 17.5 g of 3-methylsulfonyl-4-trifluoromethoxynitrobenzene.
'H-NMR (400 MHz, DMSO-d6): 8 8.69 (d, 1 H), 8.64 (d, 1 H), 7.95 (d, 1 H) 3.45 (s 3H); M.p.
102-104 °C.
Microanalysis: Calculated for C8H6F3N05S:
C, 33.69%; H, 2.12%; N, 4.91 %. Found:
C, 33.91 %; H, 2.08%; N, 4.92%.
3-Methylsulfonyl-4-trifluoromethoxynitrobenzene (17.5 g) was dissolved in methanol (400 mL) followed by addition of palladium on carbon (10%, 50% water, 3.2 g). The reaction mix-ture was hydrogenated for 17 hours at 1 atm of hydrogen, filtered and concentrated in vacuo to give 14.3 g of 3-methylsulfonyl-4-trifluoromethoxyaniline.
' H-NMR (400 MHz, DMSO-d6): 8 7.26 (d, 1 H), 7.14 (d, 1 H), 6.85 (dd, 1 H) 5.89(s, 2H) 3.21 (s, 3H); M.p. 106-109 °C.
Microanalysis: Calculated for C8H$F3N03S:
37.65% C, 3.16% H, 5.49% N. Found:
37.65% C, 3.14% H, 5.45% N.
To 3-methylsulfonyl-4-trifluoromethoxyaniline (2.0 mmol, 500 mg) dissolved in ethyl acetate (6 mL) was added 3 N hydrochloric acid in ethyl acetate (5 mL) followed by concentration in vacuo. The residue was treated with toluene (3 x 5 mL) and each time concentrated in vacuo. To the residue was added toluene (10 mL) and diphosgene (6 mmol, 0.73 mL) under a nitrogen atmosphere and the suspension was gently refluxed for 2 hours, Additional di-phosgene (6 mmol, 0.73 mL) was added and refluxing was continued overnight.
The reaction mixture was concentrated in vacuo to afford 3-methylsulfonyl-4-trifluoromethoxyphenyl iso-cyanate.

Step 3: (R)-3-f4-f1-(4-cyclohexen-1-ylphenyl)-3-(3-methanesulfonyl-4-trifluoromethoxy-phenyl)ureidomethyllbenzoylamino~-2-hydroxypropionic acid methyl ester This intermediate was prepared using general procedure (A) (steps 1, 2, 2a, and 3).

'H-NMR (DMSO-ds): 81.60 (m, 2H), 1.72 (m, 2H), 2.18 (m, 2H), 2.36 (m, 2H), 3.27 (s, 3H), 3.41 (m, 1 H), 3.51 (m, 1 H), 3.61 (s, 3H), 4.23 (q, 1 H), 4.96 (s, 2H), 5.70 (d, 1 H), 6.18 (m, 1 H), 7.19 (d, 2H), 7.33 (d, 2H), 7.39 (d, 2H), 7.53 (d, 1 H), 7.75 (d, 2H), 8.00 (d, 1 H), 8.18 (s, 1 H), 8.50 (t, 1 H), 8.85 (s, 1 H); HPLC-MS (Method B): m/z = 690 (M+1 ); Rt =
6.92 min.
Step 4:
Hydrolysis of (R)-3-{4-[1-(4-cyclohexen-1-ylphenyl)-3-(3-methanesulfonyl-4-trifluoromethoxy-phenyl)ureidomethyl]benzoylamino}-2-hydroxypropionic acid methyl afforded the title com-op und.
'H-NMR (DMSO-ds): F1.60 (m, 2H), 1.72 (m, 2H), 2.18 (m, 2H), 2.36 (m, 2H), 3.27 (s, 3H), 3.41 (m, 1 H), 3.51 (m, 1 H), 4.17 (t, 1 H), 4.96 (s, 2H), 5.50 (broad, 1 H), 6.18 (m, 1 H), 7.19 (d, 2H), 7.33 (d, 2H), 7.39 (d, 2H), 7.53 (d, 1 H), 7.75 (d, 2H), 8.00 (d, 1 H), 8.18 (s, 1 H), 8.50 (t, 1 H), 8.85 (s, 1 H), 12.55 (broad, 1 H); HPLC-MS (Method B): m/z = 676 (M+1 );
Rt = 6.50 min.
Example 26 (General procedure (A)) Trans-lR)-3-f4-f-3-(3.5-bis(methyl)phenyl)-1-(4-tert-butvlcvclohex rL?I
ureidomethyl benzo amino-2-hydroxypropionic acid O p Trans HON
OH H I ~ N~N I ~ CH3 IOI

Steps 1 and 2: Trans-4-f3-(3,5-bis(methyl)phenyl)-1-(tert-butylcyclohexyl)ureidomethyll-benzoic acid methyl ester 'H-NMR (DMSO-d6): 80.82 (s, 9H), 0.93 (m, 1H), 1.11 (m, 2H), 1.41 (m, 2H), 1.71 (m, 4H), 2.23 (s, 6H), 3.83 (s, 3H), 4.09 (m, 1 H), 4.61 (s, 2H), 6.60 (s, 1 H), 7.08 (s, 2H), 7.38 (d, 2H), 7.90 (d, 2H), 8.20 (s, 1 H); HPLC-MS (Method B): m/z = 451 (M+1 ); Rt = 8.93 min.
Step 2a: Trans-4~[3-(3.5-bis(methyl)phenyl)-1-(tert-butylcyclohexyl)ureidomethyllbenzoic acid The compound was prepared by hydrolysis of trans-4-[3-(3,5-bis(methyl)phenyl)-1-(tent-butyl cyclohexyl)ureidomethyl]benzoic acid methyl ester.
'H-NMR (DMSO-d6): X0.82 (s, 9H), 0.93 (m, 1H), 1.11 (m, 2H), 1.41 (m, 2H), 1.71 (m, 4H), 2.23 (s, 6H), 4.09 (m, 1 H), 4.61 (s, 2H), 6.60 (s, 1 H), 7.08 (s, 2H), 7.38 (d, 2H), 7.90 (d, 2H), 8.20 (s, 1 H), 12.82 (s, 1 H); HPLC-MS (Method B): m/z = 437 (M+1 ); Rt = 8.00 min.
Microanalysis: Calculated for C2~H3gN2Og:
C, 74.28%; H, 8.31 %; N, 6.42%. Found:
C, 74.31 %; H, 8.40%; N, 6.35%.
Step 3: Trans-(R)-3-;4-f-3-(3.5-bis(methyl)phenyl)-1-(4-tert-butYfcyclohexyl)ureidomethyll-benzoylamino~-2-hydroxypropionic acid methyl ester:
This compound was prepared from trans-4-[3-(3,5-bis(methyl)phenyl)-1-(tent-butylcyclo-hexyl)ureidomethyl]benzoic acid.
'H-NMR (DMSO-d6): 60.82 (s, 9H), 0.93 (m, 1H), 1.11 (m, 2H), 1.43 (m, 2H), 1.71 (m, 4H), 2.23 (s, 6H), 3.42 (m, 1 H), 3.52 (m, 1 H), 3.63 (s, 3H), 4.05 (m, 1 H), 4.23 (q, 1 H), 4.59 (s, 2H), 5.70 (d, 1 H), 6.58 (s, 1 H), 7.08 (s, 2H), 7.30 (d, 2H), 7.78 (d, 2H), 8.18 (s, 1 H), 8,47 (t, 1 H);
HPLC-MS (Method B): m/z = 538 (M+1 ); Rt = 7.43 min; M.p. 159-160 °C.
Microanalysis: Calculated for Cg~H43N305~
C, 69.25%; H, 8.06%; N, 7.81 %. Found:
C, 69.03%; H, 8.15%; N, 7.79%.

Step 4:
Hydrolysis of traps-(R)-3-{4-[-3-(3,5-bis(methyl)phenyl)-1-(4-tert butylcyclohexyl)ureido-methyl]benzoylamino}-2-hydroxypropionic acid methyl ester afforded the title compound.
'H-NMR (DMSO-ds): 80.82 (s, 9H), 0.93 (m, 1 H), 1.11 (m, 2H), 1.43 (m, 2H), 1.71 (m, 4H), 2.23 (s, 6H), 3.40 (m, 1 H), 3.55 (m, 1 H), 4.05 (m, 1 H), 4.18 (t, 1 H), 4.59 (s, 2H), 6.58 (s, 1 H), 7.08 (s, 2H), 7.30 (d, 2H), 7.78 (d, 2H), 8.18 (s, 1 H), 8.47 (t, 1 H); HPLC-MS (Method B): mlz = 524 (M+1 ); Rt = 7.08 min.
Microanalysis: Cafeulated for C3pH41N305, 1'~2 H2O:
C, 65.43%; H, 8.05%; N, 7.63%. Found:
C, 65.54%; H, 7.93%; N, 7.44%.
Example 27 (General procedure (A)) (R~-3-~4-f1-(4-Cyclohexyfphenyl)-3-(3,5-dichlorophen r~l)ureidomethyllbenzoylamino~-2-hydroxypropionic acid HON
OH H I i N N CI
O
CI
'H-NMR (CDC13): 67.64 (d, 2H), 7.49 (br s, 1H), 7.25-7.15 (m, 6H), 7.03 (d, 2H), 6.90 (m, 1 H), 6.40 (s, 1 H), 4.75 (s, 2H), 4.30 (br s, 1 H), 3.80-3.60 (m, 2H), 2.49 (m, 1 H), 1.90-1.65 (m, 5H), 1.45-1.25 (m, 5H); HPLC-MS (Method B): m/z = 584 (M+1); Rt = 5.28 min.

Example 28 (General procedure (A)) lRl-l3-f4-f1-l4-Cvclohex-1-envlahenvl)-3-(3-fluoro-5-trifluoromethvlphen r~l ureidometh benzoylamino~-2-hydroxypropionic acid HON \
OH H I ~ N N F
O
(R) 'H-NMR (DMSO-ds): X8.75 (s, 1H), 8.42 (t, 1H), 7.75 (d, 4H), 7.45-7.30 (m, 4H), 7.20 (d, 3H), 6.20 (s, 1 H), 4.96 (s, 2H), 4.15 (dd, 1 H), 3.55 (m, 1 H), 3.40 (m, 1 H), 2.35 (br s, 2H), 2.15 (br s, 2H). 1.75-1.55 (m, 4 H); HPLC-MS (Method B): m/z = 600 (M+1 ); Rt = 5.01 min.
Example 29 (General procedure (A)) (R)-3-~4-f 1-(4-Cyclohexylphenyl)-3-(3-methylsulfanylphenyl)ureidomethLrllbenzoylamino)-2-hydroxypropionic acid HON \
H
OH H I i N N
CHs (R) O
'H-NMR (DMSO-d6): s 12.2 (br s, 1 H), 8.44 (t, 1 H), 8.20 (s, 1 H), 7.78 (m, 2H), 7.40 (s, 1 H), 7.33 (m, 2H), 7.25-7.10 (m, 6H), 6.84 (d, 1 H), 4.95 (s, 1 H), 4.15 (dd, 1 H), 3.55 (m, 1 H), 3.38 (m, 1 H). 2.42 (s, 3H) 1.85-1.65 (m, 5H), 1.40-1.15 (m, 5H); HPLC-MS (Method B): m/z = 562 (M+1 ); Rt = 4.77 min.

Example 30 (General procedure (A)) (R)-3-~4-f1-(4-Cyclohex-1-en 1y phenyl)-3-(2 2 4,4-tetrafluoro-4H-benzof1.31dioxin-6-yl)ureido-methyllbenzoylamino?-2-hydroxypropionic acid HO~ H F F
OH '~ N ~~\~
O~~
(R) O i O~F
'H-NMR (CDCI3): X7.70-7.50 (m, 3H), 7.45-7.30 (m, 4H), 7.25-6.85 (m, 6H), 6.12 (s, 1H), 4.80 (s, 2H), 4.28 (m, 1 H), 3.70 (m, 2H), 2.40-2.00 (m, 4H), 1.70-1.55 (m, 4H); HPLC-MS
(Method B): m/z = 644 (M+1 ); Rt = 5.13 min.
1o Example 31 (General procedure (A)) 3-f4-f 1-(4-Cyclohex-1-enylphenyl)-3-(3,5-dichlorophenyl)ureidomethyllbenzoylamino)-2LR)-methoxypropionic acid:
/
c o y HO~N~ /
OMe H I / N~N ~ CI
(R) IO' I /
CI
Step 3:
4-[1-(4-Cyclohex-1-enylphenyl)-3-(3,5-dichloro-phenyl)ureidomethyl]benzoic acid (500 mg, 1.0 mmol), HOBt (184 mg, 1.2 mmol) and EDAC (232 mg; 1.2 mmol) was dissolved in a mix-ture of DCM (4.0 mL) and DMF (1.0 mL). The clear solution was stirred at ambient tempera-ture for 1 hour. A solutiori of 3-amino-2(R)-methoxypropionic acid methyl ester hydrochloride (257 mg, 1.5 mmol) in DCM (2.0 mL) and DMF (0.2 mL) was added followed by diisopro-pylethylamine (515 p,L). The mixture was stirred at room temperature overnight, then diluted with DCM (40 mL) and washed once with a mixture of saturated sodium chloride/water (1:2).
The organic phase was dried with anhydrous sodium sulphate and taken to dryness in vacuo.

St ~ 4:
The oil was dissolved in a mixture ofi THF (4.0 mL) and methanol (4.0 mL). 4 N
Aqueous so-dium hydroxide was added (625 wL, 2.5 mmol) and the mixture was stirred at room tempera-s ture for 2 hours. The pH was adjusted to 3.0 with 1 N hydrochloric acid, then solvent was re-moved. The product was re-dissolved in ethyl acetate (20 mL) and washed once with water (20 mL). The water phase was back-extracted once with ethyl acetate (10 mL) and the com-bined organic extracts were washed with sodium chloride (2 x 20 mL) and dried over anhy-drous sodium sulphate. After removal of solvent, 230 mg (67%) of pure title compound was 10 obtained.
H-NMR (DMSO-ds): 812.90 (bs, 1 H), 8.55 (s, 1 H), 8.54 (t, 1 H), 7.76 (d, 2H), 7.63 (s, 2H), 7.41 (d, 2H), 7.34 (d, 2H), 7.20 (d, 2H), 7.15 (s, 1 H), 6.18 (s, 1 H), 4.95 (s, 2H), 3.90 (dd, 1 H), 3.57 (m, 1 H), 3.42 (m, 1 H), 3.29 (s, 3H), 2.34 (m, 2H), 2.16 (m, 2H), 1.70 (m, 2H), 1.59 (m, 15 2H); HPLC-MS (method B): m/z = 596.2 (M+1 ); Rt = 5.93 min.
Example 32 (General procedure (A)) 3-(4-f3-(3,5-Dichlorophenyl)-1-r4-(2-methylcyclohex-1-enyl)phen rLl]ureidomethyl)benzoyl-amino)-2-(R)-hydroxypropionic acid and (R,S)-3~4-f3-(3.5-dichlorophenyl)-1-f4-(6-methylcyclohex-1-enyl)phenyllureidomethyl~benzoylamino)-2-(R)-hydroxypropionic acid O O ~ O O
HO~H ~ I ~ I H HO~H ~ I \ H
OH ~N N ~ Ci OH w N N ~ Cl O ~ / O ~ i CI CI
Using the mixture of 4-(2-methylcyclohex-1-enyl)aniline and (R,S)-4-(6-methylcyclohex-1-enyl)aniline (building block 11 ) and (R)-3-amino-2-hydroxypropionic acid methyl ester (building block 5) according to the general procedure (A) the title compounds was obtained.
(R,S)-3-(4-{3-(3,5-Dichlorophenyl)-1-[4-(6-methylcyclohex-1-enyl)phenyl]ureidomethyl}-benzoylamino)-2(R)-hydroxypropionic acid:
'H-NMR (DMSO-d6): &1,55 (s,3H), 1,63 (bs,4H), 2,03 (bs,2H), 2,19 (bs,2H), 3,47 (dm,2H), 4,16 (m,1H), 4,96 (s,2H), 5,49 (bs,1H), 7,15 (m,SH), 7,33 (d,2H), 7,61 (s,2H), 7,78 (d,2H), 8,45 (t,1H), 8,65 (s,1H), 12,53 (bs,1H); M.p.: 105-107 °C; HPLC-MS
(Method B): m/z= 596 (M+); Rt = 5,34 min.
3-(4-{3-(3,5-Dichlorophenyl)-1-[4-(6-methylcyclohex-1-enyl)phenyl]ureidomethyl}benzoyl-amino)-2(R)-hydroxypropionic acid:
'H-NMR (DMSO-ds): 80,90 (ds,3H), 1,63 (bs,4H), 2,03 (bs,2H), 2,19 (bs,2H), 3,47 (dm,2H), 4,16 (m,1H), 4,96 (s,2H), 5,49 (bs,1H), 5,93 (t,1H), 7,15 (m,SH), 7,33 (d,2H), 7,61 (s,2H), 7,78 (d,2H), 8,45 (t,1H), 8,62 (s,1H), 12,53 (bs,1H).
1 o Example 33 (General procedure (A)) 3-f4-f 1-f4-(4-tert-Butylcyclohex-1-enyl)phenyll-3-(3,5-dichlorophenyl )ureidomethy~benzoyl-amino-2-(R)-hydroxypropionic acid i O O
HON
OH H I ~ N~N ~ CI
O
CI
Using 4-(4-tert-butylcyclohex-1-enyl)aniline (building block 12) and (R)-3-amino-2-hydroxy-propionic acid methyl ester (building block 5) according to the general procedure (A) the title co J~ound was obtained..
'H-NMR (DMSO-ds): 80,88 (s,9H), 1,23 (m,2H), 1,93(m,2H), 2,27 (m,3H), 3,47 (dm,2H), 2o 4,16 (dd,1H), 4,95 (s,2H), 6,19 (m,1H), 7,13 (m1 H), 7,18 (d,2H), 7,33 (d,2H), 7,39 (d,2H), 7,62 (s,2H), 7,77 (d,2H), 8,44 (t,1H), 8,55 (s,1H), 12,53 (bs,1H); M.p.: 151-155 °C; HPLC-MS
(Method B): m/z = 638 (M+); Rt = 6,04 min.

Example 34 (General procedure (A)) (R S)-3-(4-(3-(3 5-Dichlorophenyl)-1-(4-(5-methylcyclohex-1-enyl)phenLrl)ureidomethyl)-benzoylamino)-2-hydroxypropionic acid and (R,S)-3-(4-(3-(3,5-dichlorophenyl)-1-(4-(3-methylcyclohex-1-enyl)phenyl)ureidomethyl)benzoylamino)-2-hydroxypropionic acid (R, S) (R, S) 0 O y,~ O
HON H HO~N~ H
OH H I ~ N N ~ CI OH H I i N N ~ CI
O ~ i O ~ i CI CI
Using the mixture of (R,S)-4-(5-methylcyclohex-1-enyl)aniline and (R,S)-4-(3-methylcyclohex-1-enyl)aniline (building block 13) according to the general procedure (A) gave a mixture (6:4) of the title compounds.
(R, S)-3-(4-(3-(3,5-Dichlorophenyl)-1-(4-(5-methylcyclohex-1-enyl)phenyl)ureidomethyl)-benzoylamino)-2-hydroxypropionic acid:
'H-NMR (200 MHz, DMSO-d6): 81.02 (d, 3H), 1.15-1-24 (m, 1H), 1.61-1.96 (m, 3H), 2.14 2.44 (m, 3H), 3.40 (t, 2H), 3.47-3.62 (m, 1 H), 4.10-4.19 (m,1 H), 4.95 (s, 2H), 6.16 (t, 1 H), 7.14 (t, 1 H), 7.17 (d, 2H), 7.34 (d, 2H), 7.39 (d, 2H), 7.61 (d, 2H), 7.76 (d, 2H), 8.44 (t, 1 H), 8.56 (s, 1 H), 12.08 (s br, 1 H).
(R,S)-3-(4-(3-(3,5-Dichlorophenyl)-1-(4-(3-methylcyclohex-1-enyl)phenyl)ureidomethyl)-benzoylamino)-2-hydroxypropionic acid:
'H-NMR (200 MHz, DMSO-ds): ~ 1.02 (d, 3H), 1.15-1-24 (m, 1 H), 1.61-1.96 (m, 3H), 2.14-2.44 (m, 3H), 3.40 (t, 2H), 3.47-3.62 (m, 1 H), 4.10-4.19 (m,1 H), 4.95 (s, 2H), 6.04 (d, 1 H), 7.14 (t, 1 H), 7.17 (d, 2H), 7.34 (d, 2H), 7.39 (d, 2H), 7.61 (d, 2H), 7.76 (d, 2H), 8.44 (t, 1 H), 8.53 (s, 1 H), 12.08 (s br, 1 H).

Example 35 3-f4-f3-f1 lS)-(4-Chloroahenvl)ethvll-1-(4-cvclohexvlphenvl)ureidomethvllbenzovlamino)-2(R)-~droxypropionic acid HO~H I ~ I H i I CI
OH ~N N

4-f(4-Cyclohexylphenylamino)methyllbenzoic acid methyl ester Methyl 4-formylbenzoate (47 g, 285 mmol) was dissolved in methanol (400 mL) and a solu-tion of 4-cyclohexylaniline (50 g, 0.285 mmol) in methanol (200 mL) is slowly added with me-chanical stirring. More methanol (1 L) was added and the suspension was stirred at room temperature for 3 days. Filtration, washing and drying in vaeuo afforded 90.7 g (99%) of 4-[(4-cyclohexylphenylimino)methyl]benzoic acid methyl ester. This was dissolved in N-methylpyrrolidone (855 mL) and methanol (45 mL). With mechanical stirring sodium boro-hydride pellets (42.4 g, 1.12 mol) was added in portions keeping the temperature below 40 °C. The mixture was then stirred at room temperature for 2 hours and at 40 °C for 16 hours. The mixture was cooled to 5 °C and water (2 L) was slowly added.
Then acetone (350 mL) was added and the mixture was stirred at 5 °C for 1 hour.
Filtration, washing with water (2 x 500 mL) and drying in vacuo afforded 78 g (86%) of 4-[(4-cyclohexylphenylamino)-methyl]benzoic acid methyl ester as a solid.
' H-NMR (CDCI3): 81.2-1.4 (5H, m), 1.7-1.85 (5H, m), 2.39 (1 H, m), 3.97 (3H, s), 4.04 (1 H, bs), 4.39 (2H, s), 6.55 (2H, d), 7.01 (2H, d), 7.44 (2H, d), 8.00 (2H, d).
N-Chlorocarbamoyl-4-f(4-cyclohexylphenylamino)methyllbenzoic acid methyl ester 4-[(4-Cyclohexylphenylamino)methyl]benzoic acid methyl ester (75 g, 0.23 mol) was dis-solved in THF (750 mL). Diisopropylethylamine (56.0 mL, 0.32 mmol) and 4-dimethylamino-pyridine (1.0 g; 8.1 mmol) were added. The solution was cooled to 5 °C.
Bis(trichloromethyl)-carbonate (28.0 g, 0.093 mol) was added in small portions while maintaining the internal re-action temperature below 10 °C. The mixture was stirred for a further 2 hours at 10 °C, and then transferred to a separatory funnel. Ethyl acetate (800 mL) and water (1000 mL) were added. After mixing, the organic layer was separated, dried with anhydrous sodium sulfate, and concentrated to dryness by rotary evaporation in vacuo. The product was obtained quan-titatively as a stable hard crystalline material.
'H-NMR (CDCl3): 87.92 (d, 2H); 7.40 (d, 2H); 7.25 (d, 2H); 7.17 (d, 2H); 4.98 (s, 2H); 3.83 (s, 3H); 2.5 (m, 1 H); 1.65-1.80 (m, 5 H); 1.15-1.40 (m, 5 H).
N-Chlorocarbamoyl-4-f(4-cyclohexylphenylamino)methyllbenzoic acid methyl ester 4-[(4-Cyclohexylphenylamino)methyl]benzoic acid methyl ester (75 g, 0.23 mol) was dis-solved in THF (750 mL). Diisopropylethylamine (56.0 mL, 0.32 mmol) and 4-dimethylamino-pyridine (1.0 g, 8.1 mmol) were added. The solution was cooled to 5 °C.
Bis(trichloromethyl)-carbonate (28.0 g, 0.093 mol) was added in small portions while maintaining the internal re-action temperature below 10 °C. The mixture was stirred for a further 2 hours at 10 °C, and then transferred to a separatory funnel. Ethyl acetate (800 mL) and water (1000 mL) were added. After mixing, the organic layer was separated, dried with anhydrous sodium sulphate, and concentrated to dryness by rotary evaporation in vacuo. The product was obtained quan-titatively as a stable hard crystalline material.
'H-NMR (CDCI3): 87.92 (d, 2H), 7.40 (d, 2H), 7.25 (d, 2H), 7.17 (d, 2H), 4.98 (s, 2H), 3.83 (s, 3H), 2.5 (m, 1 H), 1.65-1.80 (m, 5 H), 1.15-1.40 (m, 5 H).
4-f3-f1(S)-(4-Chlorophenyl)ethyll-1-(4-cyclohexylphenyl)ureidomethy~'benzoicacid methyl ester A 2 L reaction flask equipped with mechanical stirring was charged with N-chlorocarbamoyl-4-[(4-cyclohexylphenylamino)methyl]benzoic acid methyl ester (94 g, 0.244 mol), N-methyl-2-pyrrolidinone (1.0 L) and triethylamine (68 mL, 0.487 mol). To the clear solution was added drop wise (S)-1-(4-chlorophenyl)ethylamine (38.0 g, 0.244 mol), keeping the internal reaction temperature below 30 °C. Stirring was continued for 2 hours, then the reaction mixture was partitioned between water (1.0 L) and ethyl acetate (1.0 L). After extensive mixing, the or-ganic layer was separated, and washed with a 5% aqueous solution of citric acid (500 mL), and saturated ammonium chloride (500 mL), before drying with anhydrous sodium sulphate.
Solvent was removed, and the residual oil was evaporated once from acetonitrile. This prod-uct was sufficiently pure for further synthesis. Yield: 103 g (84°l°).

'H-NMR (DMSO-ds): x'7.88 (d, 2H), 7.32 (d, 2H), 7.30 (d, 4H), 7.19 (d, 2H), 7.08 (d, 2H), 6.28 (d, 1 H), 4.88 (dd, 2H), 4.76 (m, 1 H), 3.81 (s, 3H), 2.44 (m, 1 H), 1.65-1.80 (m, 5 H), 1.15-1.40 (m, 5 H); HPLC-MS (method B): mlz = 505 (M+1); Rt = 6.17 min.
4-f3-f1 (S)-(4-Chlorophen~ ethyll-1-(4-c~clohexylphenyl)ureidomethyllbenzoic acid 4-[3-[1 (S)-(4-Chlorophenyl)ethyl]-1-(4-cyclohexylphenyl)ureidomethyl]benzoic acid methyl ester (35.0 g, 69.3 mmol) was dissolved in ethanol (400 mL). 4 N aqueous sodium hydroxide (100 mL) was added and the clear solution was stirred at room temperature for 3 hours. The solution was neutralised with 4 N hydrochloric acid (100 mL), and placed upon an ice bath to 1 o initiate crystallization. The crystals were collected, washed extensively with water, and dried in vacuo overnight. Yield: 34.25 g (100%).
'H-NMR (DMSO-d6): 812.85 (bs, 1H), 7.85 (d, 2H), 7.32 (d, 2H), 7.30 (d, 4H), 7.19 (d, 2H), 7.08 (d, 2H), 6.27 (d, 1 H), 4.85 (m, 3H), 2.45 (m, 1 H), 1.65-1.80 (m, 5 H), 1.15-1.40 (m, 5 H);
HPLC-MS (method B): m/z = 491 (M+1 ); Rt = 5.50 min.
3-f4-f3_[1 (S)-(4-Chlorophenyl)ethyll-1-(4-cyclohexylphenyl)ureidometh~lbenzoylamino)-2(R)-hydroxyproaionic acid methyl ester 4-[3-[1 (S)-(4-Chlorophenyl)ethyl]-1-(4-cyclohexylphenyl)ureidomethyl]benzoic acid (200 mg, 0.4 mmol), HOBt (75 mg, 0.5 mmol), and EDAC (94 mg, 0.5 mmol) were dissolved in a mix-ture of DMF (200 p,L) and DCM (2 mL). The clear solution was stirred at room temperature for 90 min. A solution of R-isoserine methyl ester hydrochloride (95 mg, 0.6 mmol) in a mix-ture of DCM (1.0 mL) and DMF (0.4 mL) was added, and the reaction mixture was left stirring at ambient temperature overnight. The reaction mixture was partitioned between DCM (20 mL) and water (20 mL). The organic phase was separated and washed with a mixture of brine and water (1:2), dried with anhydrous sodium sulphate and evaporated to dryness. The residue was subsequently evaporated from acetonitrile, to give a quantitative yield of title ma-terial.
'H-NMR (DMSO-ds): b'8.48 (t, 1H), 7.73 (d, 2H), 7.34 (d, 2H), 7.30 (d, 2H), 7.24 (d, 2H), 7.18 (d, 2H), 7.08 (d, 2H), 6.27 (d, 1 H), 5.70 (d, 1 H), 4.34 (m, 1 H), 4.32 (d, 2H), 4.22 (q, 1 H), 3.62 (s, 3H), 3.52 (m, 1 H), 3.40 (m, 1 H), 1.65-1.80 (m, 5H), 1.10-1.40 (m, 9H).

3-f4-f 3-f 1 (S)-(4-Chloroahen~)ethyll-1-(4-cyclohexylahenyl)ureidomethyllbenzoylamino)-2(R)-hydroxyproaionic acid 3-{4-[3-[1 (S)-(4-Chlorophenyl)ethyl]-1-(4-cyclohexylphenyl)ureidomethyl]benzoylamino}-2(R)-hydroxypropionic acid methyl ester (280 mg, 0.473 mmol) was dissolved in a mixture of THF
(2.5 mL) and methanol (2.5 mL) and 4 N aqueous sodium hydroxide (0.355 mL) was added.
The reaction mixture was stirred at room temperature for 2 hours. The pH was adjusted to 3.0 by addition of 1 N hydrochloric acid. Solvent was removed by rotary evaporation in vacuo and the residue re-dissolved in ethyl acetate (10 mL). The organic phase was washed twice with water and once with brine, and then concentrated to dryness in vacuo leaving the title comaound as a powder. Yield: 168 mg (89%).
'H-NMR (DMSO-ds): b'8.46 (t, 1H), 7.75 (d, 2H), 7.35 (d, 2H), 7.31 (d, 2H), 7.25 (d, 2H), 7.19 (d, 2H), 7.08 (d, 2H), 6.28 (d, 2H), 4.85 (m, 1 H), 4.80 (d, 2H), 4.15 (m, 1 H), 3.55 (m, 1 H), 3.40 (m, 1 H), 1.65-1.80 (m, 5H), 1.10-1.40 (m, 9H); HPLC-MS (method B): mlz =
579 (M+1 );
Rt = 5.27 min.
Example 36 3-f4-f3-Biahenyl-2-ylmethyl-1-(4-cyclohexylahenyl)ureidomethyllbenzoylamino)-2(R)-hydroxyaroaionic acid ~ H
HO~H I , N N w I
O
This compound was prepared similarly as described in example 35 from N-chlorocarbamoyl-4-[(4-cyclohexylphenylamino)methyl]benzoic acid methyl ester and biphenyl-2-ylmethylamine followed by hydrolysis of the benzoic acid methyl ester, coupling with (R)-isoserine ethyl es-ter hydrochloride. Hydrolysis afforded the title compound.
'H-NMR (DMSO-dfi): 812.6 (s, 1 H), 8.45 (t, 1 H), 7.78 (d, 2H), 7.45-7.20 (m, 14H), 7.05 (d, 2H), 6.10 (t, 1 H), 5.50 (bs, 1 H), 4.85 (s, 2H), 4.2 (m, 3H), 3.55 (m, 1 H), 2.45 (m, 1 H), 1.85-1.70 (m, 5H), 1.40-1.20 (m, 6H); HPLC-MS (method B): mlz = 606 (M+1 ); Rt =
5.08 min.

General procedure (B) for solution phase synthesis of compounds of the general for-mulae (la) and (1b):
O 1) E-NHz Boc O/ NaOH O
R' 2) NaCNBH3 O ~ z C~_s alkyl.0 _ Ci_6 alkyl C~_6 alkyl.0 E ~ O I E CH3 RB CHO Step 1 I , NH Step 2 / N~O~CH3 'I Ta Ra R O CH3 EDAC
HOBt or HOAt ~R~Rs aq. NaOH O R~ C~-s-alkyl~0 A~NHz 0 z O
HO I E CH3 C1_s aIkyLOJLA~RN R7 E CH
Step 3 ~N O CH3 Step 4 H I , N O CH
Re O 3 R 3 "H3 1 ) BSA
HCi/EtOAc ~R~R3 O ~ 2) D-N=C=O O s O
Ci_s alkyl. ~ ~ ~R~R
Step 5 O A H I , NH Step 6 C~-s alleyl~0 A H I E H
RB a / N~N,D
R O
(la) aq. NaOH ~ R~R' O R~
HO A N~~E H
Step 7 H R I i N~N.D
O
(1b) wherein Rz, R3, R', R8, A, E and D are as defined for formula (I).
When A is -CHOH- step 6 is performed using 1 ) BSA and 2) D-N=C=O. Otherwise, step 6 is performed using only D-N=C=O.
1o The procedure is illustrated further in the following examples.

Example 37 (General procedure (B)) (Rl-3-f4-13-(4-Cvano-3-trifluoromethvlphenvl)-1-(4-cvclohexvlphen~)ureidomethvllbenzo amino}-2-hydroxypropionic acid HON
OH H I / N~N .~ F F
(R) IOI
v N
Step 1 is performed using the same method as in general procedure (A).
Step 2: 4-fftert Butoxycarbonyl-(4-cyclohexylphenyl)aminolmethyl~benzoic acid methyl ester 4-((4-Cyclohexylphenylamino)methyl)benzoic acid methyl ester (2.0 g, 6.18 mmol) was sus-pended in sodium hydroxide (1 N, 6.18 mL) and a solution of di-tart butyldicarbonate (1.67 g, 7.42 mmol) in THF (10 mL) was added dropwise. The reaction mixture was stirred overnight and was concentrated in vacuo to a solid residue, which was redissolved in diethyl ether (50 mL) and washed with water (25 mL) added sodium hydroxide (1.3 mL, 1 N). The aqueous phase was extracted again with diethyl ether (25 mL) at pH 11-12. The combined organic phases were washed with sodium hydrogen sulphate (30 mL, 10%) and water (3 x 20 mL), dried with magnesium sulphate and concentrated in vacuo. Crystallisation from ethyl acetate and n-heptane afforded 1.98 g of 4-{[tart butoxycarbonyl-(4-cyclohexylphenyl)amino]methyl}-benzoic acid methyl ester.
'H-NMR (DMSO-ds): b' 1.13-1.44 (m, 14H), 1.63-1.81 (m, 5H), 2.46 (m, 1 H), 3.83 (s, 3H), 4.88 (s, 2H), 7.12 (m, 4H), 7.48 (d, 2H), 7.92 (d, 2H); HPLC-MS (Method B):
m/z = 424 (M+1 ); Rt = 9.10 min; M.p. 99.5-101.0 °C.
Microanalysis: Calculated for C~6H33NOø:
C, 73.73%; H, 7.85%; N, 3.31 %. Found:
C, 73.30%; H, 8.07%; N, 3.26%.
Step 3: 4 ~jtert-Butoxycarbonyl-(4-cyclohexylphenyl)aminolmethyl~benzoic acid 4-~[tart-Butoxycarbonyl-(4-cyclohexylphenyl)amino]methyl}benzoic acid methyl ester was suspended in ethanol (30 mL) and sodium hydroxide (4 N, 8.1 mL) was added. The reaction mixture was stirred overnight. The mixture was concentrated to dryness, suspended in water (100 mL), acidified with hydrochloric acid (8.5 mL, 4 N) and extracted with ethyl acetate (100 mL). The aqueous phase was extracted once more with ethyl acetate (30 mL) and the com-bined organic phases were washed with water (3 x 50 mL), dried with magnesium sulphate and concentrated in vacuo. The residue was crystallised from a mixture of ethyl acetate and n-heptane to afford 1.75 g of 4-{[tert-butoxycarbonyl-(4-cyclohexylphenyl)amino]methyl}
benzoic acid.
'H-NMR (CDCI3-ds): s 1.18-1.42 (m, 14H), 1.68-1.87 (m, 5H), 2.46 (m, 1 H), 4.88 (s, 2H), 7.10 (m, 4H), 7.47 (d, 2H), 8.07 (d, 2H); HPLC-MS (Method B): m/z = 410 (M+1 ); Rt = 8.15 min;
M.p. 192.5-194.5 °C.
Microanalysis: Calculated for C25H31NOa~
C, 73.32%; H, 7.63%; N, 3.42%. Found:
C, 73.03%; H, 7.86%; N, 3.36%.
Step 4: (R)-3-(4-fftert-Butoxycarbonyl-(4-cyclohexylphenyl)aminolmethyl~benzo~ilamino)-2-hydroxypropionic acid methyl ester 4-{[tert-Butoxycarbonyl-(4-cyclohexylphenyl)amino]methyl}benzoic acid was dissolved in DMF (10 mL) and HOBt (0.40 g, 2.93 mmol) and EDAC (0.52 g, 2.73 mmol) were added.
The reaction mixture was stirred for 45 min. Then a solution of (R)-3-amino-2-hydroxy-propionic acid methyl ester in DMF (8 mL) and diisopropylethylamine (0.46 mL) were added.
The mixture was stirred overnight. The reaction mixture was diluted with water (40 mL) and extracted with ethyl acetate (75 mL). The aqueous phase was extracted with ethyl acetate (30 mL). The combined organic phases were washed with hydrochloric acid (0.2 N, 3 x 30 mL), water: saturated sodium chloride (3 x 30 mL), dried with magnesium sulphate and con-centrated in vacuo. The residue was purified by column chromatography on silica gel (100 g) using mixtures of ethyl acetate and n-heptane (1 L (1:1 ) and 0.5 L (7:3)) as eluents to afford 0.77 g (R)-3-(4-{[tent-butoxycarbonyl-(4-cyclohexylphenyl)amino]methyl}benzoylamino)-2-3o hydroxypropionic acid methyl ester.
'H-NMR (DMSO-ds): 81.16-1.41 (m, 14H), 1.63-1.81 (m, 5H), 2.46 (m, 1 H), 3.42 (m, 1 H), 3.54 (m, 1 H), 3.62 (s, 3H), 4.24 (m, 1 H), 4.84 (s, 2H), 5.70 (d, 1 H), 7.12 (m, 4H), 7.28 (d, 2H), 7.78 (d, 2H), 8.51 (t, 1 H); HPLC-MS (Method B): m/z = 511 (M+1 ); Rt =
7.63 min.

Step 5: (R)-3-f4-~(4-Cyclohexylphenylamino)methyllbenzoylamino~-2-hydroxypropionic acid methyl ester (R)-3-(4-{[tent-Butoxycarbonyl-(4-cyclohexylphenyl)amino]methyl}benzoylamino)-2-hydroxy-propionic acid methyl ester was dissolved in ethyl acetate (10 mL) and dry hydrogen chloride in ethyl acetate (3 M, 10 mL) was added. The mixture was stirred at room temperature for 2 hours and concentrated in vacuo. The residue was suspended in ethyl acetate (15 mL) and concentrated. This was repeated twice. The residue was then suspended in ethyl acetate (10 mL) and placed at 5 °C overnight. The precipitate was filtered and washed with ice-cooled ethyl acetate and dried in vacuo to afford 0.62 g of (R)-3-{4-[(4-cyclohexylphenylamino)-1 o methyl]benzoylamino}-2-hydroxypropionic acid methyl ester.
'H-NMR (DMSO-d6): ~ 1.12-1.43 (m, 5H), 1.63-1.82 (m, 5H), 2.45 (m, 1 H), 3.42 (m, 1 H), 3.53 (m, 1 H), 3.60 (s, 3H), 4.25 (t, 1 H), 4.48 (s, 2H), 7.18 (m, 4H), 7.57 (d, 2H), 7.82 (d, 2H), 8.58 (t, 1 H); HPLC-MS (Method B): m/z = 411 (M+1 ); Rt =4.93 min.
Step 6: (R)-3-f4-f3-(4-Cyano-3-trifluoromethylphen~l)-1-(4-cyclohexylphenyllureidomethyll-benzoylamino~-2-hydroxypropionic acid methyl ester 5-Amino-2-cyanobenzotrifluoride (0.07 g, 0.36 mmol) was dissolved in ethyl acetate (2 mL) and dry hydrogen chloride in ethyl acetate (3.5 M, 5.5 mL) was added. After 15 min the solu 2o tion was concentrated to dryness and co-evaporated three times from toluene (3 x 5 mL).
The residue was added toluene (2.5 mL) and flushed with nitrogen for about 10 min, before diphosgene (0.43 mL) was added. Then the mixture was gently refluxed for 1 hour under a nitrogen atmosphere. The mixture was cooled and concentrated to dryness in vacuo and then co-evaporated twice from toluene to remove excessive diphosgene to afford 4-cyano-3-trifluoromethylphenyl isocyanate.
(R)-3-{4-[(4-Cyclohexylphenylamino)methyl]benzoylamino}-2-hydroxypropionic acid methyl ester, hydrochloride (0.13 g, 0.3 mmol) was dissolved in DCM (5 mL) and BSA
(0.22 mL, 0.9 mmol) added. The mixture was stirred for 0.5 hour, and diisopropylethylamine (0.052 mL, 0.3 mmol) was added. The reaction mixture was added to the isocyanate above and the reaction mixture stirred overnight. The reaction mixture was transferred to a separatory funnel and washed twice with water (10 mL), dried with magnesium sulphate and concentrated in vacuo.
The residue was purified by column chromatography (30 g) using ethyl acetate/n-heptane (4:6) (400 mL) and then ethyl acetate (200 mL) as eluents to afford 0.085 g of (R)-3-{4-[3-(4-cyano-3-trifluoromethylphenyl)-1-(4-cyclohexylphenyl)ureidomethyl]benzoylamino}-2-hydroxypropionic acid methyl ester.
'H-NMR (DMSO-d6): 8.1.12-1.44 (m, 6H), 1.66-1.82 (m, 5H), 3.41 (m, 1 H), 3.53 (m, 1 H), 3.60 (s, 3H), 4.22 (m, 1 H), 4.47 (s, 2H), 5.69 (s, 1 H), 7.21 (m, 4H), 7.33 (d, 2H), 7.76 (d, 2H), 7.98 (s, 2H), 8.14 (s, 1 H), 8.48 (t, 1 H), 9.1 (s, 1 H); HPLC-MS (Method B):
m/z = 623 (M+1 );
R~ = 6.02 min.
St. ep 7:
(R)-3-{4-[3-(4-Cyano-3-trifluoromethylphenyl)-1-(4-cyclohexylphenyl)ureidomethyl]benzoyl-amino}-2-hydroxypropionic acid methyl ester (0.07 g, 0.124 mmol) was suspended in ethanol (3 mL) and sodium hydroxide (4 N, 0.19 mL, 0.742 mmol) was added. The reaction mixture was stirred for 1.5 hour, and concentrated to remove the ethanol. The residue was diluted with water (10 mL) and acidified with hydrochloric acid (4 N, 0.21 mL). The mixture was ex-tracted with ethyl acetate (2 x 10 mL) and the combined organic phases were washed with water (3 x 10 mL), dried with magnesium sulphate and concentrated in vacuo to afford the title compound (0.68 g).
'H-NMR (DMSO-d6): 6.1.16-1.42 (m, 6H), 1.66-1.82 (m, 5H), 3.40 (m, 1 H), 3.54 (m, 1 H), 4.16 (m, 1 H), 4.48 (s, 2H), 7.20 (m, 4H), 7.34 (d, 2H), 7.78 (d, 2H), 7.99 (s, 2H), 8.16 (s, 1 H), 8.44 (t, 1 H), 9.1 (s, 1 H); HPLC-MS (Method B): m/z = 609 (M+1 ); Rt = 7.27 min.
Example 38 (General procedure (B)) (Rl-3-f4-f3-(3-teri-Butylphenyl)-1-(4-cyclohexylphenyl)ureidomethyllbenzoylamino)-2-hydroxypropionic acid w HO~~ I H C
OH / N~N 3 CH3 II ~ CH3 (R) o ~1~~~

Step 6: (R)-3-f4-(3-(3-tert Butylphenyl)-1-(4-cyclohexylphenyl)ureidomethyllbenzoylamino~-2-hydroxypropionic acid methyl ester 3-(tert-Butyl)aniline (0.054 g, 0.36 mmol) was dissolved in ethyl acetate (2 mL) and added dry hydrogen chloride in ethyl acetate twice (3.5 M, 3 mL + 2.5 mL). After 15 min the mixture was concentrated to dryness and co-evaporated three times from toluene (3 x 5 mL). The residue was added toluene (2.5 mL) and flushed with nitrogen for about 10 min, before di-phosgene (0.43 mL) was added. Then the mixture was gently refluxed for 1 hour under a ni-trogen atmosphere. The mixture was cooled and concentrated in vacuo. This was repeated twice to remove excess of diphosgene. The mixture was concentrated to dryness and co-evaporated three times from toluene (5 mL each time). The residue was concentrated to dry-ness and co-evaporated twice from toluene. Then it was redissolved in toluene (2.5 mL) and flushed with nitrogen for about 10 min, before diphosgene (0.43 mL) was added.
The mixture was gently refluxed under nitrogen for 1 hour. After cooling, the mixture was concentrated and co-evaporated twice from toluene to remove excess diphosgene to afford 3-tert-butyl-phenyl isocyanate.
(R)-3-{4-[(4-Cyclohexylphenylamino)methyl]benzoylamino}-2-hydroxypropionic acid methyl ester, hydrochloride (0.13 g, 0.3 mmol) was dissolved in DCM (5 mL) and BSA
(0.22 mL, 0.9 mmol) was added. The mixture was stirred for 0.5 hour, and diisopropylethylamine (0.052 mL, 0.3 mmol) was added. The reaction mixture was added to the isocyanate above and stirred overnight. The reaction was transferred to a separatory funnel and washed twice with water (10 mL), dried with magnesium sulphate and concentrated in vacuo. The residue was purified by column chromatography on silica gel (30 g) using ethyl acetate and n-heptane (6:4) (400 mL) and then ethyl acetate (100 mL) as eluent to afford 0.12 g of (R)-3-~4-[3-(3-tert-butylphenyl)-1-(4-cyclohexylphenyl)ureidomethyl]benzoylamino}-2-hydroxypropionic acid methyl ester.
~H-NMR (DMSO-ds): ~ 1.23 (s, 11 H), 1.28-1.42 (m, 3H), 1.65-1.80 (m, 5H), 2.47 (m, 1 H), 3.40 (m, 1 H), 3.51 (m, 1 H), 4.22 (m, 1 H), 4.94 (s, 2H), 5.71 (d, 1 H), 6.99 (d, 1 H), 7.12-7-24 (m, 5H), 7.28 (d, 1 H), 7.36 (d, 2H), 7.42 (s, 1 H), 7.77 (d, 2H), 8.08 (s, 1 H), 8.50 (t, 1 H);
HPLC-MS (Method B): miz = (585+1 ); Rt = 8.30 min.
St" ep 7:
(R)-3-{4-[3-(3-tern Butylphenyl)-1-(4-cyclohexyfphenyl)ureidomethyl]benzoylamino}-2-hydroxypropionic acid methyl ester (0.11 g, 0.188 mmol) was dissolved in ethanol (4 mL) and sodium hydroxide (4 N, 0.28 mL, 1.128 mmol) was added. The reaction was stirred for 1.5 hour and concentrated in vacuo to remove the ethanol. The residue was diluted with water (10 mL), acidified with hydrochloric acid (4 N, 0.3 mL) and extracted with ethyl acetate (2 x mL). The combined organic phases were washed with water (3 x 10 mL) and dried with 5 magnesium sulphate and concentrated in vacuo to afford the title compound (0.10 g).
'H-NMR (DMSO-d6): 81.23 (s, 9H), 1.28-1.42 (m, 4H), 1.65-1.81 (m, 5H), 2.47 (m, 1 H), 3.38 (m, 1 H), 3.55 (m, 1 H), 4.16 (m, 1 H), 4.94 (s, 2H), 7.00 (d, 1 H), 7.11-7.24 (m, 6H), 7.28 (d, 1 H), 7.35 (d, 1 H), 7.41 (s, 1 H), 7.80 (d, 2H), 8.10 (s, 1 H), 8.46 (t, 1 H); HPLC-MS (Method B):
1 o miz = 572 (M+1 ); Rt = 7.78 min.
Example 39 (General procedure (B)) (R)-3-f4-f1-(4-Cyclohexylphenyl)-3-(3-h rLdroxymethyl-4-trifluoromethoxyphenyl)ureidomethyll-benzoylamino~-2-hydroxypropionic acid HON ~ /
OH H I / N N
OH

F-~-F
F
Preparation of 3-(tert butyldimethylsilanyloxymethyl)-4-trifluoromethoxyaniline to be used in step 6:
Fuming nitric acid (5 mL) was cooled on an ice bath. Methyl 2-(trifluoromethoxy)benzoate (5 g, 22.7 mmol) was slowly added within 30 min keeping the temperature below 15 °C. The reaction was then stirred at 60 °C for 1 hour and 2 hours at room temperature. The mixture was poured on ice water whereupon an oil separated. The aqueous supernatant was de-canted and additional water (50 mL) was added to the oil. After neutralisation with sodium hydrogen carbonate, the mixture was extracted with ethyl acetate (25 mL). The aqueous phase was extracted with ethyl acetate (15 mL) once more. The combined organic phases were washed with saturated sodium chloride (2 x 15 mL), dried (magnesium sulphate), and concentrated in vacuo to give 5.69 g of 5-nitro-2-trifluoromethoxybenzoic acid methyl ester.

'H NMR (DMSO-d6): b'3.93 (3H, s), 7.82 (1 H, d), 8.58 (1 H, d), 8.67 (1 H, s);
HPLC-MS
(method B): m/z: 266; Rt= 6.0 min.
5-Nitro-2-trifluoromethoxybenzoic acid methyl ester (5.69 g, 21.5 mmol) was dissolved in ethanol 99.9% (80 mL) and stannous (II) chloride dihydrate (24.2 g, 107 mmol) was added.
The suspension was stirred on an oil-bath at 75 °C for 2 hours and concentrated in vacuo. .
Ethyl acetate (100 mL) and water (50 mL) was added and pH was adjusted to pH 8 with 4 N
sodium hydroxide (50 mL). The liquid was decanted from the precipitation. The precipitate was washed twice with ethyl acetate. The aqueous phase was extracted twice with ethyl ace-1o tate (60 mL). The combined organic phases were washed with a saturated sodium chloride solution (2 x 100 mL), dried (magnesium sulphate) and concentrated in vacuo.
Purification by column chromatography (120 g silica) using ethyl acetate and heptane (1:1) as eluent af-forded 3.8 g of 5-amino-2-trifluoromethoxybenzoic acid methyl ester.
'H NMR (DMSO-d6): b'3.82 (3H,s), 5.63 (2H, s), 6.79 (1 H, d), 7.07 (1 H, s), 7.11 (1 H, d);
HPLC-MS (method B): m/z: 236, Rt= 4.6 min.
5-Amino-2-triffuoromethoxybenzoic acid methyl ester (3.0 g, 12.8 mmol) was dissolved in THF (20 mL) in a three-necked flask equipped with a thermometer and an addition funnel 2o under nitrogen. Under stirring and ice-cooling lithium aluminum hydride (1 M in THF, 15 mL) was added dropwise within 10 minutes. Stirring was continued at room temperature for 1 hr, and the reaction was concentrated in vacuo. The residue was suspended in DCM
(150 mL) and water (50 mL), then filtered through celite, washed with DCM and water.
The filtrate was separated, and the water phase was extracted once more with DCM (30 mL). The combined organic phases were washed with water (2 x 20 mL), dried (magnesium sulphate) and con-centrated in vacuo to give 2.47 g of (5-amino-2-trifluoromethoxyphenyl)methanol.
'H NMR (DMSO-d6): 83.92 (2H, d), 5.18 (1H, t), 5.28 (2H, s), 6.45 (1H, d), 6.91 (1H, d);
HPLC-MS (method B): m/z: 208, Rt = 7.2 min.
5-Amino-2-trifluoromethoxyphenyl)methanol (1.2 g, 5.8 mmol) was dissolved in DMF (5 mL) and imidazole (0.48 g, 7.1 mmol) and tent-butyldimethylsilyl chloride (0.99 g, 6.6 mmol) were added. The reaction mixture was stirred for 16 hours and water (20 mL) was added. The mix-ture was extracted with ethyl acetate (2 x 50 mL) and the combined organic phases were washed with water (10 mL), citric acid (10 mL, 10%) and water (2 x 10 mL), dried (magne-sium sulphate) and concentrated in vacuo. The residue was purified by column chromatog-raphy (110g, silica) using ethyl acetate and heptane (1:3) as eluent to give 1.2 g of 3-(tert butyldimethylsilanyloxymethyl)-4-trifluoromethoxyaniline.
'H NMR (DMSO-ds): 80.82 (9H, s), 3.25 (6H, s), 4.52 (2H,s), 5.23 (2H, s), 6.41 (1H, d), 6.61 (1 H, s), 6.86 (1 H,d); HPLC-MS (method B): m/z: 322; Rt= 7.17 min.
Stea 6: (R)-3-f4-~3-f3-(tert-Butyldimethylsilanyloxymethyl)-4-trifluoromethoxyphen~rll-1-(4-cyclohexylphenyl)ureidomethyllbenzoylamino)-2-hydro~propionic acid methyl ester Bis(trichloromethyl)carbonate (triphosgene) (0.09 g, 0.31 mmol) was dissolved in DCM (2 mL) and cooled in an ice-bath under nitrogen. 3-(tent-Butyldimethylsilanyloxymethyl)-4-trifluoromethoxyaniline (0.3 g, 0.93 mmol) was evaporated twice from toluene to remove any moisture and then dissolved in DCM (2 mL) and diisopropylethylamine (0.32 mL) was added.
This solution was added to the cooled triphosgene solution and the mixture was stirred at 20 °C for 2.5 hours. (R)-3-{4-[(4-Cyclohexylphenylamino)methyl]benzoylamino}-2-hydroxy-propionic acid methyl ester hydrochloride (0.37 g, 0.83 mmol) was evaporated twice from toluene and dissolved in DMF (3 mL) and diisopropylethylamine (0.141 mL, 0.83 mmol) was added. The solution was added to the isocyanate above and, with stirring, heated at 80 °C
under nitrogen for 2 hours. The reaction mixture was evaporated in vacuo and the residue was extracted with DCM (80 mL), aqueous citric acid (10%, 25 mL). The aqueous phase was extracted with DCM (30 mL). The combined organic phases were washed with aqueous citric acid (10%, 3 x 25 mL), dried with magnesium sulphate and evaporated in vacuo.
The residue was purified by column chromatography on silica gel (58 g) using ethyl acetate and n-heptane (940 mL, 1:1 and 300 mL ethyl acetate) as eluent to afford 0.03 g of (R)-3-{4-[3-[3-(tert-butyldimethylsilanyloxymethyl)-4-trifluoromethoxyphenyl]-1-(4-cyclohexylphenyl)ureido-methyl]benzoylamino}-2-hydroxypropionic acid methyl ester.
HPLC-MS (Method B): m/z = 758 (M+1 ); Rt = 9.57 min.
Step 7:
(R)-3-{4-[3-[3-(tent butyldimethylsilanyloxymethyl)-4-trifluoromethoxyphenyl]-1-(4-cyclohexyl-phenyl)ureidomethyl]benzoylamino}-2-hydroxypropionic acid methyl ester (24 mg, 0.032 mmol) was dissolved in ethanol (1 mL) and sodium hydroxide (0.05 mL, 019 mmol) was added. The reaction mixture was stirred for 2 hours and concentrated to remove the ethanol.
The residue was diluted with water (10 mL), acidified with hydrochloric acid (4 N, 0.3 mL) and extracted with ethyl acetate (2 x 10 mL). The combined organic phases were washed with water (3 x 10 mL) and dried with magnesium sulphate and concentrated in vacuo to give 17 mg of (R)-3-{4-[3-[3-(tent-butyldimethylsilanyloxymethyl)-4-trifluoromethoxyphenyl]-1-(4-cyclo-hexylphenyl)ureidomethyl]benzoy!amino}-2-hydroxypropionic acid.
HPLC-MS (Method B): m/z = 744 (M+1 ); Rt = 9.35 min.
(R)-3-{4-[3-[3-(Pert-Butyldimethylsilanyloxymethyl)-4-trifluoromethoxyphenyl]-1-(4-cyclohexyl-phenyl)ureidomethyl]benzoy!amino}-2-hydroxypropionic acid (17 mg, 0.023 mmol) was dis-solved in acetonitrile:water (9:1 ) (2 mL) and caesium fluoride (35 mg, 0.35 mmol) added. The reaction mixture was stirred at 80 °C for 6 hours and additional amounts of caesium fluoride (35 mg) added. The mixture was stirred at 60 °C overnight, concentrated in vacuo and di-luted with ethyl acetate (10 mL) and water (5 mL). The organic phase was washed with water (3 x 5 mL) and dried with magnesium sulphate and concentrated in vacuo. The residue was purified by preparative HPLC affording the title compound.
H-NMR (DMSO-d6): s 1.35 (m, 5H), 1.79 (m, 5H), 4.49 (s, 2H), 4.95 (s, 2H), 5.29 (s, 1 H), 7.12-7.26 (m, 6H), 7.34 (d, 2H), 7.49 (dd, 1 H), 7.63 (d, 1 H), 7.77 (d, 2H), 8.42 (t, 1 H); HPLC-MS (Method B): m/z = 630 (M+1 ); Rt = 6.62 min.

General procedure (C) for solid phase synthesis of compounds of the general formula (lc):
R~s - OII
HO~Z~O
HO q N Fmoc 5 Ra O Rz Rs R
Resin.Ci Resin-O' \q/ ' i -Fmoc Step 1 Ra Step 2 Resin-O q N Z R --~ Resin-O q N Z NH
Ra Step 3 Ra 1 ) BSA O R~ R3 O R5 2) D-N=C=0 or D-CHRi3-N=C=O
Resin-O q N Z N x~D
Ra E Step 5 Step 4 HO~q~N~Z~N~X~D
Ra E
(lc) 5 wherein R~, R3, R4, R5, A, Z, D and E are as defined for formula (I), X is -C(O)NH- or -C(O)NHCR12R13- wherein R'z and R'3 are as defined for formula (I), and Resin is a polystyrene resin loaded with a 2-chlorotrityl linker.
When A is -CHOH- step 4 is performed using 1 ) BSA and 2) D-N=C=O or D-CHR'3-N=C=O.
Otherwise, step 4 is performed using only D-N=C=O or D-CHR'~-N=C=O.
The procedure is illustrated in the following examples.

Example 40 (General procedure (C)) (R)-3-f4-f1-l4-tent-Butvlahenvl)-3-13.4-dichlorophenvl)ureidomethvllbenzovlamino)-2-hvdroxv-propionic acid O O
HON \
OH H I / N N CI
O
CI
Step 1: Resin bound (R)-Fmoc-isoserine 50 mg polystyrene resin functionalized with a 2-chlorotrityl chloride linker was vortexed with N-methyl-2-pyrrolidinone (500 pL) and 1,2-dichloropropane (500 pL) for 1 hour.
The resin was filtered and washed with N-methyl-2-pyrrolidinone:1,2-dichloropropane (1:1, 2 x 1 mL).
N-methyl-2-pyrrolidinone (500 pL) and 1,2-dichloropropane (500 pL) were added followed by 150 ~Imol (R)-Fmoc-isoserine and 100 pL diisopropylethylamine. After shaking the suspen-sion for 4 hours at 25 °C, the resin was isolated by filtration and washed with DCM: metha-nol:diisopropylethylamine 17:2:1 (2 x 1 mL) and N-methyl-2-pyrrolidinone (2 x 1 mL).
Step 2: Resin bound (R)-3-(4-Formylbenzoylamino)-2-hydroxypropionic acid To the above resin bound (R)-Fmoc-isoserine was added 500 pL of a 20% solution of piperidine in DMF. Upon shaking for 30 min, the resin was drained and washed with N-methyl-2-pyrrolidinone (6 x 1 mL). Then 200 pmol 4-formylbenzoic acid (30 mg) and 200 pmol HOBt (31 mg) were dissolved in N-methyl-2-pyrrolidinone (500 NL) and added to the resin followed by 200 pmol diisopropyl carbodiimide (25.2 mg) dissolved in acetonitrile (500 pL). The mixture was shaken for 4 hours at 25 °C followed by filtration and washing of the resin with N-methyl-2-pyrrolidinone (3 x 1 mL).
Step 3: Resin bound (R)-3-~4-f(4-tert-butylphenylamino)methyllbenzoylamino)-2-hydroxypropionic acid The above resin bound (R)-3-(4-formylbenzoylamino)-2-hydroxypropionic acid was treated with a 0.5 M solution of 4-tent-butylaniline (0.25 mmol) in a mixture of N-methyl-2-pyrrolidin-one and trimethylorthoformate (1:1, 0.5 mL) and glacial acetic acid (50 pL) for 1 hour at 25 °C. Sodium cyanoborohydride (250 pmol, 16 mg) dissolved in a mixture of N-methyl-2-pyrrolidinone and methanol (1:1, 0.25 mL) was added and the mixture was vortexed at 25 °C
for 4 hours followed by filtration and washing with a mixture of N-methyl-2-pyrrolidinone and methanol (1:1, 2 x 1 mL) 3 x 1 mL N-methyl-2-pyrrolidinone (3 x 1 mL) and a mixture of 1,2-dichloropropane and diisopropylethylamine (7:1, 2 x 0.75 mL).
Step 4: Resin bound (R)-3-~4-f1-(4-tent-butylphenyl)-3-(3,4-dichlorophenyl)ureidomethyll-benzoylamino)-2-hydroxypropionic acid The above resin bound (R)-3-~4-[(4-tert-butylphenylamino)methyl]benzoylamino}-2-hydroxy-propionic acid was added 1,2-dichloropropane (500 NL) and BSA (100 pL) and the mixture was vortexed at 25 °C for 1 hour. 200 pmol 3,4-Dichlorophenylisocyanate was added and shaking the mixture 5 hours at 25 °C followed by filtration and washing of the resin with 2 x 1 mL DGM, 4 x 1 mL N methyl-2-pyrrolidinone, 2 x 1 mL H20, 3 x 1 mL THF and 5 x 1 mL
DCM afforded the resin bound title compound.
Step 5: (R)-3-f4-f1-(4-tert-butylphenyl)-3-(3,4-dichlorophenyl)ureidomethyllbenzoylamino~-2-hydroxypropionic acid The above resin bound (R)-3-{4-[1-(4-tent-butylphenyl)-3-(3,4-dichlorophenyl)ureidomethyl]-benzoylamino}-2-hydroxypropionic acid was treated with 1 mL 20°!o TFA
in DCM for 1 hour at °C. The product was filtered off and the resin was washed with 1 mL
DCM. The combined 20 extracts were concentrated in vacuo to afford the title compound.
'H-NMR (CDCI3): X7.65 (d, 2H), 7.45-7.40 (m, 4H), 7.35-7.20 (m, 3H), 7.10-7.00 (m, 3H), 6.30 (s, 1 H), 4.90 (s, 2H), 4.40 (m, 1 H), 3.83 (m, 2H), 1.32 (s, 9H); HPLC-MS (Method B):
m/z = 558 (M+1 ); Rt = 4.71 min.
The following examples were made as described above.

Example 41 (General procedure (C)) (R)-3-f4-f1-l4-tert Butvlcvclohexvl)-3-(3,4-dichloroahenvl)ureidomethvllbenzovlamino)-2-~droxYpropionic acid O O
HON \
OH H I / N N CI
O /
~CI
HPLC-MS (Method B): m/z = 564 (M+1 ); Rt = 4.92 min/5.02 min.
Example 42 (General procedure (C)) (R)-3-f4-f1-(4-Cyclohexylphe~l)-3-(3,4-dichlorophenyl)ureidometh Ilb~ enzoylamino)-2-hydroxypropionic acid HON \
OH H I / N N CI
O
~CI
HPLC-MS (Method B): mlz = 584 (M+1 ); Rt = 5.12 min.
Example 43 (General procedure (C)) (R)-3-f4-f1-(4-Cyclohexylphenyl)-3-(2,2,4,4-tetrafluoro-4H-benzof1,31dioxin-6-yl)ureido-methyllbenzoylamino~-2-hydroxypropionic acid HON \
F
OH H I / N N F
O
p ~ / ~F

HPLC-MS (Method B): m/z = 646 (M+1 ); Rc = 5.24 min.

Example 44 (General procedure (C)) lRl-3-f4-f 1-(4-tent-Butvlahenvl)-3-(2.2.4.4-tetrafluoro-4H-benzof 1,3ldioxin-6-vl)ureidometh benzoylamino~-2-hydroxypropionic acid O O
HO~N~~
F
OH H ~ / N~N \ F
O
o ~~ ~F
O F
HPLC-MS (Method B): m/z = 620 (M+1 ); Rt = 4.88 min.
Example 45 (General procedure (C)) ~R)-3-f4-f1-(4-tent-Butylc clohexyl)-3-(2,2,4,4-tetrafluoro-4H-benzof1.31dioxin-6-yl)ureido-methyllbenzoylamino)-2-hydroxypropionic acid O O
HO~'N '~ F
OH H I / N N F
O
O ~ , ~F
O F
HPLC-MS (Method B): mlz = 606 (M+1 ); Rt = 5.11 min/5.20 min.
Example 46 (General procedure (C)) (R)-3-f4~1-(4-tent-Butylphenyl)-3-(3,4-difluorophenyl)ureidomethyllbenzoylamino~-2-hydroxy-propionic acid O O
HON
OH H ~ / N N F
W
O
F
HPLC-MS (Method B): m/z = 526 (M+1 ); Rt = 4.24 min.

Example 47 (General procedure (C)) lR)-3-(4-f1-(4-Cvclohexvlphenvl)-3-(3,4-difluorophenvl)ureidomethyllbenzoylamino~-2-h~ypropionic acid HON
OH H I i N N F
O
F
HPLC-MS (Method B): mlz = 552 (M+1 ); Rt = 4.65 min.
Example 48 (General procedure (C)) (R)-3-f4-f 1-(4-Cyclohex-1-enylphenyl)-3-(3,4-difluorophenyl)ureidomethyllbenzoylamino)-2-hydroxypropionic acid HO~N~\
OH H I / N~N ~ F
IO Ii F
HPLC-MS (Method A): m/z = 550 (M+1 ); Rt = 6.77 min.
Example 49 (General procedure (C)) (R)-3-~4~3-(4-Chloro-3-trifluoromethlrlphenyl)-1-(4-cyclohexylphenyl)ureidomethyllbenzoyl-amino-2-hydroxypropionic acid HO~Ny OH H I i N~N I ~ CF3 IOI
CI

HPLC-MS (Method A): m/z = 618 (M+1 ); Rt = 7.58 min.
Example 50 (General procedure (C)) ~R)-3-f4-f 1-(4-Cyclohexylphenyl)-3-(4-fluoro-3-nitrophenyl)ureidomethyllbenzoylamino)-2-~droxypropionic acid o Ho~'N~~
OH H II / N~N I ~ N02 O
F
HPLC-MS (Method A): m/z = 579 (M+1 ); Rt = 6.85 min.
Example 51 (General procedure (C)) R)-3-~4-f1-(4-Cyclohexylphenyl)-3-(4-isoprop~rlphenyl)ureidomethyflbenzoylamino'~-2-hydroxypropionic acid HO~ H
OH IrN
O I i CH3 HPLC-MS (Method A): m/z = 558 (M+1 ); Rt = 7.73 min.

Example 52 (General procedure (C)) (R)-3-(4-f1-(4-Cyclohex-1-enylphenyl)-3-(3,4-dichlorophenyl)ureidometh Ilbenzoylamino)-2-hydroxypropionic acid Ho H
I~N~CI
o I/
CI
HPLC-MS (Method B): m/z = 582 (M+1 ); Rt = 4.99 min.
Example 53 (General procedure (C)) (R)-3-~4-f3-(4-Acetylphenyl)-1-(4-cyclohexylphenyl)ureidomethyllbenzoylamino)-2-hydrox~
propionic acid HO H
ON

HPLC-MS (Method A): m/z = 558 (M+1 ); Rt = 6.42 min.
Example 54 (General procedure (C)) 3-f413-f 1 (RS)-(4-Bromophenyl)ethyll-1~4-cyclohex r~l ~henyl)ureidomethyllbenzoylamino)-2(R)-hydroxypropionic acid HON ~ ~ H / Br OH H I ~ N N ~
R
C ) O CH3 (RS) HPLC-MS (Method A): m/z = 624 (M+1 ); Rt = 7.45 min.
Example 55 (General procedure (C)) (R)-3-(4-f 1-(4-Cyclohexylphenyl)-3-(3,5-difluorophenyl)ureidomethy~lbenzoylamino)-2-hydroxVpropionic acid HON
OH H I ~ N N F
O
F
HPLC-MS (Method B): m/z = 552 (M+1 ); Rt = 4.76 min.
General procedure (D) for solid phase synthesis of compounds of the general formula (Id:
0 Ra Ra OI' HO' 'q' 'N-Fmoc HO~Z~O
Rq O Rz\ /Rs R5 Resin.Cl Resin-O' 'q' -N-Fmoc Step 1 R4 Step 2 2 3 O ~ 5 '~ ) BSq II R\ 'R II H N-E O R R 0 ~ 2) DC(O)OH or D-CHR"-C(O)OH, PyBroP
Resin-O' ' ~N~Z~Rs z ~ ~ ~
q Resin-0' \q"N' -Z NH
R Step 3 Rq E Step 4 O Rz Ra O Rs O Rz Ra O Rs ~II~ 'I X ~II ~ ~ X
Resin-O~q~N~Z~N~ ~D HO~q~N~Z~N~ ~D
Ra E Step 5 R4 E
(Id) wherein R~, R3, R4, R5, A, Z, D and E are as defined for formula (I), X is -C(O)-(CR'2R'3)r (CH2)S wherein r, s, R'2 and R'3 are as defined for formula (I), and Resin is a polystyrene resin loaded with a 2-chlorotrityl linker.
When A is -CHOH- step 4 is performed using 1 ) BSA and 2) D-C(O)OH or D-CHR'3-C(O)OH. Otherwise, step 4 is performed using only D-C(O)OH or D-CHR'3-C(O)OH.
Example 56 (General procedure (D)) (R)-3-f4-(~(4-tert Butylcyclohexyl)-f2-(4-trifluoromethoxyphenyl)acetyllamino)methyl)benzoyl-aminol-2-hydroxypropionic acid O O
HON
OH H II i~N
O
\~OCF3 Step 1: Resin bound (R)-Fmoc-isoserine 50 mg polystyrene resin functionalized with a 2-chlorotrityl chloride linker was vortexed with N-methyl-2-pyrrolidinone (500 NL) and 1,2-dichloropropane (500 pL) for 1 hour.
The resin was filtered and washed with N-methyl-2-pyrrolidinone/1,2-dichloropropane (1:1, 2 x 1 mL).
N-methyl-2-pyrrolidinone (500 NL) and 1,2-dichloropropane (500 pL) was added followed by 150 pmol (R)-Fmoc-isoserine and 100 pL diisopropylethylamine. After shaking the suspen-sion for 4 hours at 25 °C, the resin was isolated by filtration and washed with DCM:methan-ol:diisopropylethylamine (17:2:1 ) (2 x 1 mL) and N-methyl-2-pyrrolidinone (2 x 1 mL).
Step 2: Resin bound (R)-3-(4-formylbenzoylamino)-2-hydroxypropionic acid To the above resin bound (R)-Fmoc-isoserine was added 500 pL of a 20% solution of piperidine in DMF. Upon shaking for 30 min, the resin was drained and washed with N-methyl-2-pyrrolidinone (6 x 1 mL). Then, 200 pmol 4-formylbenzoic acid (30 mg) and 200 pmol HOBt (31 mg) was dissolved in N-methyl-2-pyrrolidinone (500 pL) and added to the resin followed by 200 pmol diisopropyl carbodiimide (25.2 mg) dissolved in acetonitrile (500 pL). The mixture was shaken for 4 hours at 25 °C followed by filtration and washing of the resin with N-methyl-2-pyrrolidinone (3 x 1 mL).
Step 3: Resin bound (R)-3-f4-f(4-tart-butylcyclohexylamino)methyllbenzoylamino'~-2-hydroxypropionic acid The above resin bound (R)-3-(4-formylbenzoylamino)-2-hydroxypropionic acid was treated with a 0.5 M solution of 4-terf-butylcyclohexylamine (0.25 mmol) in a mixture of N-methyl-2-pyrrolidinone and trimethylorthoformate (1:1, 0.5 mL) and glacial acetic acid (50 pL) for 1 hour at 25 °C. Sodium cyanoborohydride (250 pmol, 16 mg) dissolved in a mixture of N-methyl-2-pyrrolidinone and methanol (1:1, 0.25 mL) was added and the mixture was vortexed at 25 °C for 4 hours followed by filtration and washing with a mixture of N-methyl-2-pyrroli-dinone and methanol (1:1, 2 x 1 mL) 3 x 1 mL N-methyl-2-pyrrolidinone (3 x 1 mL) and a mix-ture of 1,2-dichloropropane and diisopropylethylamine (7:1, 2 x 0.75 mL).
Step 4: Resin bound (R)-3-f4-(~(4-tart-butylcyclohexyl)-f2-(4-trifluoromethoxyphenyl)acetyll-amino)methyl)benzoylaminol-2-hydroxypropionic acid The above resin bound (R)-3-{4-[(4-tart-butylcyclohexylamino)methyl]benzoylamino}-2-hydroxypropionic acid was added 1,2-dichloropropane (500 pL) and BSA (100 pL) and the mixture was vortexed at 25 °C for 1 hour followed by filtration. To the resin was added a solu-tion of 4-(trifluoromethoxy)phenylacetic acid (400 pmol) in a mixture of N-methyl-2-pyrrolidinone, 1,2-dichloropropane and diisopropylethylamine (4.5:4.5:1, 1 mL) was added followed by a solution of bromo-tris(pyrrolidino)phosphonium hexafluorophosphate (400 ~mol) in 1,2-dichloropropane (500 pL). The mixture was allowed to react for 3 hours at 50 °C
and the resin was allowed to cool to 25 °C while washed with N-methyl-2-pyrrolidinone (4 x 1 mL), and DCM (10 x 1 mL) afforded the resin bound title compound.
Step 5: (R)-3-f4-(f(4-tart-Butylcyclohexyl)-f2-(4-trifluoromethoxyphenyl)acetyllamino)methyl)-benzoylaminol-2-hydroxypropionic acid The above resin bound (R)-3-{4-[1-(4-terf-butylcyclohexyl)-3-(4-trifluoromethoxyphenyl)-3o ureidomethyl]benzoylamino}-2-hydroxypropionic acid was treated with 1 mL
20% TFA in DCM for 1 hour at 25 °C. The product was filtered off and the resin was washed with 1 mL
DCM. The combined extracts were concentrated in vacuo to afford the title compound.
HPLC-MS (Method A): m/z = 579 (M+1 ); Rt = 7.20 min.

The following examples were made as described above.
Example 57 (General procedure (D)) (R)-3-f4-(((4-tent-Butylcyclohexyl)-f2-(3-fluoro-5-trifluoromethylphenyl)acetyllamino~methyl)-benzoylaminol-2-hydrox~~propionic acid O O
HON
OH H I i N ~ CF3 I
O
F
HPLC-MS (Method A): m/z = 581 (M+1 ); Rt = 7.22 min.
Example 58 (General procedure (D)) (R)-3-f4-(f(2 2-Diphenylethyl)-f2-(3-fluoro-5-trifluoromethylphenyl)acetyllamino~methyl)-benzoylaminol-2-hydroxy~ropionic acid I

HON
OH H I / N ~ CF3 I
O
F
HPLC-MS (Method A): m/z = 623 (M+1 ); Rt = 6.87 min.

Example 59 (General procedure (D)) lR7-3-l4-frl5-Chlorobenzofblthioahene-3-carbonvl)-(2,2-diphenvlethYl)aminolmethyl)benzo amino)-2-hydroxypropionic acid I
0 0 ~ , HON \ S
OH H I ~ N
i O ~I
CI
HPLC-MS (Method A): m/z = 613 (M+1 ); R~ = 6.50 min.
Example 60 (General procedure (D)) (R~-3-f4-(f (2,2-DJ~henylethyl)-f2-(4-trifluoromethoxyphe n~~l)acetyllamino~methyl)benzoyl-aminol-2-hydroxypropionic acid I
0 0 ~ ' v /
HON \
OH H I ~ N

HPLC-MS (Method A): m/z = 621 (M+1 ); Rt = 6.90 min.
Example 61 (General procedure (D)) (R)-3-(4-f ((4-tent-Butylcyclohexyl)-(5-chlorobenzofblthiophene-3-carbonyl)aminolmethyl~-benzoylamino)-2-hydroxypropionic acid HON \ S
OH H I / N
O
CI
HPLC-MS (Method A): m/z = 571 (M+1 ); Rt = 7.15 min.

Example 62 (General procedure (D)) (R)-3-(4-f f(2,2-Diphenylethyl)-(5-trifluoromethoxy-1 H-indole-2-carbonyl)aminolmethyl)-benzoylamino)-2-hydroxypropionic acid o ° /
HO~H I , N / \ OCF3 O H -HPLC-MS (Method A): mlz = 646 (M+1 ); Rt = 6.93 min.
Example 63 (General procedure (D)) (R)-3-f4-(((4-Cyclohexylphenyl)-f(4-trifluoromethoxyphenyl)acetyllamino')methyl)benzoyl-aminol-2-hydroxypropionic acid HON \
OH H I ~ N
O ( ~ OCF3 HPLC-MS (Method B): m/z = 599 (M+1 ); Rt = 5.19 min.
Example 64 (General procedure (D)) (R)-3-f4-(f (4-Cyclohexylphenyl)-f (3-trifluoromethoxyphen~l)acetyllamino~methyl)benzoyl-aminol-2-hydroxypropionic acid Ho HPLC-MS (Method B): m/z = 599 (M+1 ); Rt = 5.17 min.
Example 65 (General procedure (D)) (R)-3-f4-(f (4-C~iclohexylphenyl)-((3-fluoro-5-trifluoromethylphenyl)acetyllamino)methyl)-benzoylaminol-2-hydroxypropionic acid ° ° I~
HON
OH H I / N ~ CF3 O
F
HPLC-MS (Method B): m/z = 601 (M+1 ); Rt = 5.19 min.
Example 66 (General procedure (D)) (R)-3-(4-f(('(3 5-Bis(trifluoromethyl)phenyl)acetyll-(4-cyclohexylphenyl)amino)methyl~benzoyl-amino)-2-hydroxypropionic acid HON
OH H I / N ~ CF3 O

HPLC-MS (Method B): m/z = 651 (M+1 ); Rt = 5.50 min.

Example 67 (General procedure (D)) (R)-3-f4-(f(4-Cyclohex~~lphenyl)-f(3-trifluoromethylphenyl)acetyllaminolmethyl)benzoylaminol-2-hydroxypropionic acid Ho~
OH CFs HPLC-MS (Method B): m/z = 583 (M+1 ); Rt = 5.08 min.
Example 68 (General procedure (D)) (R)-3-f4-(f(4-Cyclohexylphenyl)-f(3,4-dichloroahenyl)acetyllamino)methyl)benzoylaminol-2-hydroxypropionic acid HO~N~~ ~
OH H II /~N ~ CI
O I ~ CI
HPLC-MS (Method B): m/z = 583 (M+1 ); Rt = 5.26 min.
Example 69 (General procedure (D)) (R)-3-(4-off(3-Bromophenyl)acetyll-(4-cy-clohexylphenyi)aminolmethyl)benzoylamino)-2-hydroxypropionic acid HO~N~ ~
OH H I i N ~ Br O
2o HPLC-MS (Method B): m/z = 595 (M+1.); Rt = 5.01 min.

Example 70 (General procedure (D)) (R)-3-(4-f f (Biphenyl-4-ylacetyl)-(4-cyclohexYlphenyl)aminolmethyl)benzoylamino)-2-hydroxy-propionic acid 0 0 1~
HON
OH H I ~ N
O I ~ w i HPLC-MS (Method B): m/z = 591 (M+1 ); Rt = 5.38 min.
Example 71 (General procedure (D)) (R)-3-(4-ff(4-Cyclohexylphenyl)-(2-naahthylacetyl)aminolmethyl~benzoylamino)-2-hydroxy-~ropionic acid HON
OH H I / N
o ~ i i HPLC-MS (Method B): m/z = 565 (M+1 ); Rt = 5.10 min.

Example 72 (General procedure (D)) ~Rl-3-(4-ff(3-(3 5-Bis(trifluoromethYl)phenyl)propionYl)-(4-cyclohexylphenyl)aminolmeth benzoylamino)-2-hydroxypropionic acid O O I ~ CF3 HON
OH H I ~ N ~ I
v v ~CF3 O
HPLC-MS (Method B): m/z = 665 (M+1 ); Rt = 5.51 min.
Example 73 (General procedure (D)) (R~-3-f4-(f(4-Cyclohexy_Iphenyl)-f3-(3-nitrophenyl)propionyllamino~methyl)benzoylaminol-2-1o hydroxypropionic acid HO~H
OH
HPLC-MS (Method B): m/z = 665 (M+1 ); Rt = 5.51 min.

The following preferred compounds are within the scope of the invention and may be pre-pared according to the procedures disclosed herein. Other preferred compounds are:
O O
E
HO ~ H ~ / N N
D
O
wherein E D E D

~' \
* I / ~'~ F
\. I ~F
~HzC CH3 I / i / O F
H3C CH3 * H3 \ F'' ~F I / ~F
F F ~ O F

I * ~ \
I / y I / p F

CH3 F °H3 FF ~I / FI'F
O~F
CH3 H3c H
* 3 HC
~ \ I ' \ F * ~ \
* HzC CH3 O F I / F
O
CH3 cH, k CH k ~ ~ I o I ~ w ~ \ F'' HzC 3 I i I / ~F
O F
r CH3 , k~
O \ ~ w \ \ F
* I , I / ~F
O F
CH3 *

I / CH3 H3C CH3 ~ \ CI
CH3 ~ i 'CI
* CI

E D E D
CHa CHa H3C CHa H3C CHa * ''. I W
N
I ~ ~ I / O
H3C CHa CHa * H3C CHa F F F
F F ~- w I
°~F
CHa CHa H3C CHa HaC CHa /N
F
I ~ O~CH3 * ~~
p F
HaC CHa * F F
~ \
\ F ~ \ ~F
/ ~~N y ~ p F
CHa CHa H3C CHa F H3C CHa CI
* F ~~ \
~I / F F ~ /
* * CI
CHa H3C CHa F °
* F * ii+
F I ~ ~~N,°_ CI
CHa H3C CHa Br F i jjJJ
F \I I~( \/
~Ha o F i CHa H3C CHa O O
~~ ~ -/ CHa ~. ~ -/CFia I ~N~ w ~N~
CHa I , ~ CHa O ~ O

E D E D

* ~~ l / N~ Ha I F
i O CH3 y / S F
*
* FF
\ F
~ w I i CH3 i * F F F
CH3 _ CH

o w . .. ~'~ F
I ~ N'~'~cH, I \ F
i o i / S F
o I/ F
i o y O F

o I N~CHa F
s o ~ I / S"F
i i CHa .~
~S O _ O ~ O
3CN ~ ~ ~ ~ I / O_CHa i i H3C CH3 *
\ CI
~ F
1 / ~F
O F
CI
CH, F
H3C CH3 * F
* ~ ~ ~ F
i ~ / i ~ Br E D E D
CHa ~CHa CHa ' .N
* ~. I ~ S' ~ ~ W
~o I a ~ a v 'CHa j F~G
* F
F
* F n o ~I
I, I ~ ~ I, C F ~ F~o F
F
H3C CHa CH
a H3C CHa ~ \ ~ \
F
cH2 ~ / F y I / S.CH3 CHa CHa H3C CHa HaC CHa w ~ ~ o~cH, ~I ~ CHa o ~ v v 'CHa /CHa /CN3 W OS. IN w * * ~ IJIW
*''I ~ 'o I a ~ I a o y a CHa HaC o * CH3 CH3 * CHa * F ~ ~ '~ * * \ I W CHa H C H C CH3 ~ CHa z F F z CH3 CHa H CHa * ~
* \ ~ * , r ~ / ~F
H C H3C I / HaC H ~ F
z / * CHa ~I
~ ~ \ ~ -- CH H3C
* / CH3 cHa 0 HzC ~ / CH3 0 E D E D
* * F F
\ ~r * ~ ~ F
H3C ~ / /
O
F~F HaC CHa F
CI F F
.~i ~ \~.* \~* / ~ F
\ I / HaC
~S
HsC CH

*~i ~ o \ HaC~O \ ~~ * w .i ' I i I s ~S

* ~' \ F F
\ ,.~ * I /
H C, I F
a ~~/ \ .~ ' /
HaC CHa O ~ Hac I i CHa *
k * CI F F
~/
w ~= F
H3c I i ~/
\I i I ~~~ ~S

N F-I-F
F
k HaC ~ , ~ \
S ~' HaC CHa F~F H C I i F ' 0 0I
'CHa k \ i~ * ~ ~
HaC ~ / / S
\ ~ ~

HaC CH CH3 ~ ~S
H'~ F F
F

E D
F F
\ \F
CH3 I ~ ~ *

CI F F
~F
CH3 I ~ '' * \

*

i Furthermore, the following compounds are within the scope of the present invention and may be prepared according to the procedures disclosed herein:

O
HO~H ~ I / O
OH I / N N ~ O HON ~ I / H O
I / N~ OH H I~N~N
/ N
O
O

O
O O I % HO~ H ~ O
HO~ N ~ H O OH I / N N
OH H I / N N ~ I N
N~ o o f/ o HaC CHs O O
HON W / O O I W
O
OH H I / N~N HON ~ / O
1O I j N--~ OH H I~N~N
O O I / N
O

/
O O
O O J~ ~
I Ho~N ~ O
HON ~ / H O OH H I / N N
OH H I~/~~N~N I ~ N . ~ ( / N-a IO / O
O

HO~H I \ I / H O O O ~ /
OH ~N~N ~ CH HON ~ H O
I / CH3 OH H I~N~N I W CH3 / L'H3 O

HsC CHa /
O O
O O

HON ~ / H O OH H I / N N ~ CHa OH H I~N~N I w CH3 O I /
II CHa 0 / CHa 0 O
/ /
O 0 ( ~ O O
HO~'N ~ / H HON ~ / H
F H I / N~N I ~ CI F H I / NuN I ~ CI
IOI / IOI /
CI CI
O O O O
HO~H I \ H / I HO~H I \ I / ~ H / I CI
OH I~\~~/ N N w OH ~N N
CI
O , O
~I
I w I ~ O I w / H / HO N ~ / H / /
HO OH H I / N N ~ I OH H I / N N ~ ~ I
CI ~ v ~
O O CHa CHa H3C CHa O O
O O ~ _ HON
HO~ N ~ I / N \ ~ OH H I / N N
H I / N N
S O / ~N
o I/
F~F

O O O O
HO~N~ H HON ~ H
OH H I / N N OH H I / N N
0 I / S~CH3 0 I / S~CH3 I I
O

N~ O O
O O
HON
HON ~ H OH H I / N N
OH H I / N N
O ~S.CH3 O v _OCF II
s 0 HON ~ ~ 0 O
OH H I / N N HON
~I OH H I / N N
0 v -OCF3 ~ I W
O v _OCF3 O O O O CHs HO~H I / N N HO~H I H
OH / NuN

O O O O
H HON N H
HO OH H I / N~N ~ N CH OH H I / N~N

HO N
HON ~ N N
OH H I / N N ~ OH H
I N N ~
O / ~ O v 'OCF3 I/
/ i 0 O ~ 0 0 / I
HON ~ I / HON ~ \ H
OH H I / N N H I / N N ~ CI
S OH
O N / \ O O I / CH

O O Trans O O Trans HON ~ HON
OH H ( / N N Br OH H I / N N Br O (/ O I/
FFF
i /
O O
HO~H 0 I ~ I / H F F HO~H I \ I / H F F
OH / N N OH ~N N
w ~F W ~F
O I/ O I/
FFF
/
O O I ~ O O
HO~N~ / H HO~N~ / H
OH H I / N N S OH H I / N N S
O N / \ O O N / \
F ~ F
O-~F
F

O O
O O
HON
HO~H I ~ I ~ H OH H I ~ NuNYS
OH ~N N IIS
O N I ~ O N ~ ~ F
F O-E-F
O-~F F
F
CH3 .

i HON ~ ~ H O O
OH H I / N N S CI HO~ N
off H I / N N 5 CI
O N ~
O N
CI
CI
O O
HO~H 0 ~ I ~ H HO~H I \ I / H
OH I ~ N N S CI OH ~ N N S
O N / ~ O N ~ ~ CI
CI CI

i O O
HO~H ~ \ I O O
OH ~N N S HO~ N
off H I / N N S
O N / ~ CI
O N ~ ~ CI
CI
CI~
O I W ~ O
HO N ~ ~ H F F HO N \ ~ H F F
OH H I i N N S F OH H I / N N S F
O N ~ ~ O N
F F

I '~ O 0 HO~H O ~ ' H F F HO~H I \ H F F
OH I i N N s F OH ~N N s F
0 N ~ ~ O N
F F
(R) and (S) diastereomers of (R) and (S) diastereomers of HO~'H o I ~ I ' H ~ ~ olcF Ho~'H I ~ I ~ H ~ I o~F
OH i N N ~ F OH ~N N ~ F
0. CH3 O CH3 (R) and (S) diastereomers of (R) and (S) diastereomers of HO~'H o I '~ I ' H ~ I o'~F Ho- Y _H I ~ I ~ H ' I o~F
OH / N N W F OH ~N N W F
v ~ v O CHs O CHs (R) and (S) diastereomers of (R) and (S) diastereomers of 0 o I ~ o 0 HO~H I \ / H / I O~F HO~H I ~ / H / I O~F
OH / N N ~ F OH ~N N ~ F
a ~ v (R) and (S) diastereomers of (R) and (S) diastereomers of HO~H O I ~ I ' H ~ I o~F Ho~H I ~ I ~ H
OH / N N w F OH ~N N w F
v O O

(R) and (S) diastereomers of (R) and (S) diastereomers of /.
w o 0 HO~H O I '~ I / H / ( CI HO~H I \ I / H / I CI
OH / N N ~ OH ~N N
~CI ~ CI

/
O I W ~ O
HO N '~ / H / HO N ~ ~ H /
OH H I / N N W I OH H I / N N W I
O ~ I F O ~ I F
'F ~F
F F
O O
HO~H O ~ I / ~H / I Ho~H I \ I H
OH I~N~N w OH ~N~N w p ~ I p~F p ~ I ~F
F O F
/
O O
HO~'H O ~ I / H / I HO~H \ I / H /
OH I / N~N W OH I~N~N w I O~F IOI ~ I O~F
(R) and (S) diastereomers of (R) and (S) diastereomers of /
0 o I~ o 0 HO~ N ~ / H / HO N ~ / H /
OH H I / N N w I H I / N N w I
O CH / O CH /
I

(R) and (S) diastereomers of (R) and (S) diastereomers of /
o I w ~ o HO N ~ / H / HO N \ / H /
OH H I / N N ~ I OH H II /~N N

I F ~ I F
FF FF
(R) and (S) diastereomers of (R) and (S) diastereomers of /
o I w ~ o HO N ~ / H / HO N \ / H /
OH H I / N~N W I OH H I / N~N w I
IO' CH / F '0I CH / F
I O I_F \ I ~F
~F p F
(R) and (S) diastereomers of (R) and (S) diastereomers of /
o I ~ ~ o HO N ~ / H / HO N \ / H /
OH H I / N~N W I OH H I / NuN w I
IOI CH / I O~F IOI CH / I O~F
F ~ 1'F
/
O O I ~ O O
HO~H I ~ / H F F HO~H I \ / H F F
OH / N N ~ F OH / N N ~ F
O I / O I /
I
~I

O O I
HON W ~ H F F O O
OH H I / N N HO~ N ~ N
I W F QH H I , N N
O i ~ ~S
O ~ ~ O
F~F
i I ~ O O
HO~H O I ~ ~ H HO~H I \ / H
OH ~N N OH ~N N
O I ~ O I i . ~ I ~ I
i o I w ~ o I w ~ H HO N~ ~ H
HO OH H I / N~N I \ off H l~ / NuN I W
IOI i IOI i \\S \\S
i I ~ O O
HO~H O I ~ ~ H F F HO~H I \ / H F F
OH / N N OH ~N N
W ~F W 'F
O I / O I
\ S \ S

O O Trans O O Trans HON ~ H F F HO~H
OH H I ~ N N OH i N N \ F F
~'F 'F
O I / O I /
I
S
i O O I ~ O O I ~ _ HON ~ ~ H N~ HON ~ ~ H N \
OH H I i N~N I ~ ~ S OH H I ~ NuN I W ' S
IOI / O IO ~O
F~F F~F
~ O
HO~H O ~ I ~ H N=N,N_ HO~H I \ I / H N:N,N-OH I i NuN I ~ ~.N. CH3 OH ~N~N I ~ ~N. CH3 IOI i O IO ~O
F~F F~F
i O O
HO~H O ~ ~ H NaN,N_ HO~H I \ / H N N~N-OH I ~ N~N I ~ ~N CHs OH ~N~N I ~ ~N CH3 O ~ O
i O O I ~ O O
~ H HON ~ ~ H
HO OH H I , N N Br OH H I i N N Br O I i O
F F

/
O O I ~ O O
HO~H I \ / H HO~H I \ / H /
OH ~N~N ~ I OH / N~N w IOI I / '0I /
~I
O / I ~ O / I
HO N ~ ~ H HO H
OH H I / N N OH ~N N S
S
O N / \ O N / \
~F ~F
F F F F
/
0 O ~ O ~ / I
HO~H I \ I / H / I HO~H I / N N F F
OH ~N N w OH ~ F
1f o I /
O / F
~I
I O ~ ~I
HO~H O ~ H F HO~H I ~ H F
OH I / N~N~S O /_F OH ~N~N~g O~F
IOI NI / \ F IOI NI / \ F
/
/ I O O / I
HO~H O ~ ~ H HO~H I ~ \ H
OH I / N N S OH / N N S
O N / \ FF O N / \ FF
~F /"-' F
F F

O / I ~ O /
HO H I ~ ~ H HO H I ~ ~ H
OH / N~N~S OH / N~N~S
IOI N / \ CI IOI N / \
CI Br /
O / ~ ~ O /
HO H I ~ ~ H HO H I ~ \ H
OH / N~N~S F OH / N~N~S F
IOI N / \ IOI N / \
Br Br / /
O / ~ ~ O /
HO H I ~ ~ H HO H I ~ ~ H
OH / N~N~S OH / N~N~S
O N / \ IOI N / \
Br CF3 O / ~ ~ O /
HO N ~ ~ HO N
OH H ( / N~N~S CF OH H I / N~N~S
IOI N / \ 3 O N / \

O O / I O O
w ~ HON
HO~H ~ / N N S OH H I / N N g O N / \ CF3 ~ ~ / \
O
~F
CF3 F p F
F

/ /
O / I ~ O
HO N ~ ~ H HO N ~ ~ H
OH H I / N~N~g OH H I / N~N~S
IOI N / \ O '0I N / \ O
~. F F
F O F O ~F
F F F
O / I ~ O / I
HO H I ~ ~ H HO H I ~ ~ H
OH / N~N~S OH / N~N~S
IOf N /\ FF i '0I N /\ FF
~F F
F F
O / I ~ O / I
HO N ~ \ H F HO H
OH H I / N~N~S O F OH / N~N~S O~F
IOI N / \ ~F IOI N / \ O F
o / I ~ o / 1 HO N
HO H
OH / N~N~S F OH H I / N~N~S F
'O' tN/\S~~ IOI IN/\S~F
O / I ~ O / I
w ~ H HO N ~ ~ H
HO OH N ( / N~N~S CI OH H I / N~N~S CI
IOI N / \ CI I0I N / \ CI

/
O / ~ ~ O /
HO N
HO OH H ~ / N N g OH H I / N N g 0 N / \ O N / \ ~N
F
g--~ F F
F FF
O / ~ ~ O
HO N
HO OH H ~ / N N g OH H I / N N g O N / \ -N O N / \
F F
FF FF
O / ~ ~ O
\ H HO H \ \ H
HO OH H ~ / N N g OH I / N N g ~ N

O N / \ O N / \
F F
F F F F
O / ~ ~ O
w ~ HO N
HO OH H ~ / N N o N OH H I / N N g O N S/ \ / O N / \
Br F F
FF FF

/ /
O / I ~ O / I
~ H HO N ~ ~ H
HO OH H I / N~N~S OH H I / N~N~S
N / \ 8r IOI IN / \
F CHa F F HsC CHa /I O
~ H HO N ~ ~ H
HO OH H I / N~N~S OH H I / N~N~S O-CHa O N / \ O N / \
CHa F
H3C CHa F F
CHa H3C CHa /
O O Trans O O /
I HO~N~ H
HON ~ ~ H OH H II /~N N ~ Br OH H I / N~N~S p-CH O I

O. N / \ F
F
FF
O O / I O O / I
HON ~ ~ H F HON ~ ~ H F F
OH H I / N~N I ~ F OH H I~N~N I ~. F
IO / O~CH3 '0I ~p~CHa O p Trans O O Trans HON ~ H F F HO~H I \ F F
OH H I / N N OH ~N N
I W F ~ I ~ F
O / O~CH3 O / O V
/
O / I ~ O / I
HO N ~ ~ H F HO N ~ ~ H F F
OH H I / N~N I w F OH H I / N~N I y F
IOI / O I I O

O p Trans O O Trans HON ~ HON ~ H F F
OH H I / NuN I ~ Br OH H I / NuN I ~ F
w O v _CH3 O / CH3 /
O / I ~ O / I
HO N ~ \ HO N
OH H I / N~N I ~ Br OH H I / N~N I ~ Br ~CH3 IOI ~CH3 /
O / I . ~ O / I
HO N ~ ~ H F HO N~~~ H F F
OH H I / N~N I ~ F OH H II / N~N I W F

O O Trans O O Trans HON ~ H F F HO~H I \ H F F F
OH H I / N N OH / N N
'~ F W F
O I / Br O I /

/
O / I ~ O / I
HO N ~ ~ H F F HO H I ~ ~ F
OH H I / NuN I ~ F OH / N~N I y F
IOI / Br IO / Br /
O / I ~ O / I
HO N ~ ~ H F FF HO H I ~ ~ H F FF
OH H I / N~N I w F OH / N~N I w F
O / O
I ~ O / I
HO N ~ H F F HO H
OH H I / N N ~ F OH / N N ~ F F
OCI / OCI /
I I
HO N ~ ~ F HO N ~ ~ H FF
OH H I / N~N ' \ F OH H I / N~N I W F
IOI / O
NO~ NOZ
/ I O O / I
HO~H O ~ \ H F F HO~H ~ \ \ H F F
OH I / N N OH / N N
~F ~ I W F
O / NOZ O / NOZ

O O Trans 0 O Trans HON ~ H F HON ~ H F
OH H I / N~N I w F OH H I / N~N I w F
O / NO O
z NOz O / I ~ O / I
~ H HO N ~ ~ H
HO OH H I / N~N ~ Br OH H I / N~N ~ Br I / IOI I
Br Br /
O p /I
HO~H O ~ \ H F F HO~H I \ \ H F F
OH ( / N~N I ~ F OH / N~N I ~ F
IOI / IOI

/
O p Trans O O I HO~N~ H
HO N ~ \ H F OH H I / N N ~ CI
~H I / N N ~ ~ /
OH ~ I ~ F F O ~CH

H3C.0 O O / I O O / I
HO N ~ H F HO N ~ \ H F F
~H I / N N ~H ( / N N
w OH ~ w F
OH ~ I FF ~' I
O / OF
H C'O F F
a /
0 0 / I o o / I
HO~H I ~ \ H F F HO~H I ~ \ H CI F F
~N N F ~N N w F
OH ~ I w OH
/ O /
F
F

O p Trans O O /
HON ~ F ~ I
OH H ~ / N N ~ F Hp~H I w F
H F
I OH / N~N w F
OCI / 0 F ~ /
/ /
O O i I O O / I
HO~H I ~ \ H 01 F F HO~H I ~ \ H F F
~N N ~ F OH / N N ~ F
OH
O I i 0 I /
W
N
0 O ~ I O O ~ I
HO~H I ~ H F F HO~H I ~ H F F
~N N ~ F OH / N N w F
off o I / ~ o I / F
~N FF
/
O O / I O O / I
N ~ \ F HO N ~ \ F
HO~H ~ / N N F ~H I / N N
F OH
OH
O I ~ 'F O I / O

/
O O / I O O / I
HO N ~ \ F F HO N T ' \ H F F
~H I / N ~ ~H I / N N F
OH ~ ~ F OH
O I / O O I / F
CHs /
O o / I 0 O / I
HO~H I / N N ~ O ~ I HO~H I / N ~ F F
OH O ~ ~ F
H
o I / o O I / F
F~F
O O / O O
I I
HO~H I \ H ~~ HO~H I \ H
OH / N N ~ S ~ OH / N N ~ S,CH

I / o O I
F~F F~F
O o / I o o / I
HO N
~H I , N N S0. HO~H I / N N O SO ~ I
OH ~ I w CH3 OH
o / o O /
F~F
o o / I o o / I
HO~H I ~ \ H O~/~ ~ I HO N I
/ N N ~ S ~H~N N ~ CI
OH O I / OH
O I / CHs O O
HO~H I \ I / O O
ON / N N ~ S F HO~H I ~ I ~ H
~F OH / N~N ~ S~F
o I ~ F
i i O O ~ O O ~ I
HON ~ I ~ HON ~ \ H
OH H I i N N S H I i N N ~ CH3 F OH
0 I / ~F . O I i HsC CHs CH3 Trans O O
O 0 ~ I HON
HO~H I i N N CH3 OH H I ~ N~N I % CH3 OH
O ~ CH3 i O I W ~ O
HO OH H I , N N OS~ HO OH H ~ / N N OSo I W CHa ~ I W CH3 0 i O i i i O I w ~ O I w HO N ~ ~ F HO N ~ ~ H O
OH H I i N N F OH H I i N N
W F . \ CH3 O I i CI O II

i O O I ~ O O
O
HO~H I / N N O HO~H I / N N N. -W CHs ~ O
O I ~ O
i O O
HO~H O I ~ I ~ H HO~H I \ I / H
OH ~ N N S~CHs OH ~N N S~CHs O I i O
i i HO~H O I ~ H HO~H I H
OH ~ N N OH ~N N
O I / S.CHs O I / S.CHs O O
HO~H O I ~ I ~ H HO~H ~ \ I / H
OH ~N N OH i N N ~ S.
F'' CHs O ~ ~ S~F O I ~ O~CHs O O
HO~H O ~ ~ H ~~i~ HO~H I \ / H
OH I / N~N I ~ S.CHs OH ~N~N I ~ S.CHs ~O~CHs IOI ~CH3 O O
HO~H O I ~ ~ ~H ~~i~ HO~H I \ / H N N~N-CH
OH ~N N ~ S. OH / N N ~ ~ s I CHs ~ I W N
O v -CH O

/

HO~H O ~ / H NcNN_ HO~H I \ / H O N CHa OH I / N N ~ ~ CHa OH ~N N
W ~N ~ N CHa O I ~ O I /
/ /
O O
HO~H 0 ~ I / H O'N CHa HO~H I \ I / H
OH I / N N ~ OH ~N N
I W N CHa ~ I W OH
O / O / O
F~F
O ~ W ~ O I W
HO OH H I / N N ~SO HO OH H I / N N OSO
CHa ~ ~ W N
O ~ O O / CHa F~F
O O
HO~H O I ~ I / H ~w~ / I HO~H I \ I / H ~w~ i OH / N N S. ~ OH ~N N S.
N ~ N
O I / CHa O I /
/
O I \ ~ O I W
HO H I ~ / H ~~ ~~ ~ HO H I ~ ~ H F F
OH / N N S. ~ ~ OH ~N N
I ~ N ~ ~~O
O / O / O~F
F

r I ~ O 0 HO~H O ~ / H F F HO~H I \ / H ~~~~ /
OH I r N N OH / N N S.

O I / kF O I /

I ~ O O I W
HON O ~ / H ~w~ / I HO~H I ~ / H
OH H I / N N S. ~ OH r N N ~ O F
O I / ~CH o I / ~F

r /
O I ~ ~ 0 / H HO N ~ / H
HO OH H I / NuN ~ O~F OH H I / NuN ~ CI
IOI I/ 1F' IOI I/ CI
O I W ~ O I W
HO N ~ '~ F HO N ~ /
OH H I / N N F OH H I / N N CI
F
O I / F O I / CH

r O I W ~ O I W
HO N ~ F HO N
OH H I / N N F OH H I / N N F F
w ~F ~ ~F
O I / O I

O O I ~ _ O O I ~ _ HON ~ ~ H N \ ~ HON ~ ~ H N \ /
OH H I ~ NuN I ~ l O OH H I~N~N I ~ ' O
I0 i O IO ~O
F~F F~F
O I w ~ O
~ H HO N ~ ~ H
HO OH H ~ , N~N ~ Br OH H I / N~N ~ I
'0I I i IOI I i O I W ~ O
HO N ~ ~ H HO N ~ ~ H
OH H I ~ N~N I ~ I OH H I ~ N~N I ~ CI
IOI IOI ~Br O O
HON
OH H I ~ NuN ~ CI
Br Furthermore, the following preferred compounds (as pure enantiomers of either (R) or (S) configuration or mixtures thereof, including racemates) are within the scope of the invention and may be prepared according to the procedures set forth in the foregoing description:
/
/I o o /I
HO~H 0 I ~ ~ H HO~H I \ \ H
F / N~N I ~ O.OH3 F ~N~N I ~ O.OH3 IOI / IOI /
F F F F F F
O I W ~ O I W
/ H F HO N ~ / H F
HO F H I / N~N \ F F F H I / N~N \ F F
I / IOI I
F F
F F F F
O O I ~ O O I
HON ~ / H HON ~ / H
F H I / NuN I ~ Br F H I / N~N I ~ Br IOI ~ '0I
/
O O I ~ 0 O I
HON ~ / H HO'~N ~ / H
F H I / N N F H I / N N
F F
O I / O~F O I / O~F
F F
/

N
HO N ~ H F F HO I ~ H F F
~H I / N N H~N N F
~ F F
F
o I/ o I/

o I w ~ o I
HO N ~ H F F HO
F H I / N N ~ F F / N N ~ F F
O I / O I
F F
O O I ~ O O I
HON ~ H F F HO~H
F H I / N N ~ F F / N N ~ F F
O I / O I
II II
N N
O O
HO~H 0 ~ I ~ H F F HO~H I \ I / H F F
F I / N N ~ F F ~N N w F
o I / o Br Br H3C CH3 Trans H3C CH3 O O O O I
HON ~ F HON
F H I ~ N~N I ~ F F H I / N~N I w F F
O ~ '0I ~O~F

i O O
HO~H O I ~ I ~ H HO~H I ~ I / H
F ~N N CI F / N N ~ CI
O I / O I i /
O O I
HON O ~ / H Ho~H I \ / H
F I / N~N I ~ F ~N~N
O ~/ O
/
I ~ ~ o I ~
HO H I ~ / H / I HO H ( ~ / H / I
F / N~N ~ F / N~N W
IOI I IO
I w ~ o I w HO N ~ / H HO N \ / H
F H I / N N F H II /~N N
O I / S>GF 0 I / S>GF
/
I w ~ o I w / /
HO H I ~ H O\~ ~O HO H I ~ H Os i0 F ~N N S. F / N N S.
( w CHs ~ ~ w CH3 O / o O / O
F-I--F F-I-F
F F

0 o Trans O O /
Ho~H I / N N CH3 HON ~ ~ I H
F H I / N N CI
o I /
o CI

/
o / I ~ o /
HO N~~ H HO N~~ H
F H lI / N 1I N I ~ F F H [I / N II N I ~ F

r o ~~ I ~ o ~ I
~~ H HO N~~~ H
HO F H I / N~N ~ S.CH3 F H \ [I ~'~N~N ~ S.CH3 IOI I / O I r O O / I O O r I
w ' H HON \ \ H
HO F H I / N N p F F H I / N N O F
O I / O~F O I / O~F
F
i 0 0 ~ ~ o o y HO~N~ ~ H .i' CI HO'~N~'~ H CI
F H ~ i~N~N~ w~~ F H I r~N~N - w o O I
HO~H O ~ H F F HO~H
I I F \ N N FF
F / N N
w ~F w ~F
O I r ~ O I /
~N ~N
O O I ~ O O I
HON ~ / H H3C CH HO~H I \ / H C
F H I / N~N I r CH33 F / N O N I ~a CHHa IOI

i I\ ~ O I\
HO N \ ~ H HO H I \
F H I ~ N~N I \ OH F i N~N I \ OH
I0 ~ IO' F~F F~F
F F

O O ~I O O
HON \ ~ H HO~N~ H
F H I / N N CI F H I) /~N N CI
I ~ I
O ~ CI O ~ CI
O / I ~ O i I
HO N~~ H HO N \ \ H
F H 'I ~ NuN I \ CI F H iI , N~N I \ CI
v"CI O ~CI
i O i I ~ 0 i I
HO N ~~ H F F HO N \ \ H F F
F H I i N II N I \ O F H 'I / N II N I \ O
O \~~~~~ F O \~~ F

O O ~ I O O
HON \ ~ H F F HO~N~ H F F
F H I / N N F H II /~N N
O I ~ ~F O I , ~F
O F O F

O O / I O 0 Trans \ H HON ~ H F
HO F H I / N N F F H I / N N F
W ~ W

F F
F
O / I ~ O / I
HO N ~ ~ H HO N~~ H
F H I ~ N N F F H I / N N F
O I / F O I r F
/
O / I ~ O r I
HO N~~~ H HO N~~ H
F H (J / N~N I ~ CFa F H [I .i N~N I ~ CFa 0 v 'CI 0 ~CI
r o p ~ I o 0 '~ I
HON ~ ~ H HO~N~~ H
F H I / N N NOa F H/ \ [I /~N N NOz O I / F O I i F
I ~ O / I
NO N~~ H HO N~~ H
F H iI / N~N I \ F H iI / N~N
O ~ CH3 I0 ~ CH3 /
O / I ~ O / I
HO N \ ~ H HO
F H I / N N F / N N
\ \

/
O / I ~ O ~ I
HO N \ ~ H / Br HO N \ \ H / Br F H I/ N N ~I F H/~\'I/ N N \I

O / ~ ~ O / I
HO N \ ~ HO N~~
F H I / N N F F H I / N N F
\ \
O I / O I /
F F
O / I ~ O / I
HO N \ ~ H HO N~~ H
F H I / N N O F F H I / N N O~ F
~F ~ I / IF' F
/
O / I ~ O / I
NO N \ ~ H F HO N~~ H F
F H I / N N F F H/ \ [I /~N N \ F
\ F ~F
o I / ~~ o I / ~~
N N

r O O ~' O 0 r I I
HON \ \ H ~~~0 HO~H
F H I r N N S. F r N N S, CHa ~ I \ CHa O ~ O
r ° ~' I ~ ° ~ I
HO N~~ H HO N~~ H
F H II r N~N I \ S~F F H iI r N~N I \ S~F
O ~ F O ~ F
r O r I ~ O r I
HO N~~ H HO N~~ H
F H [I r N II N I \ I F H iI r N II N I \ I
O ~ O
r o ~ f ~ o r i HO N ~~ H HO N ~~ H
F H I r N~N I \ CHa F H I r N~N i \ CHa r IOf CHa CHa r O r i ~ O r I
HO N~~ H HO N~~ H
F H I r N~N I ~ Br F H [I .~ N~N I ~ Br IOI r O
Br Br /
I ~ o / I
HO N \ \ H F HO N~~ H F
F H II / N~N I \ F F H iI / N~N I \ F
O / O /

/
/ I ~ O /
HO N~~\ H HO N~~ H
F H II / N~N I \ Br F H iI / N~N I \ Br O r O
F F
O / I ~ O
HO H I \ ~ H O HO H I \ \ H O
F / N~N \ F / N~N \
IO' ( / ,N ~ IOI I / ,N

/
I \ ~ o I \
HO H I \ / H O, ,O HO H I / H O, .0 F / NuN I ~ ~S.CH F / N~N I ~ ~S.CH
I0 / p 3 p / p 3 ~CH3 v 'CH3 /
/ I ~ o / I
HO N \ ~ H O-N CH3 HO N~~ H 0' ~CH3 F H I / N N ~ F H II /~N N
I \ N CH3 ~ I \ N CH3 O

/
o I \ ~ o I \
w / /
HO F H I ~, N N O;S'O \ I HO F H I / N N O~S.O \ I
N ~ N
O I / CHa O ( / CHa \ O O \
HO~H O I \ I / H O, .O / I HO~H I \ I / H O~ O /
F / N N ~ ~S.N~ F / N N ~ ~S.N~
O I / ~CHa O I / ~CHa /
o I \ ~ o I \
\
HO F H I / N N O~S,O \ I HO F H I / N N O~S.O \ I
O I / CHCHa O ~ / CHCHa /
/ I ~ O r I
HO H I \ ~ H O HO H I \ \ H O
F / NuN I \ N CH F / NuN I \ N CH
\ ~ 3 I°I \ ~ 3 / CHa / CHa O O
/
O / I ~ O r HO N \ \ H HO N \ \ H
F ~ / N O N S ~i0 F H [I / N~N S ~;O
CHa I°I I ~ CHa /
° ~ I~ ~ ° ~ I
HO N \ H F HO N \ H F
F H iI / N o N I \ F F H [~ / N o N I \ F
/
F F

/
o -' I ~ o ~ I
HO N \ ~ H ~' HO N~~\ H
F H I / N N \ I F H u\lI /~N N \ I
p r O /
\ ( \ I
r \ O O
HO~H O ~ I / H O~ .O / I HO~H I \ I / H O~ O / I
F I / N N ~S. ~ F / N N ~ ~S.
N N
O I / CH'CH3 O I / CH'CH3 r O ~' I ~ O / I
HO H I \ ~ H O HO H I \ \ H 0 F / N~N ~ F r N~N \
IOI I ,r 'N~ IOI I ,' ~N
O ~F O ~F
0 / I ~ O / I
HO N \ ~ H HO N~~ H
F H I / N N F F H II /~N N \ F
O I r ~ I
O 0 ~' I O O ~' I
HON ~ ~ H HO~N~~~ H
F H I .~ N N CH3 F H II ~~ N N ~ CH3 O I / O I /

/
/ I ~ O ./ I
HO N \ \ H HO N~~ H
F H I / N N F H II ~~N N
I / CHa ~ I \ CHa O O /
O /
HO H I \ ~ H 0+ HO H I \ ~ O
F / N O N I \ N,O_ F / N O N I \ N~O_ O / I
HO H I \ ~ H p+ HO H I \ \

F / N O N I \ N,0_ F / N O N I \ N;O_ _CHa ~CHa /
/ I ~ O / I
HO N \ ~ HO N
F H I .~ N N iN F H I / N N iN
O I / O
O / I
HO N \ \ H HO N~~ H
F H/~~ll /~N N 0 F H~u\lJ /~N N 0 O I/ Ii 0 I/ I/
O / I
HO N \ ~ H NnN HO N \ ~ H N-N
F H I / N N ~ .N-CHa F H I / N N ~ .N'CHa O I \ N ~ J \ N
O /

PHARMACOLOGICAL METHODS
In the following section binding assays as well as functional assays useful for evaluating the efficiency of the compounds of the invention are described.
Binding of compounds to the glucagon receptor may be determined in a competition binding assay using the cloned human glucagon receptor.
Antagonism may be determined as the ability of the compounds to inhibit the amount of cAMP formed in the presence of 5 nM glucagon.
Glucagon Binding Assay (I) Receptor binding are assayed using cloned human receptor (Lok et al., Gene 140, 203-209 (1994)). The receptor inserted in the pLJ6' expression vector using EcoRl/SSt1 restriction sites (Lok et al.) is expressed in a baby hamster kidney cell line (A3 BHK 570-25).
Clones are se-lected in the presence of 0.5 mg/mL G-418 and are shown to be stable for more than 40 pas-sages. The Kd is shown to be 0.1 nM.
Plasma membranes are prepared by growing cells to confluence, detaching them from the sur-face and resuspending the cells in cold buffer (10 mM tris/HCI, pH 7.4 containing 30 mM NaCI, 1 mM dithiothreitol, 5 mg/L leupeptin (Sigma), 5 mg/L pepstatin (Sigma), 100 mg/L bacitracin (Sigma) and 15 mg/L recombinant aprotinin (Novo Nordisk A/S)), homogenization by two 10-s bursts using a Polytron PT 10-35 homogenizer (Kinematica), and centrifugation upon a layer of 41 w/v % sucrose at 95.000 x g for 75 min. The white band located between the two layers is diluted in buffer and centrifuged at 40.000 x g for 45 min. The precipitate containing the plasma membranes is suspended in buffer and stored at -80 °C until use.
Glucagon is iodinated according to the chloramine T method (Hunter and Greenwood, Nature 194, 495 (1962)) and purified using anion exchange chromatography (Jorgensen et al., Hor-mone and Metab. Res. 4, 223-224 (1972). The specific activity is 460 pCi/pg on the day of iodi-nation. Tracer is stored at -18 °C in aliquots and used immediately after thawing.
Binding assays are carried out in triplicate in filter microtiter plates (MADV
N65, Millipore). The buffer is 50 mM HEPES, 5 mM EGTA, 5 mM MgCh, 0.005% tween 20, pH 7.4. Glucagon is dis-solved in 0.05 M HCI, added an equal amount (w/w) of human serum albumin and freeze-dried.
On the day of use, it is dissolved in water and diluted in buffer to the desired concentrations.
Test compounds are dissolved and diluted in DMSO. 140 p,L buffer, 25 pL
glucagon or buffer, and 10 p,L DMSO or test compound are added to each well. Tracer (50.000 cpm) is diluted in buffer and 25 ~L is added to each well. 1-4 p,g freshly thawed plasma membrane protein diluted in buffer is then added in aliquots of 25 pL to each well. Plates are incubated at 30 °C for 2 hours. Non-specific binding is determined with 10-6 M of glucagon. Bound tracer and unbound tracer are then separated by vacuum filtration (Millipore vacuum manifold).
The plates are washed with 2 x 100 pL buffer/ well. The plates are air dried for a couple of hours, whereupon the filters are separated from the plates using a Millipore Puncher. The filters are counted in a gamma counter.
Functional Assay (I) The functional assay was carried out in 96 well microtiter plates (tissue culture plates, Nunc).
The resulting buffer concentrations in the assay are 50 mM tris/HCI, 1 mM
EGTA, 1.5 mM
MgS04, 1.7 mM ATP, 20 p.M GTP, 2 mM IBMX, 0.02% tween-20 and 0.1 % human serum al-bumin. pH was 7.4. Glucagon and proposed antagonist are added in aliquots of 35 p,L diluted in 50 mM tris/HCI, 1 mM EGTA, 1.85 mM MgS04, 0.0222% tween-20 and 0.111 % human serum albumin, pH 7.4. 20 p,L of 50 mM tris/HCI, 1 mM EGTA, 1.5 mM MgS04, 11.8 mM
ATP, 0.14 mM GTP, 14 mM IBMX and 0.1% human serum albumin, pH 7.4 was added. GTP was dis-solved immediately before the assay.
50 ~.L containing 5 pg of plasma membrane protein was added in a tris/HCI, EGTA, MgS04, human serum albumin buffer (the actual concentrations are dependent upon the concentration of protein in the stored plasma membranes).
The total assay volume is 140 p,L. The plates are incubated for 2 hours at 37 °C with continuous shaking. Reaction is terminated by addition of 25 p,L 0.5 N HCI. cAMP is measured by the use of a scintillation proximity kit (Amersham).

Glucagon Binding Assay (II) BHK (baby hamster kidney cell line) cells are transfected with the human glucagon receptor and a membrane preparation of the cells is prepared. Wheat Germ Agglutinin derivatized SPA beads containing a scintillant (WGA beads) (Amersham) bound the membranes.
'251-glucagon bound to human glucagon receptor in the membranes and excited the scintih lant in the WGA beads to light emission. Glucagon or samples binding to the receptor com-peted with'~51-glucagon.
All steps in the membrane preparation are kept on,ice or performed at 4 °C. BHK cells are 1 o harvested and centrifuged. The pellet is resuspended in homogenisation buffer (25 mM
HEPES, pH = 7.4, 2.5 mM CaCl2, 1.0 mM MgCl2, 250 mg/L bacitracin, 0.1 mM
Pefabloc), homogenised 2 x 10 sec using Polytron 10-35 homogenizer (Kinematics) and added the same amount of homogenisation buffer as used for resuspension. After centrifugation (15 min at 2000 x g) the supernatant is transferred to cold centrifuge tubes and centrifuged for 45 min at 40.000 x g. The pellet is resuspended in homogenisation buffer, homogenised 2 x 10 sec (Polytron) and additional homogenisation buffer is added. The suspension is centrifuged for 45 min at 40.000 x g and the pellet is resuspended in resuspension buffer (25 mM
HEPES, pH = 7.4, 2.5 mM CaCl2, 1.0 mM MgCl2) and homogenised 2 x 10 sec.
(Polytron).
The protein concentration is normally around 1.75 mg/mL. Stabilisation buffer (25 mM
HEPES, pH = 7.4, 2.5 mM CaCh, 1.0 mM MgCl2, 1 % bovine serum albumin, 500 mg/L
ba-citracin, 2.5 M sucrose) is added and the membrane preparation is stored at -80 °C.
The gfucagon binding assay is carried out in opti plates (Polystyrene Micropfates, Packard).
50 uL assay buffer (25 mM HEPES, pH = 7.5, 2.5 mM CaCl2, 1.0 mM MgCl2, 0.003%
Tween 20, 0.005% bacitracin, 0.05% sodium azide) and 5 pL glucagon or test compound (in DMSO) are added to each well. 50 pL tracer ('251-porcine glucagon, 50.000 cpm) and 50 pL mem-branes (7.5 pg) containing the human glucagon receptor are then added to the wells. Finally 50 pL WGA beads containing 1 mg beads are transferred to the well. The opti plates are in-cubated for 4 hours on a shaker and then settled for 8-48 hours. The opti plates are counted in a Topcounter. Non-specific binding is determined with 500 nM of glucagon.
The compounds according to the examples showed ICSO values below 1500 nM and many of them below 250 nM when tested in the glucagon binding assay (II).

GIP Binding Assay BHK (baby hamster kidney cell line) cells are transfected with the human GIP
receptor and a membrane preparation of the cells is prepared. Wheat Germ Agglutinin derivatized SPA
beads containing a scintillant (WGA beads) (Amersham) bound the membranes.
'251-GIP
bound to human GIP receptor in the membranes and excited the scintillant in the WGA
beads to light emission. GIP or samples binding to the receptor competed with'251-GIP.
All steps in the membrane preparation are kept on ice or performed at 4 °C. BHK cells are harvested and centrifuged. The pellet is resuspended in homogenisation buffer (25 mM
HEPES, pH = 7.4, 2.5 mM CaCl2, 1.0 mM MgCl2, 250 mg/L bacitracin, 0.1 mM
Pefabloc), homogenised 2 x 10 sec using Polytron 10-35 homogenizes (Kinematics) and added the same amount of homogenisation buffer as used for resuspension. After centrifugation (15 min at 2000 x g) the supernatant is transferred to cold centrifuge tubes and centrifuged for 45 min at 40.000 x g. The pellet is resuspended in homogenisation buffer, homogenised 2 x 10 sec (Polytron) and additional homogenisation buffer is added. The suspension is centrifuged for 45 min at 40.000 x g and the pellet is resuspended in resuspension buffer (25 mM
HEPES, pH = 7.4, 2.5 mM CaCl2, 1.0 mM MgCl2) and homogenised 2 x 10 sec.
(Polytron).
The protein concentration is normally around 1.75 mg/mL. Stabilisation buffer (25 mM
HEPES, pH = 7.4, 2.5 mM CaCl2, 1.0 mM MgCl2, 1 % bovine serum albumin, 500 mg/L ba-citracin, 2.5 M sucrose) is added and the membrane preparation is stored at -80 °C.
The GIP binding assay is carried out in opti plates (Polystyrene Microplates, Packard). 50 pL
assay buffer (25 mM HEPES, pH = 7.5, 2.5 mM CaCl2, 1.0 mM MgCl2, 0.003°I° Tween-20, 0.005% bacitracin, 0.05% sodium azide) and 5 pL GIP or test compound (in DMSO) are added to each well. 50 pL tracer ('251-porcine GIP, 50.000 cpm) and 50 pL
membranes (20 pg) containing the human GIP receptor are then added to the wells. Finally 50 pL WGA
beads containing 1 mg beads are transferred to the well. The opti plates are incubated for 3.5 hours on a shaker and then settled for 8-48 hours. The opti plates are counted in a Top-counter. Non-specific binding is determined with 500 nM of GIP.

Claims (71)

1. A compound of the general formula (I):

wherein R1, R2, R3, R4 and R5 independently are hydrogen or C1-6-alkyl, A is -C(O)-, -CH(OR6)- or-CHF-, wherein R6 is hydrogen or C1-6-alkyl, Z is arylene or a divalent radical derived from a 5 or 6 membered heteroaromatic ring con-taining 1 or 2 heteroatoms selected from nitrogen, oxygen and sulfur, which may optionally be substituted with one or two groups R7 and R8 selected from halogen, -CN, -CF3, -OCF3, -NO2, -OR9, -NR9R10 and C1-6-alkyl, wherein R9 and R10 independently are hydrogen or C1-6-alkyl, X is wherein r is 0 or 1, q and s independently are 0, 1, 2 or 3, R11, R12, R13 and R14 independently are hydrogen, C1-6-alkyl or C3-8-cycloalkyl, D is wherein R15, R16, R17 and R18 independently are .cndot. hydrogen, halogen, -CN, -CHF2, -CF3, -OCF3, -OCHF2, -OCH2CF3, -OCF2CHF2, -S(O)2CF3, -SCF3, -NO2, -OR21, -NR21R22, -SR21, -NR21S(O)2R22, -S(O)2NR21R22, -S(O)NR21R22, -S(O)R21, -S(O)2R21, -C(O)NR21R22, -OC(O)NR21R22, -NR21C(O)R22, -CH2C(O)NR21R22, -OCH2C(O)NR21R22, -OC(O)R21, -C(O)R21 or -C(O)OR21, .cndot. C1-6-alkyl, C2-6-alkenyl or C2-6-alkynyl, which may optionally be substituted with one or more substituents selected from halogen, -CN, -CF3, -OCF3, -NO2, -OR21, -NR21R22 and C1-6-alkyl, .cndot. C3-8-cycloalkyl, C4-8-cycloalkenyl, heterocyclyl, C3-8-cycloalkyl-C1-6-alkyl, C3-8-cyclo-alkyl-C1-6-alkoxy, C3-8-cycloalkyloxy, C3-8-cycloalkyl-C1-6-alkylthio, C3-8-cycloalkylthio, C3-8-cycloalkyl-C2-6-alkenyl, C3-8-cycloalkyl-C2-6-alkynyl, C4-8-cycloalkenyl-C1-6-alkyl, C4-8-cycloalkenyl-C2-6-alkenyl, C4-8-cycloalkenyl-C2-6-alkynyl, heterocyclyl-C1-6-alkyl, heterocyclyl-C2-6-alkenyl, heterocyclyl-C2-6-alkynyl, aryl, aryloxy, aryloxycarbonyl, aroyl, aryl-C1-6-alkoxy, aryl-C1-6-alkyl, aryl-C2-6-alkenyl, aryl-C2-6-alkynyl, heteroaryl, heteroaryl-C1-6-alkyl, heteroaryl-C2-6-alkenyl or heteroaryl-C2-6-alkynyl, of which the cyclic moieties optionally may be substituted with one or more sub-stituents selected from halogen, -C(O)OR21, -CN, -CF3, -OCF3, -NO2, -OR21, -NR21R22 and C1-6-alkyl, wherein R21 and R22 independently are hydrogen, C1-6-alkyl, aryl-C1-6-alkyl or aryl, or R21 and R22 when attached to the same nitrogen atom together with the said nitrogen atom may form a 3 to 8 membered heterocyclic ring optionally containing one or two further heteroatoms selected from nitrogen, oxygen and sulfur, and optionally containing one or two double bonds, or two of the groups R15 to R16 when placed in adjacent positions together may form a bridge -(CR23R24)a-O-(CR25R26)c-O-, wherein a is 0, 1 or 2, c is 1 or 2, R23, R24, R25 and R26 independently are hydrogen, C1-6-alkyl or fluorine, R19 and R20 independently are hydrogen, C1-6-alkyl, C3-8-cycloalkyl or C3-8-cyclo-alkyl-C1-6-alkyl, E is wherein R27 and R28 independently are hydrogen, halogen, -CN, -CF3, -OR32, -NR32R33, C1-6-alkyl, C3-8-cycloalkyl, C4-8-cycloalkenyl or aryl, wherein the aryl group optionally may be substituted with one or more substituents selected from halogen, -CN, -CF3, -NO2, -OR32, -NR32R33 and C1-6-alkyl, wherein R32 and R33 independently are hydrogen or C1-6-alkyl, or R32 and R33 when attached to the same nitrogen atom together with the said nitrogen atom may form a 3 to 8 membered heterocyclic ring optionally containing one or two further heteroatoms selected from nitrogen, oxygen and sulfur, and optionally containing one or two double bonds, R29, R30 and R31 independently are ~ hydrogen, halogen, -CHF2, -CF3, -OCF3, -OCHF2, -OCH2CF3, -OCF2CHF2, -SCF3, -OR34, -NR34R35, -SR34, -S(O)R34, -S(O)2R34, -C(O)NR34R35, -OC(O)NR34R35, -NR34C(O)R35, -OCH2C(O)NR34R35, -C(O)R34 or -C(O)OR34, ~ C1-6-alkyl, C2-6-alkenyl or C2-6-alkynyl, which may optionally be substituted with one or more substituents selected from halogen, -CN, -CF3, -OCF3, -NO2, -OR34, -NR34R35 and C1-6-alkyl, ~ C3-8-cycloalkyl, C4-8-cycloalkenyl, heterocyclyl, C3-8-cycloalkyl-C1-6-alkyl, C3-8-cyclo-alkyl-C2-6-alkenyl, C3-8-cycloalkyl-C2-6-alkynyl, C4-8-cycloalkenyl-C1-6-alkyl, C4-8-cyclo-alkenyl-C2-6-alkenyl, C4-8-cycloalkenyl-C2-6-alkynyl, heterocyclyl-C1-6-alkyl, heterocy-clyl-C2-6-alkenyl, heterocyclyl-C2-6-alkynyl, aryl, aryloxy, aroyl, aryl-C1-6-alkoxy, aryl-C1-6-alkyl, aryl-C2-6-alkenyl, aryl-C2-6-alkynyl, heteroaryl, heteroaryl-C1-6-alkyl, hetero-aryl-C2-6-alkenyl or heteroaryl-C2-6-alkynyl, of which the cyclic moieties optionally may be substituted with one or more sub-stituents selected from halogen, -CN, -CF3, -OCF3, -NO2, -OR34, -NR34R35 and C1-6-alkyl, wherein R34 and R35 independently are hydrogen, C1-6-alkyl or aryl, or R34 and R35 when attached to the same nitrogen atom together with the said nitrogen atom may form a 3 to 8 membered heterocyclic ring optionally containing one or two further heteroatoms selected from nitrogen, oxygen and sulfur, and optionally containing one or two double bonds, or two of the groups R29, R30 and R31 when attached to the same ring carbon atom or differ-ent ring carbon atoms together may form a radical -O-(CH2)t-CR36R37-(CH2)l-O-, -(CH2)t-CR36R37-(CH2)l- or -S-(CH2)t-CR36R37-(CH2)l-S-, wherein t and l independently are 0, 1, 2, 3, 4 or 5, R36 and R37 independently are hydrogen or C1-6-alkyl, as well as any optical or geometric isomer or tautomeric form thereof including mixtures of these or a pharmaceutically acceptable salt thereof.
2. A compound according to claim 1, wherein R1, R2, R3, R4 and R5 are hydrogen.
3. A compound according to claim 1 or 2, wherein A is ~CHF-
4. A compound according to claim 1 or 2, wherein A is ~CH(OR6)-, wherein R6 is as defined in claim 1.
5. A compound according to claim 4, wherein A is ~CH(OH)-.
6. A compound according to any one of the preceding claims, wherein Z is wherein R7 and R8 are as defined in claim 1.
7. A compound according to claim 6, wherein Z is
8. A compound according to any one of the preceding claims, wherein X is wherein q is 0 or 1, r is 0 or 1, s is 0, 1 or 2, and R12 and R13 independently are hydrogen or C1-6-alkyl.
9. A compound according to claim 8, wherein X is -C(O)NH-, -C(O)NHCH2-, -C(O)NHCH(CH3)-, -C(O)NHC(CH3)2-, -C(O)NHCH2CH2-, -C(O)CH2-, -C(O)CH2CH2-, -C(O)CH=CH-, -(CH2)s-, -C(O)-, -C(O)O- or -NHC(O)-, wherein s is 0 or 1.
10. A compound according to claim 9, wherein X is -C(O)NH-, -C(O)NHCH2-, -C(O)NHCH(CH3)-, -C(O)NHCH2CH2-, -C(O)CH2-, -C(O)CH=CH-, -(CH2)s-, -C(O)-, -C(O)O-or -NHC(O)-, wherein s is 0 or 1.
11. A compound according to claim 10, wherein X is -C(O)NH-, -C(O)NHCH2-, -C(O)NHCH(CH3)-, -C(O)NHCH2CH2-, -C(O)CH2-, -CH2-, -C(O)- or -NHC(O)-.
12. A compound according to claim 11, wherein X is -C(O)NH-, -C(O)NHCH2-, -C(O)NHCH(CH3)-, -C(O)CH2- or -C(O)-.
13. A compound according to claim 12, wherein X is -C(O)NH-.
14. A compound according to any one of the preceding claims; wherein D is wherein R15, R16, R17, R18, R19 and R20 are as defined in claim 1.
15. A compound according to claim 14, wherein D is wherein R15, R16 and R17 are as defined in claim 1.
16. A compound according to claim 14 or 15, wherein R15, R16 and R17 independently are hydrogen, halogen, -CN, -NO2, -CF3, -OCF3, -SCF3, C1-6-alkyl, C1-6-alkoxy, -S-C1-6-alkyl, -C(O)OR21, -C(O)R21, -CH2OR21, -C(O)NR21R22, -S(O)R21, -S(O)2R21, -S(O)2CF3, -S(O)2NR21R22, C3-8-cycloalkyl, C3-8-cycloalkyl-C1-6-alkoxy or C3-8-cycloalkyl-C1-6-thioalkyl, or aryl, heteroaryl or aryloxy, which may optionally be substituted with ~CF3, ~OCF3, C-16-alkyl, halogen or -C(O)OR21, or two of the groups R15, R16 and R17 when placed in adjacent positions together form a bridge -(CR23R24)a-O-(CR25R26)c-O-, wherein R21 and R22 independently are hydrogen or C1-6-alkyl, and a, c, R23, R24, R25 and R26 are as defined in claim 1.
17. A compound according to claim 16, wherein R15, R16 and R17 independently are hydro-gen, halogen, -CN, -CF3, -OCF3 or C1-6-alkoxy or wherein R15 and R16 together form a bridge -CF2-O-CF2-O- and R17 is hydrogen.
18. A compound according to claim 17, wherein R15, R16 and R17 independently are hydro-gen, halogen, -CN, -CF3, -OCF3 or C1-6-alkoxy.
19. A compound according to claim 14, wherein D is wherein R15, R16, R19 and R20 are as defined in claim 1.
20. A compound according to claim 19, wherein D is wherein R15 and R16 are both hydrogen and R19 is C1-6-alkyl, C3-8-cycloalkyl or C3-8-cycloalkyl-C1-6-alkyl.
21. A compound according to claim 19, wherein D is wherein R15 and R16 are both hydrogen and R19 and R20 are both C1-6-alkyl.
22. A compound according to any one of the preceding claims, wherein E is wherein R27, R28, R29, R30 and R31 are as defined in claim 1.
23. A compound according to claim 22, wherein E is wherein R27 and R28 are as defined in claim 1.
24. A compound according to claim 23, wherein E is wherein R27 and R28 are as defined in claim 1.
25. A compound according to claim 23 or 24, wherein R27 and R28 independently are hydro-gen, C1-6-alkyl, C3-8-cycloalkyl, C4-8-cycloalkenyl or phenyl, wherein the phenyl group is op-tionally substituted as defined in claim 1.
26. A compound according to claim 25, wherein R27 and R28 independently are hydrogen, C1-6-alkyl, C3-8-cycloalkyl or C4-8-cycloalkenyl.
27. A compound according to claim 26, wherein R27 is hydrogen and R28 is C1-6-alkyl, C3-8-cycloalkyl or C4-8-cycloalkenyl.
28. A compound according to claim 27, wherein R27 is hydrogen and R28 is C1-6-alkyl or C3-8-cycloalkyl.
29. A compound according to claim 22, wherein E is wherein R29, R30 and R31 are as defined in claim 1.
30. A compound according to claim 29, wherein E is wherein R29, R30 and R31 are as defined in claim 1.
31. A compound according to claim 29 or 30, wherein R29, R30 and R31 independently are ~ hydrogen, -CHF2, -CF3, -OCF3, -OCHF2, -OCH2CF3, -OCF2CHF2, -SCF3, -OR34, -NR34R35, -SR34, -S(O)R34, --S(O)2R34, -C(O)NR34R35, -OC(O)NR34R35, -NR34C(O)R35, -OCH2C(O)NR34R35, -C(O)R34 or -C(O)OR34, ~ C1-6-alkyl, C2-6-alkenyl or C2-6-alkynyl, which may optionally be substituted with one or more substituents selected from halogen, -CN, -CF3, -OCF3, -NO2, -OR34, -NR34R35 and C1-6-alkyl, ~ C3-8-cycloalkyl or C4-8-cycloalkenyl, which may optionally be substituted with one or more substituents selected from halogen, -CN, -CF3, -OCF3, -NO2, -OR34, -NR34R35 and C1-6-alkyl, wherein R34 and R35 independently are hydrogen, C1-6-alkyl or aryl, or R34 and R35 when attached to the same nitrogen atom together with the said nitrogen atom may form a 3 to 8 membered heterocyclic ring optionally containing one or two further heteroatoms selected from nitrogen, oxygen and sulfur, and optionally containing one or two double bonds.
32. A compound according to claim 31, wherein R29, R30 and R31 independently are hydrogen, C1-6-alkoxy, halogen, -CF3, -OCF3 or -NR34R35, wherein R34 and R35 are as defined in claim 1, or C1-6-alkyl, C3-8-cycloalkyl or C4-8-cycloalkenyl, which are optionally substituted as defined in claim 1.
33. A compound according to claim 32, wherein R29, R30 and R31 independently are hydrogen or C1-6-alkyl, C3-8-cycloalkyl or C4-8-cycloalkenyl, which are optionally substituted as defined in claim 1.
34. A compound according to claim 32, wherein R29, R30 and R31 independently are hydrogen or C1-6-alkyl, C3-8-cycloalkyl or C4-8-cycloalkenyl, ~ which may optionally be substituted with one or more substituents selected from halogen, -CN, -CF3, -OCF3, -NO2, -OR34, -NR34R35 and C1-6-alkyl, ~ wherein R34 and R35 independently are hydrogen, C1-6-alkyl or aryl, ~ or R34 and R35 when attached to the same nitrogen atom together with the said nitro-gen atom may form a 3 to 8 membered heterocyclic ring optionally containing one or two further heteroatoms selected from nitrogen, oxygen and sulfur, and optionally containing one or two double bonds.
35. A compound according to claim 34, wherein R29 and R31 are both hydrogen, and R30 is different from hydrogen.
36. A compound according to claim 34, wherein R29 and R31 are both hydrogen, and R30 is C3-8-cycloalkyl or C4-8-cycloalkenyl, ~ which may optionally be substituted with one or more substituents selected from halogen, -CN, -CF3, -OCF3, -NO2, -OR34, -NR34R35 and C1-6-alkyl, ~ wherein R34 and R35 independently are hydrogen, C1-6-alkyl or aryl, ~ or R34 and R35 when attached to the same nitrogen atom together with the said nitro-gen atom may form a 3 to 8 membered heterocyclic ring optionally containing one or two further heteroatoms selected from nitrogen, oxygen and sulfur, and optionally containing one or two double bonds.
37. A compound according to claim 36, wherein R29 and R31 are both hydrogen, and R30 is C4-8-cycloalkenyl, ~ which may optionally be substituted with one or more substituents selected from halogen, -CN, -CF3, -OCF3, -NO2, -OR34, -NR34R35 and C1-6-alkyl, ~ wherein R34 and R35 independently are hydrogen, C1-6-alkyl or aryl, ~ or R34 and R35 when attached to the same nitrogen atom together with the said nitro-gen atom may form a 3 to 8 membered heterocyclic ring optionally containing one or two further heteroatoms selected from nitrogen, oxygen and sulfur, and optionally containing one or two double bonds.
38. A compound according to claim 37, wherein R29 and R31 are both hydrogen, and R30 is cyclohexenyl, ~ which may optionally be substituted with one or more substituents selected from halogen, -CN, -CF3, -OCF3, -NO2, -OR34, -NR34R35 and C1-6-alkyl, ~ wherein R34 and R35 independently are hydrogen, C1-6-alkyl or aryl, ~ or R34 and R35 when attached to the same nitrogen atom together with the said nitro-gen atom may form a 3 to 8 membered heterocyclic ring optionally containing one or two further heteroatoms selected from nitrogen, oxygen and sulfur, and optionally containing one or two double bonds.
39. A compound according to claim 37 or 38, wherein R30 is substituted with one C1-6-alkyl substituent.
40. A compound according to claim 33, wherein R29, R30 and R31 independently are hydro-gen, C1-6-alkyl, C3-8-cycloalkyl or C4-8-cycloalkenyl.
41. A compound according to claim 40, wherein R29 and R31 are both hydrogen and R30 is C1-6-alkyl, C3-8cycloalkyl or C4-8-cycloalkenyl.
42. A compound according to claim 1 of the general formula (I1):
wherein R1, R2, R3, R4, R5, R6, R7, R8, X, D and E are as defined in claim 1 or in any one of the preceding claims.
43. A compound according to claim 1 of the general formula (I2):
wherein R1, R2, R3, R4, R5, R6, R7, R8, D and E are as defined in claim 1 or in any one of the preceding claims.
44. A compound according to claim 1 of the general formula (I3):
wherein R1, R2, R3, R4, R5, R6, R7, R8, R15, R16, R17, R29, R30, and R31 are as defined in claim 1 or in any one of the preceding claims.
45. A compound according to claim 42, 43 or 44, wherein R1, R2, R3, R4, R5, R6, R7 and R8 are hydrogen.
46. A compound according to claim 1 of the general formula (I4):
wherein R1, R2, R3, R4, R5, R7, R8, X, D and E are as defined in claim 1 or in any one of the preceding claims.
47. A compound according to claim 1 of the general formula (I5):
wherein R1, R2, R3, R4, R5, R7, R8, D and E are as defined in claim 1 or in any one of the pre-ceding claims.
48. A compound according to claim 46 or 47, wherein R1, R2, R3, R4, R5, R7 and R8 are hy-drogen.
49. A compound according to any one of the preceding claims, which has an IC50 value of no greater than 5 µM as determined by the Glucagon Binding Assay (I) or Glucagon Binding Assay (II) disclosed herein.
50. A compound according to claim 49, which has an IC50 value of less than 1 µM, preferably of less than 500 nM and even more preferred of less than 100 nM as determined by the Glu-cagon Binding Assay (I) or Glucagon Binding Assay (II) disclosed herein.
51. A compound according to any one of the preceding claims, which is an agent useful for the treatment and/or prevention of an indication selected from the group consisting of hyper-glycemia, IGT, Type 2 diabetes, Type 1 diabetes, dyslipidemia and obesity.
52. A compound according to any one of the claims 1 to 51 for use as a medicament.
53. A pharmaceutical composition comprising, as an active ingredient, at least one com-pound according to any one of the claims 1 to 51 together with one or more pharmaceutically acceptable carriers or excipients.
54. A pharmaceutical composition according to claim 53 in unit dosage form, comprising from about 0.05 mg to about 1000 mg, preferably from about 0.1 mg to about 500 mg and espe-cially preferred from about 0.5 mg to about 200 mg of the compound according to any one of the claims 1 to 51.
55. Use of a compound according to any one of the claims 1 to 51 for the preparation of a medicament for the treatment and/or prevention of disorders or diseases, wherein a gluca-gon antagonistic action is beneficial.
56. Use of a compound according to any one of the claims 1 to 51 for the preparation of a medicament for the treatment and/or prevention of glucagon-mediated disorders and dis-eases.
57. Use of a compound according to any one of the claims 1 to 51 for the preparation of a medicament for the treatment and/or prevention of hyperglycemia.
58. Use of a compound according to any one of the claims 1 to 51 for the preparation of a medicament for lowering blood glucose in a mammal.
59. Use of a compound according to any one of the claims 1 to 51 for the preparation of a medicament for the treatment and/or prevention of IGT.
60. Use of a compound according to any one of the claims 1 to 51 for the preparation of a medicament for the treatment and/or prevention of Type 2 diabetes.
61. Use according to claim 60 for the preparation of a medicament for the delaying or prevention of the progression from IGT to Type 2 diabetes.
62. Use according to claim 60 for the preparation of a medicament for the delaying or pre-vention of the progression from non-insulin requiring Type 2 diabetes to insulin requiring Type 2 diabetes.
63. Use of a compound according to any one of the claims 1 to 51 for the preparation of a medicament for the treatment and/or prevention of Type 1 diabetes.
64. Use of a compound according to any one of the claims 1 to 51 for the preparation of a medicament for the treatment and/or prevention of obesity.
65. Use of a compound according to any one of the claims 1 to 51 for the preparation of a medicament for the treatment and/or prevention of dyslipidemia.
66. Use according to any one of the claims 55 to 65 in a regimen which comprises treatment with a further antidiabetic agent.
67. Use according to any one of the claims 55 to 66 in a regimen which comprises treatment with a further antiobesity agent.
68. Use according to any one of the claims 55 to 67 in a regimen which additionally com-prises treatment with a further antihyperlipidemic agent.
69. Use according to any one of the claims 55 to 68 in a regimen which additionally com-prises treatment with an antihypertensive agent.
70. A method for the treatment and/or prevention of disorders or diseases, wherein a gluca-gon antagonistic action is beneficial, the method comprising administering to a subject in need thereof an effective amount of a compound according to any one of the claims 1 to 51 or a pharmaceutical composition according to claim 53 or 54.
71. The method according to claim 70, wherein the effective amount of the compound is in the range of from about 0.05 mg to about 2000 mg, preferably from about 0.1 mg to about 1000 mg and especially preferred from about 0.5 mg to about 500 mg per day.
CA002411552A 2000-06-23 2001-06-21 Glucagon antagonists/inverse agonists Abandoned CA2411552A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200000984 2000-06-23
DKPA200000984 2000-06-23
DKPA200001734 2000-11-17
DKPA200001734 2000-11-17
PCT/DK2001/000435 WO2002000612A1 (en) 2000-06-23 2001-06-21 Glucagon antagonists/inverse agonists

Publications (1)

Publication Number Publication Date
CA2411552A1 true CA2411552A1 (en) 2002-01-03

Family

ID=26068842

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002411552A Abandoned CA2411552A1 (en) 2000-06-23 2001-06-21 Glucagon antagonists/inverse agonists

Country Status (14)

Country Link
EP (1) EP1296942A1 (en)
JP (1) JP2004501897A (en)
KR (1) KR20030029061A (en)
CN (1) CN1437581A (en)
AU (1) AU2001265834A1 (en)
BR (1) BR0111908A (en)
CA (1) CA2411552A1 (en)
CZ (1) CZ20024105A3 (en)
HU (1) HUP0301501A2 (en)
IL (1) IL153181A0 (en)
MX (1) MXPA02012273A (en)
NO (1) NO20026149L (en)
PL (1) PL359619A1 (en)
WO (1) WO2002000612A1 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030203946A1 (en) * 2000-11-17 2003-10-30 Carsten Behrens Glucagon antagonists/inverse agonists
JP2005511683A (en) * 2001-12-03 2005-04-28 ノボ　ノルディスク　アクティーゼルスカブ Novel glucagon antagonist
US6881746B2 (en) 2001-12-03 2005-04-19 Novo Nordick A/S Glucagon antagonists/inverse agonists
US6762318B2 (en) 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
AU2003234831A1 (en) * 2002-05-22 2003-12-02 Sanwa Kagaku Kenkyusho Co., Ltd. Obesity preventive or ameliorator containing methylidene hydrazide compound as active ingredient
JP2006500325A (en) * 2002-06-27 2006-01-05 ノボ　ノルディスク　アクティーゼルスカブ Novel glucagon antagonist
AU2003291959A1 (en) * 2002-12-20 2004-07-14 Novo Nordisk A/S Novel glucagon antagonists
WO2004063147A1 (en) * 2003-01-10 2004-07-29 Novo Nordisk A/S Salts and solvates of glucagon antagonists
WO2004069158A2 (en) 2003-01-27 2004-08-19 Merck & Co., Inc. Substituted pyrazoles, compositions containing such compounds and methods of use
JP2007503453A (en) * 2003-05-14 2007-02-22 ノボ　ノルディスク　アクティーゼルスカブ Novel compounds for treating obesity
PT1656139E (en) * 2003-07-21 2011-11-04 Merck Serono Sa Aryl dicarboxamides
EP1689707A1 (en) * 2003-11-25 2006-08-16 Novo Nordisk A/S Novel compounds for the treatment of obesity
WO2005058845A2 (en) * 2003-12-19 2005-06-30 Novo Nordisk A/S Novel glucagon antagonists/inverse agonists
BRPI0512058A (en) * 2004-06-14 2008-02-06 Lilly Co Eli compound or a pharmaceutically acceptable salt thereof, pharmaceutical composition, and use of a compound
CN101146762A (en) 2005-03-21 2008-03-19 默克公司 Substituted aryl and heteroaryl derivatives
JP2008534593A (en) 2005-03-30 2008-08-28 メルク エンド カムパニー インコーポレーテッド Glucagon receptor antagonist compounds, compositions containing such compounds, and methods of use thereof
JP2009502923A (en) 2005-07-26 2009-01-29 メルク エンド カムパニー インコーポレーテッド Method for the synthesis of substituted pyrazoles
TW200745031A (en) 2005-10-13 2007-12-16 Merck & Co Inc Acyl indoles, compositions containing such compounds and methods of use
BRPI0618745A2 (en) * 2005-11-23 2011-09-13 Lilly Co Eli compound or a salt thereof, pharmaceutical composition, and use of a compound or a salt thereof
EP2001472A2 (en) 2006-03-23 2008-12-17 Merck and Co., Inc. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
CA2650619A1 (en) 2006-05-16 2007-11-29 Merck And Co., Inc. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
TW200821284A (en) 2006-10-03 2008-05-16 Merck & Co Inc Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
KR20180099916A (en) 2007-02-09 2018-09-05 메타베이시스 테라퓨틱스, 인크. Novel antagonists of the glucagon receptor
EP2291358B1 (en) 2008-05-16 2018-03-28 Merck Sharp & Dohme Corp. Glucagon receptor antagonists, compositions, and methods for their use
EP3153501B1 (en) 2008-08-13 2018-11-28 Metabasis Therapeutics, Inc. Glucagon antagonists
NZ611529A (en) 2010-12-23 2015-06-26 Pfizer Glucagon receptor modulators
JP5562495B2 (en) 2011-02-08 2014-07-30 ファイザー・インク Glucagon receptor modulator
KR20140023441A (en) 2011-07-22 2014-02-26 화이자 인코포레이티드 Quinolinyl glucagon receptor modulators
US9725427B2 (en) 2012-03-16 2017-08-08 Biohaven Pharmaceutical Holding Company Limited Prodrugs of riluzole and their method of use
US9649294B2 (en) 2013-11-04 2017-05-16 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2015191900A1 (en) 2014-06-12 2015-12-17 Ligand Pharmaceuticals, Inc. Glucagon antagonists
IL309666A (en) 2021-07-09 2024-02-01 Plexium Inc Aryl compounds and pharmaceutical compositions that modulate ikzf2

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6174905B1 (en) * 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
BR9810378A (en) * 1997-07-01 2000-08-29 Novo Nordisk As Compound, use of the same, pharmaceutical composition, and, processes of treating type i or type ii diabetes, of treating hyperglycemia, and of decreasing blood glucose in a mammal
US6613942B1 (en) * 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
BR0010651A (en) * 1999-05-17 2002-03-19 Novo Nordisk As Compound, use of a compound, pharmaceutical composition, and method for the treatment and / or prevention of disorders or diseases mediated by an antagonistic action of glucagon

Also Published As

Publication number Publication date
EP1296942A1 (en) 2003-04-02
KR20030029061A (en) 2003-04-11
MXPA02012273A (en) 2003-04-25
NO20026149L (en) 2003-02-21
HUP0301501A2 (en) 2003-08-28
IL153181A0 (en) 2003-06-24
AU2001265834A1 (en) 2002-01-08
BR0111908A (en) 2003-04-01
PL359619A1 (en) 2004-08-23
CN1437581A (en) 2003-08-20
NO20026149D0 (en) 2002-12-20
JP2004501897A (en) 2004-01-22
CZ20024105A3 (en) 2003-05-14
WO2002000612A1 (en) 2002-01-03

Similar Documents

Publication Publication Date Title
US6562807B2 (en) Glucagon antagonists/inverse agonists
CA2411552A1 (en) Glucagon antagonists/inverse agonists
EP1509509A1 (en) Glucagon antagonists/inverse agonists
EP1183229B1 (en) Glucagon antagonists/inverse agonists
US6875760B2 (en) Glucagon antagonists/inverse agonists
US6649641B2 (en) Glucagon antagonists/inverse agonists
WO2003048109A1 (en) Novel glucagon antagonists
US6762318B2 (en) Glucagon antagonists
WO2004002480A1 (en) Novel glucagon antagonists/inverse agonists
WO2002040444A1 (en) Glucagon antagonists/inverse agonists
WO2004056763A2 (en) Novel glucagon antagonists
WO2005058845A2 (en) Novel glucagon antagonists/inverse agonists
EP1345891A1 (en) Glucagon antagonist/inverse agonist
US20040152750A1 (en) Novel glucagon antagonists
US6706744B2 (en) Glucagon antagonists/inverse agonists
US6821960B2 (en) Glucagon antagonists/inverse agonists

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued